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Professor Paul H. Schlesinger, Chair 
 
 The BCL2 protein family is the primary gatekeeper of mitochondrial apoptosis and 
governs integrity of the organelles’ outer membranes. Permeabilization of mitochondrial outer 
membranes permits egress of cytochrome c and other apoptogenic factors, resulting in 
apoptosome formation, caspase activation, and subsequent proteolytic demolition of cells. 
Proapoptotic BAX & BAK effect the release of cytochrome c while their antiapoptotic 
counterparts like BCL-2, BCL-XL, & MCL-1 oppose this permeabilization. A third class of the 
BCL2 family, the prodeath BH3-only proteins, act as sentinels of cell stress and exert their 
influences by occupying antiapoptotic BCL2 members and/or activating BAX/BAK. Cell-free 
reconstitution assays have revealed that BAX/BAK undergo significant conformational changes 
to oligomerize and form pores in membranes. 
 Previously unresolved was the basis for the outer cell membranes’ escape from BAX 
poration during apoptosis. Unlike outer cell membranes, which are roughly 40% cholesterol, 
mitochondrial outer membranes are only 5-10% cholesterol. Vesicle leakage assays 
demonstrated that BAX pore activation is severely inhibited by the sterol. Inclusion of the total 
enantiomer of cholesterol in our assays uncovered that this BAX functional suppression was 
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due to bilayer structure alteration rather than a stereospecific protein-cholesterol interaction. 
Real-time observation of BAX-vesicle binding showed that cholesterol curbs membrane 
integration by the protein, thus suppressing oligomerization and pore formation. 
 Oxysterols and bile acids are physiological derivatives of cholesterol. Further 
employment of our vesicle leakage regime revealed that 25-hydroxycholesterol at low 
micromolar concentrations accelerates BAX pore formation, suggesting a compensatory 
mechanism for BAX inhibition by cholesterol. Bile acids lithocholic and chenodeoxycholic 
acids are toxic and induce apoptosis at high concentrations, thus we reasoned that the 
physiological detergents may directly activate BAX. While truncated BAX (ΔC) was effectively 
activated by monomeric detergent, the full-length protein required micellar bile acids, implying 
that bile acids could play at most only an amplification role in BAX-mediated apoptosis. 
 In nonstressed cells, BAX exists as a soluble, cytosolic monomer or loosely affiliated 
with mitochondria while cellular recognition of death signals induces BAX transition to a 
membrane-integral state. The physical basis of this translocation and locale of BAX activation 
are poorly characterized. Assemblage of a cell-free scheme comprising full-length BAX, 
antiapoptotic BCL-XL, and BH3-only activators cBID & BIMS, and synthetic vesicles revealed 
that BIMS more effectively activates BAX and is less suppressible by BCL-XL. Each of these four 
proteins can independently adsorb to membranes and that BCL-XL “outraces” BAX to their in-
membrane functional sites. Membrane-bound cBID and BIMS robustly accelerate the bilayer 
integrations of BAX & BCL-XL; the two activators recruit equivalently at the membrane 
surface, however, suggesting that BIMS, unlike cBID, can activate BAX prior to interaction on a 
bilayer scaffold. 
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Introduction 
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1.1 | Distillation 
 BAX is a proapoptotic member of the BCL2 family and lies at the convergence of a 
multitude of cell death signaling pathways. This dissertation is primarily concerned with 
interrogating the sequence of events culminating in BAX pore formation which, inside 
mammalian cells, results in cytochrome c liberation from mitochondria and subsequent cellular 
demise. BAX is a soluble, cytosolic, and monomeric protein that transitions to a bilayer-
integral, oligomeric assemblage that permeabilizes biological membranes. This process can be 
delineated into three basic steps: 1) translocation to a membrane, 2) integration, and 3) 
oligomerization from which membrane pores emanate (Fig. 1.1). This first chapter describes 
the tripartite regulatory scheme of the BCL2 protein family which governs BAX activation. 
The second chapter details our investigation of BAX-membrane integration and 
oligomerization kinetics and the inhibitory effect of cholesterol on the proceeding. Chapter 
Three extends our study of BAX pore activation as influenced by cholesterol derivatives. The 
fourth chapter examines BAX translocation, integration, and pore formation and their 
modulations by anti- and proapoptotic BCL2 kin. Chapter Five proposes further investigative 
efforts and Appendix I marshals biophysical and structural evidences to proffer a model of 
active, membrane-integral BAX. Appendices II-V comprise experimental inquiries, to which 
this dissertation’s author contributed substantially, that address BAX in-membrane 
oligomerization and elucidate physical mechanisms by which BAX induces bilayer poration. 
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Fig. 1.1 
 
 
 
 
 
 
Fig. 1.1 | Sequence of BAX pore formation. Translocation to membranes, integration, 
and subsequent oligomerization.  
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1.2  | Vertebrate Apoptosis 
Apoptosis is the most prevalent form of programmed cell death in animals and is a 
tightly-regulated process used to sculpt tissue during development and is critical for 
maintaining homeostasis (1). First defined morphologically, apoptosis was characterized by cell 
shrinkage, membrane blebbing, chromatin condensation, and DNA fragmentation (2). 
Dysregulation of this death program manifests as a multitude of pathologies – insufficient 
ablation of aberrant cells can lead to cancer or autoimmunity whereas excess educes the likes of 
type I diabetes and neurodegeneration (3). 
The apoptotic process is a coordination of genetic and biochemical pathways, 
proximally effected by cysteine-aspartate proteases (i.e. caspases) which drive the demolition 
and packaging of dying cells for clearance (4). Caspases are produced as proenzymes and thus 
require activation to become catabolically competent. In vertebrates, caspase activation is 
elicited primarily by two pathways—the extrinsic and intrinsic (or mitochondrial) (Fig. 1.2). 
The extrinsic pathway promulgates death signals received via cell membrane death receptors 
like TNFR1 (tumor necrosis factor 1), Fas (APO1/CD95), and TRAILR1/2 (TNR-related 
apoptosis inducing ligand receptor 1/2) which are activated when engaged by their cognate 
death ligands outside the cell (1). Active receptors then assemble into a death-inducing 
signaling complex (DISC), resulting in activation of initiator caspases-8 and -10 which then 
cleave and activate effector caspases-3 and -7. 
The intrinsic apoptotic pathway is a complementary death signaling cascade that 
responds to genotoxicity, ER and oxidative stresses, and cytokine or growth factor deprivation. 
These signals converge at mitochondria, resulting in their outer membrane permeabilization 
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(MOMP) and egress of apoptogenic factors into the cytosol. MOMP occurs at an indefinite 
time after reception of a death signal due to varying intracellular concentrations of signaling 
molecules; caspase activation and apoptosis, however, usually ensue permeabilization within 
minutes (5). Foremost of the mitochondrial proapoptotic factors is cytochrome c, whose 
liberation from the intermembrane space allows it to bind inactive adapter protein Apaf-1 (6). 
Cytochrome c binding initiates the adapter’s conformational change and heptamerization into 
a complex termed the apoptosome which then recruits and activates caspase-9 for subsequent 
cleavage and activation of effector caspases-3 and -7 (7). MOMP also releases other 
proapoptotic factors such as Smac/DIABLO, AIF, HtrA2/Omi, and EndoG to further 
promulgate death signals (8,9). Notably, the extrinsic and intrinsic pathways operate largely in 
parallel but not without some intersection. Cells undergoing apoptosis induced by Fas are 
grouped into two categories: type I cells, such as lymphocytes, are effectively killed by the 
extrinsic pathways whereas type II cells, like pancreatic β–cells and hepatocytes, require 
amplification of the death signal via the intrinsic pathway (10). 
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Fig. 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2 | Convergence of intrinsic & extrinsic apoptosis pathways. Executioner 
caspases can be activated either directly by initiator caspases or through apoptosome 
assembly consequent of MOMP. The BCL2 family governs MOMP via complex balance of 
interactions between pro- and antideath members. Adapted from Y-L P. Ow et al. (2008) 
Nat Rev Mol Cell Biol 9, 532-542. 
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1.3 | The BCL2 Family 
The BCL2 protein family is the primary governor of mitochondrial outer membrane 
integrity; it comprises both anti- and proapoptotic members whose regulation and interactions 
dictates a cell’s commitment to survival or suicide (11) (Table 1.1). Membership in this family 
is largely assigned by conservation in four sequence-defined BCL2 homology (BH1-4) domains 
that control binding between members. The antiapoptotic members encompass all four BH 
domains and are typically localized to their active sites—mitochondrial outer membranes—but 
also may be cytosolic or affiliated with ER and nuclear membranes (12) (Fig. 1.3 & Table 1.1). 
BCL-2, BCL-XL, MCL-1, A1/BFL-1, & BCL-w constitute the predominant members of the 
class and antagonize MOMP via heterotypic binding of proapoptotic BCL2 proteins. The 
proapoptotic members are subdivided into multidomain effectors and BH3-only signaling 
proteins. BAX and BAK are the pore-forming effectors and include BH1-3 and a degenerate 
BH4 (13,14); counterintuitively, BAX/BAK share a similar tertiary fold with the antiapoptotic 
proteins despite their oppositional functions (15,16) (Fig. 1.4). While BAK constitutively 
affiliates with mitochondrial outer membranes, BAX resides largely in the cytosol or loosely 
associated with intracellular membranes (17-19). Following activation, BAX/BAK 
homodimerize and further assemble into multimeric complexes which elicit MOMP (20). As 
even healthy cells express both BAX and BAK abundantly, the two death proteins’ are 
neutralized until damage is recognized (21-23). 
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Table 1.1 | BCL2 family proteins (non-exhaustive compilation) 
 
 
 
 
Fig. 1.3 
 
 
 
 
 
 
 
 
Antiapoptotic 
(multidomain; BH1-4) 
 
 
Proapoptotic 
(multidomain; BH1-4) 
 
 
Proapoptotic 
(BH3-only) 
Direct 
Activator 
Sensitizer 
 
    BCL-2     BAX     BID X  
    BCL-XL     BAK     BIM X  
    MCL-1      PUMA X  
    A1      BAD  X 
    BCL-w      NOXA  X 
      BIK/BLK  X 
      BMF  X 
      HRK/DP5  X 
      Beclin-1  X 
      BNIP3/NIP3  X 
      BNIP3L/NIX  X 
Fig. 1.3 | Generalized schematic of BCL2 protein structure. Depicted are representations 
of 1° and 2° structures of multidomain (anti- & proapoptotic) and BH3-only proteins (top 
& bottom panels respectively). α-helices in blue indicate central, mostly hydrophobic 
hairpin and α-helices in red signify membrane anchors. 
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Fig. 1.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BAX (1F16) 
BCL-XL (1LXL; 
modified) 
BID (2BID) 
Fig. 1.4 | Ribbon representations of BAX, BCL-XL, & BID. Illustrated are representatives 
of pro- and antiapoptotic multidomain BCL2 proteins. BID also depicted to demonstrate 
structural homology; it is the lone BH3-only protein known to adopt a defined tertiary 
fold. Colors of domains correlate with Fig. 1.3: central hairpin (blue), membrane anchor 
(red), and BH3 domain (green). For BID, the N-terminal, solubilizing fragment is colored 
magenta. For BCL-XL, the C-terminus is homology-modeled based on BAX & BCL-w. 
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BH3-only proteins are the most diverse and least conserved of the BCL2 family, 
containing only the titular BH3 domain (24-26). These proteins integrate disparate cell stress 
pathways and are classified according to their multidomain BCL2 binding partners – 
sensitizer/derepressor BH3s antagonize only the antiapoptotic contingent while direct 
activator BH3s interact both with the antiapoptotics and trigger activation and 
multimerization of prodeath effectors BAX and BAK (27,28). The complex interaction 
network between the three classes of BCL2 proteins—antiapoptotic, BH3-only, and 
proapoptotic effectors—shifts the balance toward or away from MOMP and apoptosis. 
Distinct BH3-only proteins initialize the cell death program in response to a host of 
cellular insults, thus their activities are stringently regulated by transcriptional and post-
translational mechanisms. BH3s that are transcriptionally-upregulated include PUMA, BIK, & 
NOXA (by tumor suppressor p53) and BIM & BNIP3L (by FOXO3A) (29-33). 
Modifications like phosphorylation or proteolytic cleavage are also common—BID becomes 
active and translocates to mitochondria after cleavage by caspase-8, calpains, granzyme B, or 
cathepsin (34,35). BAD is activated by dephosphorylation in an Akt-dependent manner 
(36,37). BIM is further governed by multiple mechanisms: alternative splicing, 
phosphorylation, and sequestration away from mitochondria (38,39). RNA interference has 
recently emerged as a means for regulating BMF, PUMA, & BIM (40-42). 
1.4 | Two Schemes of BAX/BAK Activation 
The process by which BAX/BAK transition from inactive monomers to apoptotically-
proficient oligomers has been scrutinized for nearly 18 years since discovery of the first 
proapoptotic BCL2 family member, BCL-2 associated X protein (i.e. BAX) (43); subsequently, 
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BAX comrade-in-arms BAK (BCL-2 homologous antagonist/killer) was uncovered as another 
prodeath BCL2 member (44-46). Genetic knockout mouse models of bax-/- and bak-/- have 
shown the two to be largely compensatory but, when both ablated, indispensable for eliciting 
MOMP (22,23,47,48). With the discovery of BAX, BCL2 family governance of apoptosis (and 
MOMP) was initially proposed to be a rheostat, a simple ratio between BCL-2 and BAX that 
tilted cells from living to dying (43). This model was soon obviated by discoveries of multiple 
antiapoptotic, BCL-2-like proteins and the BH3-only protein subclass; genetic and biochemical 
evidence was marshaled in support of two succeeding models – the displacement and the direct 
activation schemes (28,49). The displacement model posits that BAX/BAK are intrinsically 
active and the proteins’ oligomerization must be continually repressed via sequestration by 
antiapoptotics to prevent MOMP. Upon death signaling, BH3-only proteins liberate 
BAX/BAK from inhibitory interactions thus allowing the prodeath effectors to 
homooligomerize and induce MOMP. Conversely, the direct activation model provides that 
BAX/BAK are intrinsically nonactive and require interaction with some activating molecule 
(typically a BH3-only protein) to trigger the prodeath effectors’ oligomerization. Accordingly, 
antiapoptotics sequester BH3-only proteins to preclude BAX/BAK activation and also bind 
BAX/BAK to prevent homooligomerization. The direct activation regime has since been 
further refined by the hierarchical and embedded-together schemes – the former defines three 
BAX/BAK direct activator BH3s (BID, BIM, & PUMA) with other BH3s serving to occupy 
the antiapoptotics and the latter integrating the protein conformational changes induced by 
membrane localization (27,50). 
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The origin of this rift in models of BCL2 function derives from conflicting evidence 
from differing experimental systems. A few lines of evidence support the displacement model 
(51): when first identified, overexpression of BAX and BAK resulted in mammalian cell death 
(43-45). Ectopic BAX expression in yeast, which have no endogenous BCL2 homologs, induces 
a lethal phenotype by abrogating mitochondrial respiration, an effect suppressible by co-
expression of BCL-2 or BCL-XL (52,53). Direct interactions of BH3-only proteins with 
BAX/BAK are difficult to detect via immunoprecipitation from cellular extracts and in vitro 
measures of BAX/BAK binding to BH3-only proteins or BH3 peptides reveal very weak 
affinities (54-56). Double knockout bid-/- bim-/- mouse models have unimpaired apoptosis and 
complementary cultured tissue experiments found that mutating antiapoptotics to prevent 
BAX/BAK incarceration are driven to apoptosis without stimulus (57,58). 
Despite these findings, the displacement model has been largely subverted by evidence 
from cell-free reconstitution and other biochemical/physical assays where components are 
tightly coordinated. BAX applied to synthetic vesicles requires an activator BH3 peptide or 
BH3-only protein to efficiently induce leakage (59-61). Employment of hydrocarbon-stapled 
BH3 peptides (to enforce α-helicity) allowed measurement of nanomolar BAX affinities for 
activator BH3s BID and BIM (56) and an engineered soluble BAK construct was found by 
NMR to weakly bind a BID BH3 peptide (15). Perhaps most convincingly conveying the direct 
activation model was discovery of FRET (Förster resonance energy transfer) between labeled 
BAX and tBID, but only when the two proteins were bound to vesicles (62). As in vivo 
validation of the direct activation paradigm, recent work demonstrated that a bid-/- bim-/- puma-
13 
 
/- triple knockout mouse model evoked a similar phenotype as the bax-/- bak-/- double knockout 
(63). Notable, however, was a disparity in embryonic lethality, with the TKO surviving 
postnatally with much greater success than the bax-/- bak-/- DKO, suggesting that while BID, 
BIM, and PUMA may provide the dominant activating function, BAX/BAK can become 
apoptotically proficient by other means. 
Indeed, the less severe lethality of bid-/- bim-/- puma-/- TKO is not unexpected as 
BAX/BAK activators beyond those three BH3-only proteins have been identified. Specifically, 
both changes in pH and mild heat can induce BAX/BAK activity (64-66). The tumor 
suppressor p53 can directly interact with and activate BAX & BAK (67,68) and prostaglandins 
were recently shown to activate BAX (69). Nonionic detergents drastically alter BCL2 protein 
structure and elicit a BAX conformation that porates vesicles and isolated mitochondria 
(70,71). A new report employing BH3 peptides found that while BID & BIM most potently 
activate BAX/BAK, BMF & NOXA could also mildly activate, while PUMA, BIK, & HRK 
weakly activated (and BAD was completely ineffective) (72).  In fact, the binary delineation 
between intrinsically active (on) vs. intrinsically inactive (off) may be artificial, as in vitro 
experimental regimes have shown a small degree of BAX/BAK activity on synthetic LUVs 
(which lack antiapoptotic defense mechanisms of mitochondria) in the absence of activators 
(72-75). 
1.5 | Structural Details of BCL2 Interactions 
During the first eight years of BCL2 study, the biochemical bases of their oppositional 
anti- and proapoptotic functions remained elusive. Clearly demonstrated, however, was that 
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homo-* and heterodimerization were decisive in the mortality decision and that BCL2 proteins 
localized to intracellular membranes, especially the mitochondrial outer membrane (76). BCL2 
governance of mitochondrial outer membrane integrity was significantly alluded to by a pair of 
1996 discoveries: 1) that egress of cytochrome c from the intermembrane space could induce 
apoptosis and 2) the elucidation of BCL-XL structure (77,78). BCL-XL was found to comprise a 
tertiary fold remarkably similar to those of bacterial pore-forming colicins A & E1 and 
diphtheria toxins—a central, mostly hydrophobic α-hairpin (α5-6) shielded from solution by 
six amphipathic α-helices. Research then coalesced around the premise that BCL2 proteins 
formed ion channels (79-82); subsequently, the liberation of cytochrome c was found to be a 
function of BAX and BAK and their homooligomerizations (83-87). 
* [An unfortunate early diversion in the BCL2 field was discovery of BCL-2 homodimers in cell extracts 
(43,88). It was not until five years later that non-ionic detergents were found to substantially alter the 
conformations of BCL2 proteins (71,89). Homodimerizations between full-length BCL-2 and BCL-XL 
isoforms were actually artifacts of extraction by non-ionic detergents (90). These detergents, like Triton 
X-100 or n-octylglucoside, destabilize the BCL2 core and induce eversion of their BH3 helices to allow 
homodimerization. These findings, however, pointed to the relevance of shortened forms of BCL-2, 
BCL-XL, and MCL-1, deleted of their stabilizing BH4 domains, that genuinely expose their BH3s to 
allow incarceration (91-94).]  
In addition to BCL-XL, the structures of antiapoptotic BCL-2, MCL-1, BCL-w, A1, & 
BCL-B, proapoptotic BAX & BAK, and BH3-only BID have been solved by x-ray 
crystallography and NMR (15,16,95-101). The multidomain proteins all share a conformation 
that is strikingly similar to that of BCL-XL; even BH3-only BID adopts an α-helical fold 
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reminiscent of the multidomain proteins. BID, however, is an outlier of its subclass, as other 
BH3-only proteins are intrinsically disordered in solution (102); BID requires proteolytic 
cleavage for activation which generates a carboxy-terminal p15 fragment that is α-helical but 
dynamically disordered when separated from its amino-terminal p7 fragment (103). 
For multidomain BCL2 proteins, the conserved BH domains 1-3 define a pocket on 
the protein surface that can accommodate an α-helix (Fig. 1.5). Solution structures of BAX and 
BCL-w (& BCL-XL) reveal that these proteins occlude this pocket with a hydrophobic C-
terminal α-helix that is common to all multidomain BCL2 members and can be utilized as a 
membrane anchor (16,104) (Yong Yao, personal communication). Whereas proapoptotic BAX 
is predominantly cytosolic, its co-executioner BAK obligately associates with mitochondrial 
outer membranes via its C-terminus where it is incarcerated by the mitochondrial porin 
VDAC2 (105). Localization to membranes via tail anchor is the typical means of targeting 
BH3-only proteins as well (106); BID again is an exception as it lacks a lengthy C-terminal 
helix but employs its hydrophobic central hairpin (α6-7) to target mitochondria (107).  
The hydrophobic pocket bounded at one end by BH1-2 (&3) of BCL-2 was initially 
identified by mutational analyses as being required for homodimerization and 
heterodimerization with BAX (88). A year later, BAX/BAK BH3 domains were revealed to be 
necessities for their homodimerizations and sequestration by antiapoptotic proteins (108,109). 
Solution of the BCL-XL structure led to speculation that the pocket formed by BH1-3 (and α3-
4) could act as an acceptor surface for another BH3 domain (78). This hypothesis was 
confirmed biochemically by the discovery of BH3-only BID, whose incarceration by BCL-2 was 
uncovered to be dependent on BID BH3 and the BCL-2 BH1-3 pocket (26), and structurally 
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by NMR of BCL-XL bound to an α-helical BAK BH3 peptide (110) (Fig. 1.6). To date, all the 
major antiapoptotic BCL2 proteins have been structurally resolved, as monomers or complexed 
with pocket-bound BH3 peptides. 
A number of studies have undertaken quantification of antiapoptotic/BH3 peptide 
affinities and have established that antiapoptotic BCL2 proteins promiscuously bind BH3s but 
with varying proclivities (101,111,112). For example, BAD is sequestered by BCL-2, BCL-XL, 
and BCL-w while NOXA is restrained only by MCL-1 and A1. Nevertheless, all antiapoptotics 
tightly incarcerate direct activator BH3s BID, BIM, & PUMA as well as BH3s from BAX & 
BAK (111). 
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Fig. 1.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BAX 
(1F16) 
Fig. 1.5 | BAX BH domains. Connolly surface representations of BAX with BH domains 
colored as in Fig. 1.3: BH1 (orange), BH2 (blue), BH3 (green), BH4 (purple). Top panel 
shows BAX canonical BH3 binding groove, bounded partly by BH1-3 & occluded by its C-
terminal (α9) membrane anchor. Bottom panel depicts fold-stabilizing (α1) BH4 helix. 
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Fig. 1.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.6 | Connolly surface representations of BAX & BCL-XLΔC/BAX BH3 complex. BAX 
(top) in solution occludes its canonical BH3 binding pocket with a C-terminal membrane 
anchor (red). BCL-XLΔC (bottom) sequestering a BAX BH3 peptide. Helices are colored 
similar to Fig. 1.3. Surface residues are pigmented: polar (grey), nonpolar (yellow), acidic 
(red), basic (blue). 
BAX 
(1F16) 
BCL-XLΔC/BAX BH3 
(3PL7) 
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The BH4 region, identified last and least conserved sequentially, embodies the first α-
helix of the BCL2 core and is structurally distant from the hydrophobic pocket defined by 
BH1-3 (113,114) (Fig. 1.5). BH4, however, acts to stabilize the overall fold of the proteins 
(78,97,115). When the BH4 domain is proteolytically-cleaved from BCL-2, the protein 
reverses its anti-death role and becomes proapoptotic (116). Nuclear receptor Nur77 has been 
shown to bind BCL-2; this interaction triggers BH4 disengagement, BH3 eversion, and allows 
heterodimerization with BCL-XL (93,94). BCL-XS and MCL-1S, uncommon splicing 
variants which delete BH1 & 2, heterodimerize with and antagonize full-length BCL-XL and 
MCL-1 respectively (91,92). Proteolytic removal of BH4 from proapoptotic BAX has also been 
suggested to render the protein non-functional as a pore-former but retains antagonism of 
antiapoptotics (117). In neurons, BAK can be regulated by mRNA splicing, resulting in a 
protein that lacks BH1 & 2 and functions like a BH3-only signaler (118). These findings 
collectively uncover that multidomain BCL2 members can be transmuted into prodeath, BH3-
only-like proteins by post-transcriptional and -translational mechanisms. Their relevance in 
cellular mortality decisions, however, is not well-plumbed. 
What is clear is that BAX & BAK activation to pore competence encompasses multiple 
conformational intermediates (Fig. 1.1; detailed further in Appendix I). For instance, BAX 
targeting to membranes is consequential of exposure of the C-terminal α9 helix and this 
exposure correlates to eversion of the N-terminal α1 (119,120). The two pore-forming effectors 
evict their BH3 helices, normally packed against α5.6, for homodimerization or sequestration 
by antiapoptotic proteins (75,110,111,121) (Fig. 1.6). These rearrangements result in 
membrane insertion of the α5-6 hairpin to disrupt bilayer integrity (73,122,123). 
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CHAPTER 2 
 
Cholesterol Effects on BAX Pore Activation 
 
 
(The content of this chapter has been adapted from Christenson E., Merlin, S., Saito, M., 
Schlesinger, P. (2008) J Mol Biol 381, 1168-1183) 
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2.1 | Summary 
The importance of BCL2 family proteins in the control of cell death has been clearly 
established. One of the key members of this family, BAX, has soluble, membrane-bound, and 
membrane-integrated forms that are central to the regulation of apoptosis. Using purified 
monomeric human BAX, defined liposomes, and isolated human mitochondria, we have 
characterized the soluble to membrane transition and pore formation by this protein. For the 
purified protein, activation, but not oligomerization, is required for membrane binding. The 
transition to the membrane environment includes a binding step that is reversible and distinct 
from the membrane integration step. Oligomerization and pore activation occur after the 
membrane integration. In cells, BAX targets several intracellular membranes but notably does 
not target the plasma membrane while initiating apoptosis. When cholesterol was added to 
either the liposome bilayer or mitochondrial membranes, we observed increased binding but 
markedly reduced integration of BAX into both membranes. This cholesterol inhibition of 
membrane integration accounts for the reduction of BAX pore activation in liposomes and 
mitochondrial membranes. Our results indicate that the presence of cholesterol in membranes 
inhibits the pore-forming activity of BAX by reducing the ability of BAX to transition from a 
membrane-associated protein to a membrane-integral protein. 
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2.2 | Introduction 
Genetically programmed apoptotic cell death occurs in all multicellular organisms (1). 
Control of the death decision prominently involves a three-part regulatory ensemble of 
proteins, the BCL2 family (2). Twenty-five genes comprise this family and they generate three 
functional classes of proteins: proapoptotic and antiapoptotic actors with a supporting cast of 
BH3-only proteins that modulate their interaction (3,4). To function as the apoptotic decision 
agent, these proteins collaborate to form a gateway, “pore”, in the outer mitochondrial 
membrane (OMM) (5-7). The formation of this pore requires the availability of active and 
uninhibited BAK or BAX in the OMM (8). BAX and many of the other proteins are soluble 
and move to the mitochondrial outer membrane in concert with the death signaling (9,10). 
Others have demonstrated the formation of BAX homo-oligomers in mitochondria and 
inferred a correlation with a mortality decision in the OMM (11-14). However, the nature of 
the BCL2 family protein interactions while in membranes is not clear. Furthermore, the 
molecular events and environmental conditions that trigger BAX transformation to an active 
state have remained elusive. Recent studies have indicated that suppression of BAX inhibition 
is critical in the mortality decision (15-17). While it is possible that negative regulation is a 
dominant theme in apoptosis, this gives no explanation of the mechanism by which BAX 
becomes situated in the OMMs and is availed of the negative regulation. Furthermore, if the 
regulation is entirely negative by antiapoptotic BCL2 family members in the OMM, then the 
escape of the remaining and vastly larger membrane surface of the cell from BAX predation is a 
mystery. 
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Both pore-forming and regulatory interactions of BCL2 family proteins occur at the 
mitochondrial outer membrane. Previously, we have shown that one proapoptotic protein, 
genetically engineered active BAX (BAXΔC), can form large pores in planar lipid bilayers (18). 
Subsequently, we characterized these pores in defined liposomes as consisting of dimers and 
tetramers of BAXΔC. The tetrameric pore was able to accommodate cytochrome c for release 
from the liposome (19). From the kinetics of pore activation upon addition of soluble 
monomeric BAXΔC, we concluded that the oligomerization into pores occurred after 
membrane insertion and postulated that it would be dependent upon the membrane 
environment. Therefore, we have undertaken studies to explore the role of membrane lipids on 
BCL2 family protein pore activation. 
In these studies, we have determined the BAXΔC pore activation in the presence of 
cholesterol and the enantiomer of cholesterol (20). Cholesterol is necessary for membrane 
function in eukaryotic cells, but the chemical and physical basis for the cholesterol requirement 
remains unclear (21). Cholesterol is synthesized in the endoplasmic reticulum and is 
internalized with the plasma membrane and by receptor-mediated endocytosis. From both the 
endoplasmic reticulum and the late endosomal pathway, cholesterol enters other compartments 
of the cell (22). In steroidogenic tissues, for example, adrenal and placenta, hormone 
production is initiated by side-chain cleavage in the mitochondrial matrix (23,24). In other 
cells, mitochondrial cholesterol oxidation occurs at lower rates but can become pathogenic 
when the cells are cholesterol overloaded (25). When cholesterol is taken up by mitochondria, 
it first resides in the OMM and is then transferred through the contact sites using the 
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peripheral benzodiazepine receptor to the matrix for oxidation (26,27). It has been suggested 
that movement of cholesterol from the OMM to the inner mitochondrial membrane, where 
oxidation occurs, is facilitated by a cholesterol recognition/ interaction amino acid consensus 
motif that is observed in the peripheral benzodiazepine receptor (28). In mammalian cells, the 
plasma membrane has the highest cholesterol content but significant cholesterol, oxysterols, 
and bile acids are found in the mitochondria because of the matrix oxidative production of 
these steroids (29,30). Cholesterol has been reported to be elevated in cultured tumor cells 
(31,32). Recently, bilayer cholesterol content has been shown to influence BAX 
oligomerization and trypsin resistance in liposomes and mitochondria (33). Others have 
reported complex relationships among lipids, cholesterol, BAX, and permeability transition 
pore activation (34). These observations have been used to explain the effects of cholesterol 
upon cellular apoptosis. We have studied the effect of cholesterol on BAX pore formation in 
liposomes and mitochondria and conclude that the cholesterol content of the plasma 
membrane protects it from the pore formation when BAX is activated. In particular, the 
addition of cholesterol to the outer membrane of mitochondria inhibits pore formation by 
BAX. We discuss the mechanism of cholesterol inhibition of BAX pore activation in terms of 
membrane binding and integration and speculate on how this might influence apoptosis in 
mammalian cells. 
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2.3 | Results 
Although the BCL2 family proteins are clearly the arbiters of a mortality decision, the 
biochemical steps that conclude in the mitochondrial death decision are not yet clear. We have 
pursued a reconstitution methodology to study these phenomena in order to clearly define the 
biochemical and biophysical processes in the reaction steps leading to the initiation of 
apoptosis. Initially, these studies revealed that a carboxy-terminally truncated form of active 
BAX, BAXΔC, could form a cytochrome c competent pore in liposomes (19). Hill analysis 
revealed that in liposomes, active BAXΔC inserted into the membrane as a monomer, formed a 
functioning pore as a dimer, and displayed a concentration-dependent progression to a tetramer 
complex that transferred cytochrome c out of the liposomes. We are revisiting this method of 
analysis in order to study the effects of lipid environment on BAX membrane integration and 
pore formation. 
Human BAX expression, purification, and studies of pore activation 
Native BAX in mammalian cells is a soluble protein that must be activated to induce 
apoptosis (3,35). This protein can be activated in vitro in several ways. In this study, we have 
used a genetically-engineered form of active human BAX, BAXΔC, which has a portion of the α-
helix 9 removed. In 0.1% n-octylglucoside, this form of human BAXΔC is monomeric with a 
molecular weight of 19,000 ± 1200 Da as determined by dynamic light scattering and SDS-
PAGE (Fig. 2.1A). In these studies, we used the human BAXΔC because we would employ 
human mitochondria to study pore formation in these organelles. The pore activation and 
stoichiometry of human BAXΔC have not been previously reported. The human and mouse 
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BAX proteins are very similar in sequence but arginine 64 in the critical BH3 region is replaced 
with a lysine. In addition, there is a rearrangement of the prolines adjacent to the first α-helix 
(residues 46–53). Proteolytic cleavage and phosphorylation in this region of BAX influence the 
mitochondrial translocation and pore formation (36,37). 
We concluded that confirmation of a similar mechanism of pore formation by the 
human protein was warranted. Using liposomes loaded with carboxyfluorescein (CF) at 
quenching concentrations, we studied the activation of pores by human BAXΔC (Fig. 2.1B). 
The time-series data normalized to the total dequenching for each preparation of liposomes are 
an exponential release. This is consistent with a single pore producing full dequenching from a 
liposome and the exponential time course representing pore activation in the liposomes. The 
measured time constants were used in a Hill analysis of the human BAXΔC pore activation (Fig. 
2.1C). The concentration dependence of human BAXΔC activation in liposomes indicates a 
pore activation stoichiometry of 2 and 4, similar to the previously published model for the 
murine protein (19).  
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A B 
Fig. 2.1 | Human BAXΔC pore-forming activity in liposomes. Using human BAXΔC, we 
studied the kinetics of pore activation in liposomes by the purified protein. The liposome 
assay was done as previously described (19). A, Preparation of human BAXΔC expressed 
and purified as described in Materials and Methods and run on SDS-PAGE gel to 
demonstrate size and purity. B, Time-series examples of human BAXΔC pore activation as 
added protein concentration is increased. Using the time-series data curve fitting to an 
exponential function, we determined the time constant and the extent of release. C, The 
time constants determined from the time series and concentration dependence of pore 
activation were subjected to Hill analysis. Each plotted point represents the average of 
two to three determinations with standard deviations shown when they were bigger 
than the symbol. The data were fitted to a polynomial using the Levenberg–Marquardt 
algorithm. The slope of the fitted line was determined at each point and is plotted in the 
inset graph. 
C 
Fig. 2.1 
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Mitochondrial preparation for the study of OMM permeability 
The permeability of the OMM is a key factor in the apoptosis death decision (38). 
These studies have used HeLa cell mitochondria and human BAX protein. We have adapted 
the fusion of liposomes with purified mitochondria to create a preparation for the study of 
OMM permeability (39,40). The unfused liposomes were removed by low-speed pelleting of 
the resulting mitochondria. The fused mitochondria (fM) have a normal double-membrane 
morphology (Fig. 2.2A). The captured CF produced photoconversion of diaminobenzidine 
and electron-dense deposition in the intermembrane space (Fig. 2.2A, photoconverted). CF-
containing mitochondria and liposomes were identified by this method, but the insoluble 
photoconversion product obscures the membranes (41,42). 
Cytochrome c-dependent oxygen consumption can be used to evaluate the continuity 
of the OMM (43). When our preparation was studied using a Clark electrode to determine site 
IV-dependent oxygen consumption in the presence of saturating substrate and oxygen, they 
consumed 43.1 ± 0.4 nAtom mg−1 min−1, which is similar to that of rat liver mitochondria 
(48.5 ± 0.4 nAtom mg−1 min−1) but less than that of skeletal muscle or kidney mitochondria 
(44). This rate of oxygen uptake suggests that in the preparation, the OMM is intact and 
cytochrome c is retained within the intermembrane space. Using the membrane-active peptide 
melittin, we interrupted the uptake of oxygen by the mitochondria as shown in Fig. 2.2B. This 
reduction is reversed by the addition of 100 μM horse cytochrome c to the electrode chamber. 
The oxygen consumption in these preparations is dependent upon ADP and phosphate and is 
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sensitive to azide. We conclude that our isolated mitochondria have an intact OMM and that 
cytochrome c is retained during the isolation procedure. 
Ca2+ dependence of fM permeability 
The fM preparation was performed in media containing ethylene glycol bis(β-
aminoethyl ether)N,N′-tetraacetic acid (EGTA) so that Ca2+ concentration is less than 10 nM. 
At this low calcium concentration, the CF is retained within the OMM barrier. Increasing the 
media calcium to 100 or 200 μM initiated rapid dequenching of the CF from the 
intermembrane space (Fig. 2.2C). Dequenching is normalized to the maximum dequenching 
produced by 1% Triton X-100. The dequenching is rapid and dependent upon calcium 
concentration and is consistent with activation of the voltage-dependent anion-selective 
channel (VDAC) of the OMM (45). 
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Fig. 2.2 
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Fig. 2.2 | Studies on isolated mitochondria after fusion with CF liposomes. A, 
Mitochondria were prepared and fused with 200 nm liposomes containing 20 mM CF as 
described in Materials and Methods. These mitochondria were then pelleted, fixed, and 
embedded for sectioning and electron microscopy. In all cases, the mitochondria have a 
traditional two-membrane morphology after fusion with liposomes. Exposure of the 
isolated mitochondria to UV light photoconverted the CF and photooxidized 
diaminobenzidine, producing the electron-dense depositions in the intermembrane 
space. Two large unilamellar liposomes that were used in the fusion loading of the 
mitochondria are seen on the right. The upper liposome was photoconverted and the 
lower one was not exposed to UV light (see Materials and Methods). B, After isolation 
and fusion with liposomes containing CF, the mitochondrial suspension was diluted to 1 
mg/mL protein and O2 consumption was measured. At the first arrow, 10 mM ascorbate 
and TMPD were added, initiating rapid O2 uptake that was dependent upon cytochrome 
c and cytochrome oxidase; at the second arrow, 200 nM melittin was added; at the third 
arrow, 100 μM horse cytochrome c was added. C, Mitochondria were isolated and fused 
with liposomes as described in Materials and Methods in the presence of 1 mM EGTA. 
Subsequently, the washed mitochondrial suspension was diluted 1:100 into the assay 
buffer or buffer added with 100 or 200 μM CaCl2 (from bottom to top), and fluorescence 
dequenching followed for the indicated times. All dequenching values were normalized 
to the 1% Triton X-100-initiated dequenching. 
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Presence of porin-like channel activity in the mitochondrial preparation 
The release of anionic CF by Ca2+ elevation suggests that VDAC is present but in a low 
conductance state in our fM preparation (45). We have directly assessed the channel activity of 
the fM in planar lipid bilayers. Using our preparation of mitochondria that was post-liposome 
fusion, we allowed these to interact with a planar lipid bilayer. After addition of the fM to the 
cis bilayer chamber, fusion transients were observed within 5 min. of continuous stirring. After 
fusions had occurred, the resulting bilayer currents were studied using a ± 60-mV voltage ramp 
or by voltage steps under voltage clamp (Fig. 2.3A and 2.3B). The ramp current pattern was 
typical of many studies of VDAC currents in mitochondrial membrane preparations or 
reconstituted VDAC protein (46,47). The conductance of these currents was decreased when 
the Ca2+ was reduced with EGTA, consistent with the reported calcium-dependent shift of 
VDAC to a low conductance channel (45,48) (Fig. 2.3C). The fM currents also displayed 
voltage-dependent inactivation as described for the VDACs (49). 
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Fig. 2.3 | Channel activity in membranes of liposome–fused mitchondria. A, Isolated, 
liposome–fM from cultured HeLa cells were studied in planar lipid bilayers as described 
in Materials and Methods. Mitochondria were added to the cis chamber of a planar lipid 
bilayer cuvette with a 450- to 150-mM KCl from the cis to trans chambers. After 3–7 
min., current levels stabilized and the cis solution was perfused to 150 mM KCl. Using 
voltage clamp configuration, command ramps (lower panel) were applied to the bilayer 
after fusion events were observed. B, Using buffer containing 100 μM CaCl2 ± 100 μM 
EGTA, we studied the stable voltage dependence of fM. Data were obtained by holding 
the indicated membrane potential for 10 s and using the average current of the final 2 s. 
EGTA (100 μM) was added to the cis chamber, and after 5 min., the voltage dependence 
was determined again. The high-calcium perfusion, voltage dependence, EGTA addition, 
and voltage dependence redetermination were repeated until the bilayer membrane 
collapsed (three cycles). These were averaged for this panel, and the standard deviation 
at each point is shown in the figure. C, Bilayer conductance was calculated from voltage 
ramps (± 60 mV) collected at 1.67 kHz with a 1.2 s duration for each ramp. The bilayers 
were formed and Ca2+ concentration was adjusted as described in (A). The currents were 
normalized to a peak conductance of 1 for comparison. 
B 
C 
A 
Fig 2.3 
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BAXΔC pore activation in the OMM 
Isolated mitochondria used in these studies were loaded with CF by pH-dependent 
fusion of liposomes with the OMM as described in Experimental Procedures. This fusion-
mediated transfer effectively loads the mitochondria intermembrane space with CF but at 
reduced concentration from that present in the liposomes. Therefore, the dequenching 
response of the mitochondria per mole of lipid is less than that of the primary liposomes. 
Consequently, in the assay of BAX pore activation using the fM, we have increased the 
concentration of mitochondria lipid to 4.3 μM, which compensated for the reduced 
dequenching from the fM preparation. The application of BAXΔC to this mitochondrial 
preparation produces a rapid time course of CF dequenching. As shown in Fig. 2.4A, the 
kinetics and concentration dependence of BAXΔC-initiated dequenching from mitochondria 
are qualitatively consistent with that observed in defined liposomes. There is a distinct 
difference between specific activity of BAXΔC pore formation in mitochondria and liposomes. 
The higher activity of BAX in liposomes can be compensated by correcting for the difference in 
lipid content in the assay (Fig. 2.4B). After this adjustment of the rate of pore activation for the 
increased lipid in the mitochondrial assay, the Hill analysis for pore formation in mitochondria 
closely resembles what we have observed in liposomes (Fig. 2.4C). Because of the additional 
lipid in the mitochondrial assay, the lowest BAXΔC concentrations (≈ 1 nM) do not generate 
sufficient activity for accurate analysis. 
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B 
Fig. 2.4 | BAXΔC pore activation in isolated mitochondria. Mitochondria were isolated 
from cultured HeLa cells and fused with liposomes using a modification of a previously 
described technique as described in Materials and Methods. A, Mitochondria were 
diluted into a 500 μL assay volume to give a protein concentration of 0.3 mg/mL and a 
phospholipid concentration of 4.3 μM. The fractional dequenching was fitted to an 
exponential model in order to determine the time constant (τ) for analysis of the kinetics 
of BAX pore activation. B, Comparison of the rate of BAXΔC pore activation in 
mitochondria (up triangle, open) and liposomes (circle, open). Both sets of data are fitted 
by Hill functions (black and gray lines, respectively). The rate of pore activation in 
mitochondria was then normalized for the increased lipid in this assay and then was 
fitted by the dotted black line. The normalized pore activation data points are not shown 
in this panel. C, The pore activation time constants that have been normalized for lipid 
concentration are plotted in the standard logarithmic form for Hill analysis. The data 
were fitted as in Fig. 2.1, and the fitted curve was plotted in black. The liposome fitted 
line is shown in gray for comparison. 
A 
C 
Fig. 2.4 
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Effect of cholesterol on BAX pore activation in defined liposomes 
BAX is found in the cytosol of most eukaryotic cells, but when activated in response to 
proapoptotic stimuli, it becomes integrated into the mitochondrial outer membrane and the 
endoplasmic reticulum (50). Because the membranes in which BAX integrates in vivo have less 
cholesterol than the plasma membrane, we have studied the effect of this sterol on interaction 
of BAX with membranes. 
Cholesterol-containing liposomes were prepared and characterized as described in 
Experimental Procedures. The final cholesterol concentration in the liposomes was 20 mol%, 
and the size of the liposomes was verified by dynamic light scattering. The effect of the 
cholesterol was to dramatically decrease the BAXΔC pore activation (Fig. 2.5A and B). As a 
consequence, τ values (time constants) were large as was the error in their determination. From 
these data, we could analyze the Hill plot but not the pore size. Here, we have succeeded in 
extending the Hill analysis to low enough BAX concentrations that we can discern the 
curvature in spite of the greater error in the measurements of the time constant. When we plot 
the time constants, the effect of cholesterol is dramatic and increases at lower BAX 
concentrations (Fig. 2.5C). 
The sterol-mediated inhibition of BAXΔC pore formation could be due to a direct and 
stereospecific interaction between steroids and the BAX protein. To test this, we prepared 
liposomes using the enantiomer of cholesterol. This analog of cholesterol has the configuration 
inverted at each asymmetric site in the cholesterol molecule (20). This compound was a 
generous gift from Dr. D. Covey of the Department of Developmental Biology, Washington 
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University School of Medicine. The comparison of pore activation in liposomes containing nat-
cholesterol (natural enantiomer of cholesterol) or ent-cholesterol (full enantiomer of 
cholesterol) indicates that the enantiomer is as effective as the natural compound at the 
inhibition of BAX pore activation (Fig. 2.5D). This suggested that the effect resulted primarily 
from cholesterol condensing and other effects upon the lipid membrane environment and not 
from a stereospecific interaction with BAX (51-53). 
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Fig. 2.5 | BAX pore activation and binding in liposomes ± cholesterol. Liposomes 
containing cholesterol were prepared as described in Materials and Methods. A, Selected 
examples of time-series dequenching by human BAXΔC in DOPC:DOPA:C (mole fraction, 
0.59:0.21:0.20) liposomes. Fractional dequenching was computed by comparison with 
Triton X-100 dequenching. B, Hill analysis of the human BAXΔC pore activation in 
DOPC:DOPA:C liposomes. Each determination of the time constant is shown with the 
standard deviation error bars (n ≥ 3). The series of time constants was fitted to a 
polynomial, and the slope of the fitted line is determined and presented in the inset plot. 
Also shown is the fitting from Fig. 2.1C in DOPC:DOPA liposomes, indicated by the dotted 
line. C, Comparison of the concentration dependence of the time constant for pore 
activation in DOPC:DOPA (up triangle, open) and DOPC:DOPA:C (diamond, filled) 
liposomes. Each of the determinations is shown with standard deviation (n ≥ 3). Dotted 
lines are the nonlinear least-squares fitting of the time constants to the Hill equation. D, 
Comparison of BAX pore activation in liposomes composed of DOPC:DOPA:C (up triangle, 
open) and DOPC:DOPA:ent-C (mole fraction, 0.59:0.21:0.20) (circle, open). Each of the 
determinations is shown with standard deviation (n ≥ 3). Dotted lines are the nonlinear 
least-squares fitting of the time constants to the Hill equation. E, Defined liposomes were 
suspended in 200 nM BAXΔC and incubated for 10 min. at room temperature. As 
indicated in the figure, the liposomes were ± cholesterol. The liposomes were 
sedimented at 150,000 × g as described in Materials and Methods to give the pellet (P) 
and alkaline extraction (AE) or supernatant (S). Each sample was separated by SDS-PAGE 
with silver staining. The region at 19–20 kDa of the gel was analyzed for density, and the 
percent distribution of the protein in each fraction was calculated for the figure. 
46 
 
Effect of cholesterol on BAX pore activation in mitochondria 
The inhibition of BAXΔC pore activation by the inclusion of cholesterol in the liposome 
membrane composition is dramatic. The simple composition of our liposomes might 
contribute to this inhibition and generate an artificially large inhibition that will not be seen in 
a more complicated membrane. We wanted to test the effect of cholesterol in a physiologic 
membrane in which we could alter the composition in a known fashion. Our fM fulfilled these 
requirements. The native mitochondria supported BAXΔC pore formation well, and by fusing 
them with dioleoylphosphatidylcholine (DOPC)/dioleoylphosphatidic acid (DOPA)/C 
liposomes, we could increase the cholesterol content of the OMM to at least 16 mol% during 
the fusion step. It has previously been shown that the cholesterol of the OMM is slowly 
metabolized in isolated mitochondria, indicating that the elevated cholesterol was maintained 
during our experiments (23). The addition of cholesterol to OMM produced a substantial 
inhibition of the pore activation (Fig. 2.6). However, this reduced the BAXΔC activity to such 
an extent that it was not possible for us to characterize the effects on oligomerization and pore 
size. 
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Fig. 2.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.6 | Inhibition of BAX∆C pore activation by sterols in mitochondria. The effect of 
cholesterol on BAX pore activation in isolated mitochondria fused with liposomes 
containing 20 mol% cholesterol. Pore activation in these mitochondria (circles, open) was 
greatly reduced compared to mitochondria fused with DOPC:DOPA liposomes (down 
triangle, open). Mitochondria were also fused with liposomes prepared using the 
enantiomer of cholesterol (up triangle, open). The dotted lines are the results of 
nonlinear least-squares fitting of the time constants for pore activation in mitochondria 
fused to liposomes and cholesterol liposomes. Time constants of pore activation in 
mitochondria fused with liposomes prepared with the enantiomer of cholesterol are not 
fitted. 
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BAX interaction with liposome membranes 
BAX pore formation requires the translocation of the soluble BAX protein to a bilayer 
membrane. This step is critical in vivo and is thought to be a consequence of BAX activation in 
cells (37,54,55). The mechanism of the membrane translocation of BAX must progress along a 
binding followed by an integration model (56). The progress of translocation will be influenced 
by contributions from both the protein structure and the membrane environment. The 
interaction of BAX with membranes can be clearly shown in a defined liposome experimental 
system (Fig. 2.5E). Furthermore, the effect of cholesterol appears to be a reduction of 
membrane-incorporated BAX protein. We have extended the use of defined liposomes to the 
study of BAX membrane translocation by employing surface plasmon resonance. In this 
approach, defined liposomes were supported at the sensor surface using the hydrophobic chips 
(L1) from the Biacore Corporation (57). With the use of these immobilized liposomes, it was 
possible to study the interaction of BAXΔC with the liposome bilayer membrane in 
concentration- and time-dependent experiments. 
For three preparations of activated BAXΔC, the concentration dependence and time 
course of binding and membrane integration were determined and averaged (Fig. 2.7A). The 
membrane-associated BAX populations were characterized by total binding to supported 
liposome membranes at the end of the injection period (60 s) and the mean stable bound 
protein after an extended wash period (300–350 s). These populations were determined and 
are plotted in Fig. 2.7B as the average of the individual trials along with the fitted lines. The 
total BAX membrane binding at 60 s was tested against one- and two-state interaction models. 
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A χ2 analysis indicated a two-state model to be preferable with residuals that were reduced 10-
fold. The resulting high- and low-affinity estimates for membrane binding are listed in Table 
2.1. The concentration dependence of BAX integration into the liposome membrane was 
clearly dominated by a single interaction, and the results of that analysis are also presented in 
Table 2.1. From this analysis of the binding and integration curves, the size of the membrane 
populations of BAX was estimated and is presented as mole fractions to correct for small 
changes in liposome immobilization on the Biacore chip. Inspection of these fitted results for 
membrane association reveals three populations of membrane-associated BAX: high- and low-
affinity populations that rapidly dissociate and the membrane-integrated fraction that slowly 
dissociates. The ratio of total membrane-bound to membrane-integrated BAX increases at low 
BAX concentrations and then begins to fall as membrane capacity becomes saturated (Fig. 
2.7C). 
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Fig. 2.7 
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Fig. 2.7 | BAX∆C binding to supported DOPC/DOPA liposomes. The binding and 
membrane integration of BAX∆C were studied by surface plasmon resonance using 
supported liposomes. A, BAX∆C was injected over an L1 chip covered with immobilized 
DOPC/DOPA (74:26 mol%) liposomes as described in Materials and Methods. This 
protein was prepared as described above without the use of detergent. Prior to exposure 
of the BAX∆C to detergent, the protein did not bind to the liposomes as shown by the 
open circles (○ ○ ○) at the bottom of the graph that indicate the averaged RU response 
for the 25–3000 nM BAX∆C concentration range. After treatment with detergent, the RU 
response for the following concentrations is shown: 25.8 nM (solid), 51.7 nM (dash), 
103.7 nM (dot), 207 nM (dash–dot), 414 nM (dash–dot–dot), 828 nM (short dash). The 
injection phase is indicated by the solid line and the wash phase is denoted by the 
dashed line at the top of the graph. B, Comparison of membrane-associated (□) and 
membrane-integrated (○) protein using the criteria described in the text and calculating 
the average values and standard deviation as described in Materials and Methods. The 
dotted lines represent the best fit to an interaction model as described in the text. C, The 
ratio of binding and integration fraction of protein plotted as the added concentration of 
BAX∆C is increased. Means and standard deviations are computed as described in 
Materials and Methods. 
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Table 2.1 | Analysis of BAX∆C membrane interaction 
Type of membrane 
interactiona 
K1 (M) BAX 
(mole fraction)b 
K2 (M) BAX  
(mole fraction)b 
DOPC:DOPA     
    Membrane binding 2.2 ± 0.4 × 10-6 5.9 ± 0.7 × 10-3 1.37 ± 0.45 × 10-8 0.78 ± 0.31 × 10-3 
    Membrane integration   2.5 ± 0.27 × 10-7 1.8 ± 0.07 × 10-3 
     
DOPC:DOPA:C     
    Membrane binding 1.6 ± 1.2 × 10-6 8.6 ± 4.2 × 10-3 1.4 ± 0.46 × 10-8 1.2 ± 0.2 × 10-3 
    Membrane integration   1.06 ± 0.22 × 10-8 0.86 ± 0.3 × 10-3 
 
a  As described in the text, the BAX membrane populations were identified by binding and integration with 
the membrane. 
b  We have used mole fraction to represent membrane-associated BAX populations to allow a direct 
comparison between experiments as a membrane concentration (58). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
BAX interaction with liposome membranes containing cholesterol 
In cells, BAX pores are described in the OMM but pores in other membranes have not 
been noted. Specifically, pores in the plasma membrane produce osmotic lysis and necrosis 
(59,60). The osmotic lysis of cells would be inconsistent with the apoptotic program of cells, 
and the molecular basis for this membrane selectivity is important to explaining the physiology 
of cell death. One of the distinctions between intracellular membranes and the plasma 
membrane is the high cholesterol composition of the plasma membrane in most cells. Using 
cholesterol-containing liposomes and mitochondria, we and others observed reduced BAX pore 
activation (33). In the preceding section, we have shown that BAXΔC interaction with 
membranes involves a rapid but reversible binding to the membrane followed by integration 
into the membrane, resulting in a very slow dissociation of the integrated protein population 
from the bilayer. Using surface plasmon resonance, we investigated the effect of cholesterol on 
the liposome binding and integration of BAX. 
The cholesterol-containing liposomes loaded onto the L1 chip similarly to the 
DOPC:DOPA liposomes and blocked albumin access to the chip surface (see Experimental 
Procedures). The interaction of human BAXΔC with liposome membranes containing 
cholesterol is shown in Fig. 2.8. As with the DOPC:DOPA liposomes, detergent activation of 
human BAXΔC was required for significant interaction with the cholesterol-containing 
membranes. For three preparations of activated BAXΔC, the concentration dependence of 
binding and membrane integration were determined and averaged (Fig. 2.8A). Visual 
inspection of BAXΔC interaction with DOPC:DOPA:C liposomes indicated that it was 
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distinct from the BAXΔC interaction with DOPC:DOPA liposomes. The initial membrane 
association was still rapid and larger for the cholesterol-containing membranes. Paradoxically, 
from this larger pool of membrane-associated BAX, the membrane integration was reduced 
(Fig. 2.8B). Analysis of the concentration-dependent membrane association once again 
demonstrated both low- and high-affinity binding populations as shown in Table 1. The 
binding pools were approximately 60% larger than those in the DOPC:DOPA liposomes. In 
spite of this, the integrated fraction was significantly reduced and reached a maximum value 
that was 58% of that seen in the liposomes without cholesterol. In addition, the ratio of 
membrane-integrated to membrane-associated BAX demonstrated a very distinct 
concentration dependence in that there was no increase of the integrated fraction at low 
concentrations of added BAX (Fig. 2.8C). 
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Fig. 2.8 
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Fig. 2.8 | BAXΔC binding to supported DOPC/DOPA/cholesterol-containing liposomes. 
The binding and membrane integration of BAXΔC were studied by surface plasmon 
resonance using supported liposomes containing cholesterol. A, BAXΔC was injected over 
an L1 chip covered with DOPC:DOPA:C (59:21:20 mol%) liposomes. This protein was 
prepared as described in Materials and Methods without the use of detergent. Prior to 
exposure of the BAXΔC to detergent, the protein did not bind to the liposomes as shown 
by the open circles (○ ○ ○) at the bottom of the graph that indicate the averaged RU 
response for the 25–3000 nM BAXΔC concentration range of unactivated protein. After 
treatment with detergent, the RU response for the following concentrations is shown: 9 
nM (solid), 17.9 nM (dash), 35.8 nM (dot), 71.7 nM (dash–dot), 287 nM (dash–dot–dot), 
573 nM (short dash). The injection phase is indicated by the solid line and the wash 
phase is denoted by the dashed line at the top of the graph. B, Comparison of 
membrane-associated (up triangle, open) and membrane-integrated (down triangle, 
open) protein using the criteria described in the text and calculating the average values 
and standard deviation as described in Materials and Methods. The dotted lines 
represent the best fit to an interaction model as described in the text. C, The ratio of 
binding and integration of protein plotted as the fraction integrated as concentration of 
BAXΔC is increased. Means and standard deviations are computed as described in 
Materials and Methods. 
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2.4 | Discussion 
Because BCL2 family proteins are central arbiters of the mitochondrial mortality 
decision, (3) we have undertaken a detailed analysis of their biochemical activities. Although 25 
genes comprise this family and they generate both pro- and antiapoptotic proteins, (8) 
apoptosis regulation centers on the activation of a “pore” in the mitochondrial outer membrane 
by BAX and BAK (61). We have taken the view that by studying this pore activation in detail, 
it will become possible to clarify the influences of the regulatory BCL2 family members. 
Therefore, we have compared BAX pore activation in liposomes with that activity in 
mitochondria. Our reconstitution approach permitted a detailed study of the stages of BAX 
membrane translocation using surface plasmon resonance. This analysis was applied to the 
mechanism of cholesterol inhibition of BAX pore activation. 
Mitochondrial preparation for the study of BAXΔC pore activation 
The in vivo death decision polling occurs in the OMM, which has a complex 
composition of protein and lipid. We have developed a mitochondrial preparation in which to 
study the translocation and pore-forming activity of BAX protein. Photoconversion of the CF 
produced deposition of an electron-dense polymeric product in the intermembrane space 
representing the localization of the CF between the inner mitochondrial membrane and OMM 
(62). We conclude that the fM preparation is an intact double-membrane mitochondrion 
having an OMM that provides a diffusion barrier similar to that described for native 
mitochondria (39,63,64). 
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BAXΔC pore activation in the OMM 
Our mitochondrial preparation, fM, satisfied morphologic, metabolic, and OMM 
functional criteria to be a useful preparation for the study of BAX pore-forming activity. By 
using the fM preparation, we are able to study the activation of human BAXΔC in some detail. 
The pore activation rate and kinetics in mitochondrial and liposome BAXΔC activity are 
comparable, as shown in Fig. 4C. The activation of this pore is proposed to be a critical decision 
point in cell death, with the OMM forming the environment for the BCL2 family proteins to 
negotiate this decision (3,8,65). By using fM, a strong correlation with the pores that we have 
characterized in defined liposomes is apparent. The specific activity of the purified pore-
forming protein is very similar once the necessary correction of the lipid concentration in our 
assays is considered. Our Hill analysis suggests that the added BAX undergoes a two-stage 
oligomerization in the membrane that is consistent with our studies in defined liposomes. This 
comparison suggests that the BAX forms a dimer and tetramer pore in the OMM, a model that 
is consistent with chemical cross-linking of BAX in the OMM (13,66). 
Effect of cholesterol on BAX pore activation in defined liposomes and mitochondria 
Cholesterol is an important component of eukaryotic membranes, having many effects 
upon membrane characteristics and the activity of membrane components. In beginning these 
studies, we were attracted by the possibility that the difference in cholesterol content between 
the plasma membrane and the OMM was an important factor in directing the formation of 
BAXΔC pores. Our data and the data of others support this conclusion (33). Adding cholesterol 
(≈ 20 mol%) to liposomes and the OMM significantly inhibits BAXΔC pore formation. This 
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has more cholesterol than the concentrations reported to be present in the OMM and is less 
than the cholesterol content of the plasma membranes (23,32,67,68). Therefore, we conclude 
that the sterol concentrations of defined liposome membranes can play a role in regulating the 
pore formation by BAX. To verify that cholesterol was effective in a complex lipid 
environment, we used liposomes to adjust the cholesterol content of the mitochondrial outer 
membrane. Direct analysis of the cholesterol content of the fM indicates that the incorporation 
was successful and produced a cholesterol concentration of ≈20 mol%. Although cholesterol 
side-chain oxidation can be brisk in isolated mitochondria, this occurs in the inner membrane, 
whereas outer-membrane cholesterol is quite stable and not oxidized in the isolated organelle 
(23). Therefore, our experiments show that the incorporation of exogenous cholesterol into the 
OMM reduced BAXΔC pore formation substantially compared with mitochondria fused with 
liposomes containing only phospholipids. The observation that the cholesterol effect was 
similar in the simple liposome and the complex mitochondrial membrane environment seems 
to favor a direct interaction between the sterol and the BAX protein. Direct interactions are 
also suggested by the putative cholesterol recognition/interaction motif in α-helix 5 (at 
positions 113–120) (28,69). However, in both liposomes and mitochondria, the ent-cholesterol 
was as effective as the natural compound in reducing BAX pore formation, strongly indicating 
that cholesterol exerts its effect by influencing the lipid environment and having secondary 
effects upon BAX pore formation (20,70). In addition, the reduced pore activation by ent-
cholesterol at high BAX concentrations in both liposomes and mitochondria may reflect chiral 
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sterol–phospholipid interactions that are reported for the ent-cholesterol in phospholipid 
monolayers (71). 
We conclude that cholesterol could have a significant effect on the mortality decision in 
cells that are overloaded with this steroid. Mitochondrial cholesterol overload has rarely been 
studied but has been observed in tumor cell lines (31,72,73) and in cultured cells where 
mitochondrial cholesterol has been increased pharmacologically (33). Likewise, cholesterol 
depletion is reported to enhance apoptosis in statin treatment (74). However, the 
mitochondrial membrane environment is complex and steroid oxidation is an active process in 
these organelles (23,24). Therefore, when multiple membrane parameters are changed, 
decreased permeability transition pore activation has also been reported (34). Our studies have 
focused on cholesterol in a controlled experimental situation to understand the mechanism by 
which cholesterol inhibits BAX pore activation. 
The interaction of BAXΔC with liposomes studied by surface plasmon resonance 
In order to address the mechanism of cholesterol inhibition of BAX pore activation, we 
have used surface plasmon resonance to compare the interaction of BAXΔC with immobilized 
liposomes (± cholesterol). Surface plasmon resonance has been applied to the study of 
membrane binding and integration of a number of pore-forming proteins and peptides (75-79). 
We have used the attached liposome configuration to quantitatively study the rapid binding of 
soluble BAXΔC and concentration-dependent membrane integration of the membrane-bound 
protein. The data in Fig. 7 clearly demonstrate that the membrane binding of BAXΔC is 
completely dependent upon detergent activation of the purified protein. The maximum 
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response to nonactivated BAXΔC was ≈5 RU, which is consistent with the predicted response 
from the mass of nonassociated protein [3.3 μM BAXΔC] injected over the supported 
liposomes. Therefore, essentially no membrane association occurs by the nonactivated BAX 
protein. In cells, BAX also does not associate with the mitochondrial membrane until it is 
activated (54,61). 
These surface plasmon resonance studies confirm that the interaction of activated BAX 
with liposome membranes clearly displays the two observed stages of binding and integration 
(54). The binding stage is rapid and displays high- and low-affinity components. Membrane 
integration of BAX is slower but dissociates very slowly, if at all. Analysis of the concentration 
dependence of binding indicates a high- and a low-affinity population of membrane-associated 
BAX. The concentration dependence of BAX membrane integration suggests a single 
population. We plotted the ratio of membrane-integrated to total membrane-associated BAX 
to study the relationship between these two. In the DOPC/DOPA liposomes, the ratio has an 
increasing phase, suggesting that binding of BAX to the liposomes enhances the integration 
step. Membrane binding and integration of BAX saturate even though no protein or typical 
molecular receptor is present in the membrane. This saturation occurs as the maximum mole 
fraction (solubility) of the BAX protein associated with the membrane surface or integrated 
into the membrane is reached. This saturation produces the falling ratio of membrane-
integrated to total membrane-associated BAX as higher concentrations of added BAX engage 
nonproductive modes of membrane association. Interestingly, in the DOPC/DOPA/C 
membranes, the increasing ratio at low BAX concentration is eliminated. However, since both 
binding populations are increased in the DOPC/DOPA/C membranes, the integration 
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promoting step and its cholesterol inhibition must occur after the binding steps that we have 
observed. 
Analysis of the cholesterol inhibition of BAXΔC pore activation 
The results of our analysis of BAX association with membranes are presented in Table 
1. In this table, the effect of cholesterol on BAX integration into bilayer membranes is 
apparent. BAX binds to a greater extent (both high- and low-affinity pools are increased by 
60%) to membranes that contain cholesterol, but membrane integration is dramatically 
inhibited (42% reduction). These changes produce the inhibition of BAX pore formation that 
we observe in liposomes and mitochondria. The effect upon BAX pore activation is consistent 
with our proposed mechanism of pore activation that includes the in-membrane dimer and 
tetramer oligomerization of BAX protein. In this model of in-membrane oligomerization, a 
reduction of membrane integration by cholesterol will suppress pore activation. Cholesterol is 
known to have a condensing effect upon membranes by reducing the phospholipid area that is 
especially prominent for the liquid-disordered phase that we have in our DOPC/DOPA 
liposomes (52,80). This condensation can be observed as a lateral phase separation in 
membranes of appropriate composition (81). Membrane condensation itself could reduce BAX 
integration without a direct cholesterol–BAX interaction. The equivalence of cholesterol and 
ent-cholesterol inhibition at low BAX integration levels favors membrane condensation over 
direct sterol–protein interaction. The increased inhibition by ent-cholesterol as BAX 
integration approaches membrane-saturating levels might reflect stereospecific cholesterol 
interactions with BAX or with membrane phospholipids (71). If we extrapolate the effect of 
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cholesterol upon the concentration dependence of membrane integration, it appears to explain 
the inhibition of pore activation. Thus, we have no evidence to suggest stereospecific 
interaction with the BAX and inhibition of the in-membrane oligomerization steps. However, 
this does not necessarily contrast with the prior report on effects of cholesterol on BAX (33). 
That work compared the BAX integrated to the total membrane-associated protein using 
trypsin sensitivity. This measure is very similar to the ratio that we calculate, and although we 
observe that the ratio in DOPC/DOPA/C membranes has a distinct BAX concentration 
dependence, there is a range where it is similar to that in DOPC/DOPA membranes. Our data 
only support a cholesterol effect on the membrane integration of BAX that is mediated by 
altering the membrane environment. 
There have now been three investigations showing that the pore-forming activity of 
BAX is inhibited by cholesterol in liposome membranes. All have increased the cholesterol of 
the OMM to produce BAX inhibition in that membrane also. By comparison with our results, 
the cholesterol levels of cell surface membranes will certainly reduce BAX pore formation. It 
remains to be demonstrated how the cholesterol levels of intracellular membranes change and 
influence cell death. Resistance of tumor cells to therapy, the persistence and growth of 
atheromatous lesions and their final rupture, the extent of reperfusion cell death in infarct and 
stroke regions, and skeletal muscle apoptosis may all be affected by cholesterol levels and the 
inhibition of BAX activity. 
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2.5 | Conclusion 
The 25 BCL2 family proteins are central regulators of apoptosis. As one of these, BAX is a 
critical instigator of apoptosis by transitioning from a soluble protein to a membrane-integrated 
pore. We have characterized this transition in liposomes and human mitochondria. Activation 
of the soluble protein is required for membrane binding, membrane integration, and in-
membrane oligomerization to form pores. Cholesterol is a major inhibitor of BAX pore 
activation in mitochondria and liposomes. This inhibition does not require direct interaction 
with the BAX protein but appears to function on the membrane environment to inhibit BAX 
integration into the membrane bilayer. 
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2.6 | Experimental Procedures 
Preparation of BAXΔC 
Two methods for producing recombinant BAXΔC were employed. For dequenching 
experiments, the cDNA for human BAX, with the putative transmembrane carboxy-terminal -
helix truncated, was subcloned into pGEX-KG vector, expressed in BL21(DE3) Escherichia coli, 
and purified as a glutathione S-transferase fusion protein. After harvesting by centrifugation, 
cells were resuspended in lysis buffer [phosphate-buffered saline, pH 7.4, 1% Triton X-100, 1 
mM DTT, and Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN)] and 
sonicated, and the clarified lysate was applied to glutathione–agarose. Resin was subjected to 
high salt wash (including 0.1% Triton X-100) and flushed with cleavage buffer [50 mM Tris, 
pH 7.5, 150 mM NaCl, 0.1% n-octyl-β-D-glucopyranoside (OG), 2.5 mM CaCl2, and 1 mM 
DTT], and BAXΔC was cleaved from glutathione S-transferase tag using thrombin (Novagen, 
Madison, WI). 
For surface plasmon resonance experiments, human BAXΔC cDNA was subcloned into 
pTYB1 vector (NEB, Ipswich, MA), expressed in BL21(DE3) E. coli, and purified as an 
intein/chitin-binding domain fusion protein. After harvesting by centrifugation, cells were 
resuspended in lysis buffer [phosphate-buffered saline, pH 7.4, and Complete Protease 
Inhibitor Cocktail (Roche)] and sonicated, and clarified lysate was applied to a chitin affinity 
column. Resin was subjected to high salt wash followed by flushing with cleavage buffer (20 
mM Tris, pH 8.0, 500 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), and 50 mM 
DTT) and incubated at 4 °C for 48 h to allow intein self-cleavage and release of recombinant 
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BAXΔC. Eluted proteins were estimated to be > 95% pure by Coomassie staining SDS-PAGE 
gels and stored at 4°C. BAXΔC was activated by addition of 2% OG for 1 h at 4°C and then 
dialyzed overnight against EB (10 mM HEPES, pH 7.0, 100 mM KCl, and 0.01% NaN3). 
BAXΔC retained pore-forming capacity for > 72 h after dialysis with no diminution of activity. 
Liposome preparation by reverse-phase method 
Liposomes were prepared using the reverse-phase procedure of Szoka and 
Papahadjopoulos (82). Lipids were obtained as solutions in chloroform from Avanti Polar 
Lipids, Inc. (Alabaster, AL). Mixtures of DOPC and DOPA (monosodium salt) and 5-
cholestene-3β-ol [cholesterol (C); Sigma-Aldrich, St. Louis, MO] were prepared at a mole 
fraction ratio of DOPC:DOPA=0.74:0.26 or DOPC:DOPA:C=0.59:0.21:0.20 in chloroform. 
Chloroform was first evaporated under a stream of N2 gas and then further removed by vacuum 
(10− 5 Torr) for 2 h. Dried lipids were stored in N2 gas at −20°C. CF (molecular weight = 376 
Da) (Molecular Probes, Eugene, OR) was prepared at 20 mM in EB, adjusted to pH 7.2, and 
stored at 4°C. Dried lipids were reconstituted by addition of 1 mL ethyl ether and 0.5 mL CF 
solution. The suspension was sonicated at 1200 W for 20 s, producing a stable suspension, and 
ether was evaporated on a rotary evaporator at 40 rpm under reduced pressure (water 
aspiration) for 13 min. at room temperature. The 0.5 mL suspension was supplemented with an 
additional 0.5 mL of the 20 mM CF solution. This mixture was passed through a 22-gauge 
needle affixed to a mini-extruder (Avanti) containing a 200-nm membrane (Nuclepore, 
Pleasanton, CA) for three complete cycles. The extravesicular CF was removed by passing the 
liposome–dye mixture over a 1 × 20 cm Sephadex G-25-80 (Sigma, St. Louis, MO) column in 
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EB. A liposome peak was collected and analyzed by dynamic light scattering (N5 Submicron 
Particle Size Analyzer, Beckman Coulter, Fullerton, CA), with a diameter of 207 ± 12.5 nm. 
Phospholipid concentration in this fraction was determined to be 3.3 mg/mL (83). 
Dequenching analysis of BAX pore activation 
We have used the analysis of dequenching to study the activation of pores in bilayer 
membranes (19,84-86). Using monodisperse unilamellar vesicles, we studied the activation of 
membrane pores by measurement of the increased fluorescence as CF exits from the membrane 
compartment and is diluted into the assay volume. All assays were done at a total lipid 
concentration of 0.4 ± 0.05 μM. The time dependence of the dequenching from our liposome 
and mitochondria preparations is well described in Eq. (1), without additional exponential 
terms. 
F520 = F0A1(1 − e(time/τ)) + m × time    (1) 
The formation of a 10- to 30-Å pore in a 200-nm vesicle (or mitochondrion, see Fig. 2) will 
permit the equilibration of CF with the media within 30–100 ms (87,88). In the timescale of 
our assay, a single pore opening will not be resolved and the exponential dequenching we 
observe represents the kinetics of pore activation. A linear component in the time series was 
frequently not observed but represents pores that are unstable and which close before single 
vesicle dequenching is complete with subsequent pore activation being required to complete 
dequenching (89). For a time-series experiment, the fractional dequenching at each time point 
was determined by normalizing the fluorescence (Fl) with the Triton X-100-generated total 
dequenching for each assay [Eq. (2)]. 
68 
 
F520 = (Fltime – Flbaseline) / (FlTriton X100 – Flbaseline)   (2) 
The analysis of BAX pore activation was undertaken by determining the time constant, τ, and 
the total exponential fluorescence change, A1, for each time-series dequenching. The kinetic 
constants were determined by nonlinear least-squares analysis using the Levenberg–Marquardt 
algorithm, which yielded χ2 values of < 0.001 for each time series.  
Assessment of BAXΔC –liposome interaction by centrifugation and silver staining 
OG-activated BAXΔC was dialyzed overnight against EB. BAX was applied to liposomes 
± cholesterol (1.1 μM total lipid concentration), incubated for 10 min. at room temperature, 
and ultracentrifuged at 150,000 × g for 20 min. at 4°C. The supernatant was collected and the 
proteoliposome pellet was subjected to alkaline extraction by resuspension in 100 mM sodium 
carbonate for 30 min. on ice. Samples were again ultracentrifuged and supernatant and pellet 
fractions were collected. After SDS-PAGE and silver staining, relative intensities of BAX bands 
were quantified using QuantityOne software (Bio-Rad, Hercules, CA). 
Preparation of mitochondria 
Mitochondria were prepared from cultured cells following published procedures 
(90,91). The mitochondria were isolated from HeLa cells maintained in culture where the 
unstimulated rate of apoptosis is < 5%. We used 250 mM sucrose for osmotic stabilization (pH 
7.0, 10 mM HEPES) and added 1 mM EGTA to maintain low Ca2+. All procedures were 
performed at 4°C on ice baths except as noted. Cell cultures were washed with ice-cold sucrose 
solution to remove media and serum, and the cells were mechanically scraped from the dishes. 
After homogenization (40 strokes with a loose Dounce), the nuclei and undisrupted cells were 
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removed by centrifugation at 500 × g. Mitochondria were then collected by centrifugation at 
9000 × g. The mitochondrial pellet was resuspended, and protein concentration was 
determined using the Micro BCA Protein Assay Kit (Pierce Chemical Co., Rockford, IL). The 
mitochondria were suspended at 1 mg/mL protein in the unilamellar liposome preparation for 
fusion as described previously (39,40). The CF-loaded liposomes were 1 mM in lipid and 
contained 2 × 1012 liposomes/mL. The mitochondria and liposomes were incubated together at 
15°C for 60 min. and then the pH dropped to 6.5 by addition of 60 μL of 100 mM PIPES (pH 
6) for 5 min. The fM were pelleted at 9000 × g and washed two further times in 250 mM 
sucrose buffer to remove unfused liposomes. Lipid analysis by Dr. Richard Gross of the 
Department of Medicine at Washington University allowed us to adjust the fusion protocol in 
order to incorporate the desired amount of cholesterol into the mitochondria. This analysis 
showed that the liposome fusion increased DOPA to three times the DOPA in the isolated 
mitochondria before fusion (92). We used this ratio to calculate the OMM cholesterol 
concentration, which increased to 16 ± 0.4 mol%, when we were using liposomes containing 20 
mol% cholesterol. Cholesterol in liposome and mitochondria preparations was converted to 
trimethylsilyl ethers and determined using gas chromatography–mass spectrometry by Dr. Dan 
Ory of the Department of Medicine, Washington University School of Medicine (93). 
Mitochondria fused to these levels were used in all of the experiments to test the effect of 
cholesterol on BAX activity in mitochondria. 
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Electron microscopy and photoconversion of the mitochondrial preparations 
Mitochondria were purified as above and fixed with 2.5% glutaraldehyde in 0.1 M 
sodium cacodylate for 30 min. on ice, after which they were spun at top speed in a tabletop 
microcentrifuge to form a tight pellet. After rinsing, the pellet was sequentially stained with 
osmium tetroxide and uranyl acetate and then dehydrated and embedded in Polybed 812. 
Tissue was thin sectioned on a Reichert–Jung Ultracut, viewed on a Zeiss 902 electron 
microscope, and recorded with Kodak E.M. film. For photoconversion, the mitochondria were 
washed after fixation and treated with 6 mM potassium cyanide and then suspended in 
cacodylate buffer with 2.8 mM 3,3′-diaminobenzidine tetrahydrochloride for exposure to a 75-
W xenon lamp. After 6 min., the mitochondria are washed by centrifugation and processed for 
electron microscopy as above. 
Measurement of mitochondrial oxygen consumption 
Mitochondria were prepared as described above. Mitochondria at a protein 
concentration of ≈ 1 mg/mL  were placed into the Instech dissolved oxygen measuring system 
(Warner Instruments, Hamden, CT) in 150 mM KCl (pH 7.0), 1 mM EGTA, and 5 mM 
DTT at 20°C. The buffer was equilibrated with 95% O2 and stored in an airtight syringe prior 
to use. The concentration of dissolved O2 was corrected for atmospheric pressure. During the 
assay, the mitochondria were sequentially treated with 5 mM malate, 5 mM ADP, 2 μM 
rotenone, 5 mM succinate, 10 mM ascorbate, and N,N,N,N-tetramethyl-p-phenylenediamine 
(TMPD) and a baseline obtained in 10 mM azide. After the addition of ascorbate–TMPD, the 
rate of oxygen consumption was dependent upon site IV, which employs cytochrome c and 
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cytochrome oxidase in the transfer of electrons to molecular oxygen (94). The rates of oxygen 
consumption were normalized for protein concentration. 
Planar lipid bilayer studies on isolated fM 
Planar lipid bilayers were prepared from the phospholipids DOPC:DOPA (74:26 
mol%). Phospholipids were obtained from Avanti Polar lipids in chloroform solution and were 
mixed to the correct ratio, and the chloroform was removed under nitrogen. The lipids were 
then stored under nitrogen at −20 °C until dissolved in decane at 20 mg/mL. Briefly, 2 μL of 
lipid solution was applied to 0.25 mm orifice of a polystyrene cuvette (Warner Instruments), 
and the solvent was allowed to evaporate. The cuvette was then placed into a bilayer chamber 
and connected to a bilayer clamp (BC525-c; Warner Instruments) by Ag/AgCl electrodes via 
agar bridges. Data were collected using CLAMPEX 9.0 (Axon Instruments, Foster City, CA), 
archived on videotape using a Neurocorder DR-484 (Neuro Data Instruments, Delaware 
Water Gap, PA), and analyzed using Origin (OriginLab Corporation, Northampton, MA) and 
CLAMPFIT (Axon Instruments). Bilayers were formed by spreading with a polished glass rod 
and allowed to thin to a capacitance of 0.4 μF/cm2, at which point the noise was typically 0.2 
pA and the leak conductance was 2 pS. The salt concentrations are described in the appropriate 
figure legends. Outward (positive) currents were defined as K+ moving cis to trans. All solutions 
were buffered to pH 7.0 with 10 mM K-HEPES. Mitochondria (10 μg of protein) were added 
to the cis chamber with mixing. To vary calcium concentration, we added EGTA and CaCl2 as 
indicated. The milliQ water employed for buffers in these studies averaged 30 μM Ca2+, and 
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mitochondrial isolation buffer contained 1 mM EGTA to reduce free Ca2+ to < 1 μM. Calcium 
was varied by adding 100 μM CaCl2 or 100 μM EGTA to the bilayer chamber. 
Surface plasmon resonance studies of BAX–liposome interaction 
These studies were done using Biacore X instrumentation and software (Biacore 
Division of GE Healthcare, Uppsala, Sweden) at an ambient temperature of 20°C. Buffers were 
filtered through 0.22 μm filter prior to use. Liposomes were prepared as described above. The 
buffer was EB unless noted. The sensor surface of an L1 chip (Biacore) was equilibrated in EB. 
Liposomes were injected at a phospholipid concentration of 0.6 mg/mL across the sensor 
surface at a flow rate of 3 μL/min. for 12 min. Loosely associated liposomes were washed from 
the surface by increasing the flow rate of running buffer to 500 μL/min. for 30 s. Bovine serum 
albumin (1 mg/mL) was injected at 15 μL/min. for 2 min. to ascertain the extent of liposome 
coverage of the surface and to block remaining nonspecific binding sites (58). The 
DOPC:DOPA liposomes loaded to 13 ± 0.9 ng lipid/μm2 and the DOPC:DOPA:C liposomes 
loaded to 12.3 ± 1.2 ng lipid/μm2. Variation in loading was primarily due to variation in the 
liposome size distribution. BAXΔC protein was injected over supported liposomes at 30 
μL/min., and the dissociation was observed for 5 min. at the same flow rate at which the protein 
was injected. The response was corrected for injection artifacts. Data were analyzed and 
displayed using BIAevaluation (Biacore) and Origin 7.5 (OriginLab Corporation) software. At 
each concentration of BAX protein, the line presented results from the averaging of two to four 
independent binding studies. The standard deviation from this averaging is shown in the 
binding plots when its value is larger than the symbols or line that is being displayed.  
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Steroid Effects on BAX Pore Activation 
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3.1 | Summary 
 The cell suicide program of apoptosis is regulated not only by protein constituents but 
also lipids and steroids. The BCL2 protein family provides a conduit through which 
lipid/steroid imbalance effects cell death. As we’ve demonstrated, membrane cholesterol 
inhibits the pore-forming ability of BAX by interfering with its bilayer integration. The 
functional locales of BAX, mitochondria, perform many enzymatic modifications of cholesterol 
to generate oxysterols and bile acids. These molecules are known to induce apoptosis in a 
variety of cell types but the molecular mechanisms are poorly characterized. In this chapter, we 
extend our BAX-vesicle leakage assay to investigate the effects of steroids 25-hydroxycholesterol 
(25-HC) and lithocholic acid (LCA) on the efficiency of BAX pore activation. At low 
micromolar concentrations, 25-HC accelerates formation of BAX pores. This promotion by 
25-HC lies in contrast to inhibition by cholesterol; we attribute this functional disparity to the 
two sterols’ oppositional effects on membrane fluidity, with cholesterol condensing the bilayer 
and 25-HC spreading it. The bile acid lithocholic acid was found to activate BAXΔC at sub-
critical micelle concentrations whereas activation of full-length BAX required micellar LCA.  
From these data, we conclude that instigation of cellular apoptosis by 25-HC and LCA is likely 
a product of cell stress recognition, not direct allosteric perturbation of inactive BAX, but the 
two steroids may intensify BAX’s membrane attack by modulation of bilayer physical 
properties. 
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3.2 | Introduction 
 Lipids compose the local environment in which the BCL2 family functions. While the 
proteinaceous machinery of mitochondrial apoptosis has been subjected to intense scrutiny, 
complementary research into lipidic components has lagged (1). During apoptosis, the lipid 
composition of MOM is altered substantially, especially by oxidative stress (2). Most of the 
phospholipid changes, however, appear to occur subsequent to mitochondrial outer membrane 
permeabilization (MOMP) with the exception of lysolipid (including monolysocardiolipin) 
accumulation (1) and likely play at most an amplificatory role in forwarding the death signal. 
 Mitochondria are cholesterol-poor organelles (3) but, as we and others have 
demonstrated, the presence of cholesterol in vesicle and mitochondrial outer membranes 
(MOM) inhibits the efficiency of BAX pore activation (4-6). Enhancement of the 
mitochondrial cholesterol store has been implicated in the pathogeneses of steatohepatitis, 
(hepato)carcinomas, and Alzheimer’s disease (7). Mitochondrial cholesterol pools are dynamic 
as the organelles perform cholesterol modifications necessary for steroid, bile acid, and oxysterol 
syntheses. Besides acting in cellular signaling, conversion of cholesterol into an oxysterol 
significantly improves solubility and facilitates clearance from the system during states of 
cholesterol excess (8).  
The relationship between elevated levels of oxysterols and atherosclerosis has been 
widely-investigated using both in vivo and in vitro models; evidence is mounting that oxysterols 
also play a role in the pathogenesis of degenerative diseases like Alzheimer’s and Parkinson’s 
diseases, multiple sclerosis, and age-related macular degeneration (9-12). Oxysterols are known 
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to be inducers of apoptosis in a variety of cell types (13) and the apoptotic signal is propagated 
by both death receptor and mitochondrial pathways (but the latter appears to be dominant) 
(14). Of vascular wall constituent cell types, 25-hydroxycholesterol (25-HC) can instigate 
apoptosis in monocyte/macrophage, aortic endothelial, and smooth muscle cells (15-17). 
Lymphoid cell lines have also been observed to undergo apoptosis after exposure to 25-HC 
(18). A number of reports have demonstrated that oxysterols induce cytochrome c release in a 
variety of cell types (14). In vascular SMCs, oxysterol-induced apoptosis appeared to be 
dependent on BAX translocation to mitochondria (19,20). In macrophage-like cell lines, 
siRNA knockdown of BAX completely ablated apoptosis induced by 25-HC (21) while 
overexpression of BCL-2 could partially suppress cell death (22).  
 Besides oxysterols, other physiologically-significant cholesterol derivatives are bile acids. 
These molecules act essentially as biological detergents, secreted into the intestinal lumen to 
solubilize ingested lipids. High concentrations of bile acids, however, are toxic and can induce 
apoptotic and necrotic cell death. Multiple studies have demonstrated that bile acids induce 
apoptosis in a variety of cell types, including colon cancer cells and hepatocytes (23-31). 
Though the direct mechanism is not well-characterized, cell death by bile acids appears to be a 
function of both intrinsic and extrinsic apoptotic pathways. Several studies have found that bile 
acids can induce mitochondrial dysfunction (32-37); unclear is the molecular specificity of this 
relationship, be it a detergent-like disruption of mitochondrial membranes or protein 
interaction. 
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 Our collaborators Drs. Bryson Katona & Doug Covey discovered that the prominent 
intestinal bile acid lithocholic acid (LCA) could induce apoptosis in cultured colon 
adenocarcinoma cells and that BAX translocation to mitochondria occurred rapidly in response 
to application of the bile acid. This finding piqued our curiosity, as BAX activation has been 
(until recently) largely nebulous and revelation of a non-proteinaceous, but physiologically-
tolerable, activator could prove pharmacologically useful. 
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3.3 | Results 
 For this chapter, two forms of BAX were employed—C-terminally truncated BAX 
(BAXΔC) and full-length BAX. While BAXΔC was useful as a probe of the final step of BAX 
activity, i.e. the kinetics of pore formation (Chap. 2), we sought to more closely mimic the 
physiological molecule and its regulation, thus experimental adoption of full-length BAX. Also 
adopted into our regime was BH3-only protein BID which is the prototypical BAX-activating 
protein; activation of BID into apoptotically-proficient cBID was performed by cutting the 
protein with recombinant caspase-8. Hence, for this chapter, we use two BAX forms (BAXΔC & 
FL BAX) and two activation methods (incubation with detergent & cBID) (38,39). Also, LUV 
compositions differ depending on which BAX is under study. Vesicles encapsulate either 5(6)-
carboxyfluorescein (0.38 kDa) for BAXΔC or 10 kDa FITC-dextran for BAX. The two 
formulations were necessary because while native BAXΔC interacts very weakly with membranes 
(and fails to induce leakage), full-length BAX binds more avidly and can generate small 
disruptions sufficient for small dye leakage (see Chap. 4). 
25-hydroxycholesterol enhances BAXΔC pore activation 
  Since we found that cholesterol inhibited BAXΔC-mediated vesicle leakage and that 
oxysterols have been shown to induce apoptosis, we were curious as to whether the cholesterol 
derivative 25-hydroxycholesterol (25-HC) could promote BAX activity in our reconstituted 
leakage assays. Incorporation of 25-HC to the vesicles was accomplished simply by diluting the 
oxysterol into assay cuvets—25-HC is more hydrophilic than cholesterol but readily partitions 
from an aqueous environment into bilayers (40). As depicted in Fig. 3.1, 25-HC does indeed 
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have an effect contrary to that of cholesterol—the oxysterol accelerates pore formation by 
detergent-activated BAXΔC. Promotion of leakage by 25-HC is dramatic as shown by the 
representative traces in Fig. 3.1A. Visual examination of the data suggested that the leakage-
enhancing effect of 25-HC saturates at high concentrations of the oxysterol. To quantify the 
degree of this acceleration of pore formation, we applied the method from Chap. 2 and fit the 
leakage traces to a single exponential to extract time constants, τ (4,41). From this kinetic 
analysis, we observed the leakage enhancing effect of 25-HC is most pronounced below 10 μM 
with the time constants dropping from ≈110 to under 50. Effectively, the oxysterol can double 
the leakage rate elicited by BAXΔC (Fig. 3.1B). 
 
 
 
 
 
 
 
 
 
 
 
 
84 
 
Fig. 3.1 | 25-hydroxycholesterol accelerates BAXΔC pore formation. A, CF LUVs (70:30 
DOPC:DOPA), 5 μM total lipid, were equilibrated (1 hr) with indicated solution 
concentrations of 25-HC. Detergent-activated BAXΔC (see Chap. 2) was then added to 
induce CF leakage at 22°C. B, BAXΔC pore acceleration saturates above 10 μM 25-HC. CF-
leakage traces (not shown) were fit to a single exponential [Chap. 2, Eq. 1: F520 = F0A1(1 
− e(time/τ)) + m × time] to extract τ values. τ values at constant [BAXΔC] were then plotted 
as a function of 25-HC concentration. 
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cBID activates BAX and is potentiated by cardiolipin 
 The membrane targeting specificity of the BCL2 family is partly dependent on a unique 
lipid—cardiolipin (CL). This anionic lipid comprises four acyl chains and is synthesized in 
mitochondria. Previous studies have indicated that cardiolipin acts in a receptor-like fashion for 
BH3-only protein BID, which is typically localized to the cytosol (42-44). As we were 
interested in investigating the regulatory sequence of BAX activation leading to pore formation, 
not only that final step, it was necessary to assess the fidelity of our reconstituted vesicle leakage 
system. 
 We first employed LUVs comprising the small dye 5(6)-carboxyfluorescein (0.38 kDa). 
This formulation, however, proved to be ill-suited as BAX and cBID separately induced 
substantial leakage (see Chap. 4). We then adapted a method devised by Kuwana et al. whereby 
a large dye, 10 kDa dextran conjugated to FITC (FD10), was incorporated into LUVs (45). 
Illustrated in Fig. 3.2, these FD10 vesicles provided a useful means of observing cBID-BAX 
pore activation. Notably, and in accordance with prior findings, replacement of 10 mol% 
DOPA with 10 mol% CL in our vesicles drastically accelerated leakage (Fig. 3.2, black vs. 
magenta traces). Inclusion of CL more than 5-fold enhanced the efficacy of cBID-BAX 
activation (red vs. magenta traces). BAX by itself caused only trivial leakage, also in agreement 
with its default intracellular inactivity (green trace). These results revealed that our 
experimental model broadly recapitulates the physiological process and would likely be 
extensible for addition of modulating factors (e.g. oxysterols). 
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Fig. 3.2 | Cardiolipin dependence of cBID activation of BAX. The presence of 
mitochondrial lipid cardiolipin substantially enhances BAX pore formation. LUVs 
encapsulating FD10 were synthesized with a composition of 70:20:10 DOPC:DOPA:CL or 
70:30 DOPC:DOPA (mol%) and diluted into cuvets for a final concentration of 10 μM 
total lipid. BAX ± cBID was then added to LUVs and leakage monitored at 22°C. 
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25-hydroxycholesterol enhances cBID-BAX pore activation 
 Having established the viability of our cell-free system including full-length BAX and 
activator cBID, we then revisited incorporating 25-HC. Since the oxysterol proved effective in 
promoting LUV poration by a detergent-treated, truncated BAX, we hypothesized that 25-HC 
would similarly affect poration by native BAX + cBID. Of concern to us was the inclusion of 
another protein (cBID) and the unusual diphospholipid CL and their potential confounding 
effects. These concerns turned out to apparently unwarranted as 25-HC enhanced vesicle 
leakage by BAX as it did in Fig. 3.1. 
 Time courses in Fig. 3.3A & B show dose-dependent 25-HC promotion of BAX pore 
formation as elicited by 10 nM and 20 nM cBID respectively. To better illustrate this 
acceleration, the inverse times to half-maximal dequenching (1/t1/2) were plotted in Fig. 3.3C. 
(Unlike τ [in Fig. 3.1B] which decreases as BAXΔC pore formation becomes more rapid, 1/t1/2 
increases as full-length BAX pore formation accelerates. The second metric was devised since 
cBID-BAX pore activation shows an initial lag phase and cannot be fit by a single exponential 
like BAXΔC pore activation.) Congruous with the enhancement of BAXΔC pore formation, 
promotion of cBID-BAX pore formation levels off above 10 μM 25-HC (Fig. 3.3C). 
Interestingly, the oxysterol enhances activation by 10 nM cBID proportionately greater than by 
20 nM cBID; the rate of leakage induced by 10 nM cBID-BAX increases 62% (2.1×10-4 s-1  
3.4×10-4 s-1) while the rate of 20 nM cBID-BAX increases only 41% (2.7×10-4 s-1  3.8×10-4 s-
1). 
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 Visual comparison of the leakage kinetics between Fig. 3.2 and 3.3 reveals a large 
disparity—the leakage in Fig. 3.2 is very rapid relative to that in Fig. 3.3. The source of this 
discrepancy is the age and aggregation state of the BAX protein preparations. Frustratingly, 
BAX aggregates over time and loses as much as ½ of its activity in one week (46,47) (data not 
shown). For Fig. 3.2, the BAX was freshly purified but for Fig. 3.3 the protein had been in 
storage at 4°C for a couple weeks. These experiments were performed prior to our discovery of 
this complication. While the two datasets in Fig. 3.2 and 3.3 cannot be directly compared, 
meaningful comparisons of the data in 3.3 can be made since all were collected on the same day. 
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Fig. 3.3 | 25-hydroxycholesterol accelerates full-length BAX pore formation. A & B, 
LUVs (10 μM lipid) encapsulating FD10 were equilibrated with indicated solution 
concentrations of 25-HC for an hour; vesicle composition was 70:20:10 DOPC:DOPA:CL 
(mol%). 100 nM BAX and 10 nM cBID (A) or 20 nM cBID (B) were then added to induce 
FD10 leakage. Assays were performed at 22°C. C, Saturation of 25-HC enhancement of 
BAX pore formation. 1/t1/2 values were derived from curves in A & B and defined as the 
inverse of the time to half-maximal leakage. 1/t1/2 values were then plotted as a 
function of 25-HC concentration at constant [BAX] (100 nM) and two concentrations of 
activator cBID (10 & 20 nM). 
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Bile acids can activate BAX 
 Biochemical studies have indicated that synthetic, non-ionic detergents alter the 
conformation and activate the pore-forming capacity of BAX (38,48-50); conversely, the 
zwitterionic detergent CHAPS elicited no such changes. Notably, these detergent-evoked BAX 
alterations required the presence of detergent micelles. Given that bile acids act as physiological 
non-ionic detergents and have been demonstrated to induce apoptosis, we adduced a 
reductionist mechanism whereby bile acids could directly activate BAX to drive cells to their 
deaths. Graciously provided by Drs. Katona & Covey, we incorporated lithocholic acid (LCA), 
a known apoptosis promoter, to our BAX-LUV leakage system. Initial experiments were 
promising—non-active BAXΔC could be effectively activated by micromolar concentrations of 
LCA (Fig. 3.4A). Importantly, the tested concentrations—1-100 μM—are well-below the 
critical micelle concentration of LCA (≈275 μM).  LCA’s activating effect on BAXΔC also 
displayed intriguing concentration dependence. A second bile acid, chenodeoxycholic acid 
(CDCA), was also tested; this bile acid was previously shown to elicit mitochondrial 
cytochrome c release (32,33,36). CDCA also provoked BAXΔC pore activation, albeit less 
efficiently (data not shown). 
 Having success in purification of full-length BAX, we chose to revisit our bile acid 
activation findings. Using the same activation protocol, we found that full-length BAX was 
resistant to the detergent and required LCA micelles to produce an active protein, similar to 
BAX activation by synthetic, non-ionic detergents (Fig. 3.4B). Only with LCA concentrations 
91 
 
of 400-800 μM was even mild activation demonstrated. Parallel assays with CDCA (CMC ≈10 
mM) revealed no BAX activation (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
92 
 
Fig. 3.4 | Lithocholic acid activations of BAXΔC and full-length BAX. A, Non-micellar 
lithocholic acid (LCA; critical micelle concentration ≈275 μM) activates BAXΔC. Non-
active, detergent-free BAXΔC was incubated overnight with indicated concentrations of 
LCA and applied to CF LUVs (5 μM lipid) at 22°C; vesicle composition was DOPC:DOPA 
70:30 (mol%). B, Full-length BAX activated by LCA micelles. BAX was incubated 
overnight with indicated concentrations of LCA and applied to FD10 LUVs (5 μM lipid) at 
22°C; vesicle composition was DOPC:DOPA 70:30 (mol%). LCA solution concentration in 
the assay cuvets was <4 μM which failed to cause dye leakage (data not shown). 
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3.4 | Discussion 
25-HC promotion of BAX pore formation 
The mechanisms of cholesterol homeostasis and related pathogeneses have been under 
investigation for some time. Well-established is the notion that cellular proteins directly bind 
to cholesterol and other steroids to mobilize the sterols and effect changes in various signaling 
and synthesis pathways. Becoming recognized is that sensing of bulk membrane environment 
modulation also contributes to cellular recognition of sterol content, as well as to the apoptotic 
and pathological effects of sterol imbalance (40,51). 
Having two hydroxyl groups (one on each end) affords 25-hydroxycholesterol much 
greater solubility in aqueous solution than cholesterol. Whereas cholesterol orients 
perpendicular to the membrane surface to maximize hydrogen bonding for its 3-OH, 25-HC 
can adopt a variety of orientations, including parallel to the plane of the bilayer where both 
hydroxyls are solvent-exposed (13,40,52). Thus cholesterol condenses and thickens the bilayer 
by decreasing the mobility of phospholipid acyl tails while 25-HC can induce an opposite 
bilayer effect.  
We attribute the acceleration of BAX pore formation by 25-HC to the sterol’s capacity 
to increase the mean area per lipid, i.e. spread apart the lipids, to facilitate BAX membrane 
integration. This effect is the converse of our finding that cholesterol inhibits poration by 
suppressing BAX membrane integration (4-6). Enhancement of pore activation by 25-HC was 
demonstrated regardless of how a membrane-competent BAX form was generated, by both 
detergent and BH3-only activator cBID. Significantly, enhancement was noted at ≤1 μM 25-
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HC, suggesting that even mild intracellular accumulation of the oxysterol could render 
mitochondrial membranes more susceptible to BAX predation and tilt the life/death balance 
toward apoptosis. 
Bile acid activation of BAX 
 Elucidation of BAX (& BAK) activation and identification of BAX/BAK regulators 
are the subjects of continuing research. Preliminary work on the naturally-occurring bile acid 
lithocholic acid hinted that it may be one of these strongly sought after BAX activators. 
Unfortunately, in vitro interrogation of this hypothesis provided mixed results at best. Deletion 
of the C-terminal α-helix of BAX allowed activation by monomeric, non-micellar LCA. 
Conversely, full-length BAX required LCA micelles to elicit a pore-competent conformation, a 
finding reminiscent of previous reports employing non-physiological detergents (38,48,50). 
This ninth α-helix (truncated from BAXΔC) serves to address BAX to mitochondrial 
membranes yet also stabilizes its globular, cytosolically-localized conformation (53-55). Given 
that it is unlikely for bile acids to sufficiently accumulate inside cells to generate micelles—such 
aggregates would disrupt membranes and instigate necrosis—physiological detergents like LCA 
probably induce apoptosis by typical cell stress recognition pathways. Indeed, after failure to 
produce active BAX in vitro by low concentrations of LCA, Dr. Katona uncovered that LCA 
exerts an apoptotic influence via increased oxidative stress, which leads to caspase-8 activation, 
BID cleavage, and subsequently BAX/BAK activation (56). 
Though LCA seems to compel apoptosis via stress pathways rather than direct 
remodeling of inactive BAX, the hydrophilic bile acid tauroursodeoxycholic acid (TUDCA) 
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has been shown to protect isolated mitochondria against BAX membrane integration and 
cytochrome c liberation (57). TUDCA was chosen as protective agent since it is used as a 
therapy against chronic cholestatic liver diseases and can inhibit apoptosis in hepatocytes and 
non-liver cells alike (58). Protection by TUDCA appears to be conferred at least partly by 
stabilization of organelle membranes (59). 
 In conclusion, we have employed a simplified reconstitution scheme to illuminate that 
steroids can enhance the activity of proapoptotic BAX. A direct alteration of BAX structure by 
low micromolar 24-HC and LCA are not supported but instead their modulation of 
membrane properties facilitates BAX perforation. In cells, where the balance between life and 
death is finely calibrated, even small perturbations can have dire consequences. 
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3.5 | Experimental Procedures 
Protein expression and purification 
 BAXΔC was produced as described in Chap. 2. For oxysterol experiments, BAXΔC was 
purified in the presence of detergent to activate the protein. For bile acid experiments, BAXΔC 
was prepared detergent-free so as to leave the protein inactive unless activated by incubation 
with bile acids. Purifications of BAX and BID are fully described in Chapter 4. Briefly, full-
length BAX and BID were expressed as chitin-binding domain/intein fusion proteins and 
purified without detergent. After affinity column binding and on-column cleavage, proteins 
were further polished by anion exchange FPLC. BID was then cut by addition of caspase-8 to 
generate the active form, cBID. 
 For activation of BAXΔC and BAX by bile acids, the steroids were first dissolved in 
isopropanol to generate 35 mM stock solutions. From these stocks, the bile acids were diluted at 
least 44-fold into 10 μ M BAXΔC/BAX solutions to produce figure-indicated solution 
concentrations of bile acid. Protein/bile acid mixtures were then incubated overnight at 4°C for 
use in dequenching assays. Protein/bile acid mixtures were diluted at least 200-fold into assay 
cuvets, producing a final bile acid solution concentration of <4 μM, a quantity that resulted in 
no dye leakage. 
Large unilamellar vesicle preparation 
 LUVs were prepared by two methods. Carboxyfluorescein-containing liposomes of 
indicated lipid compositions were produced by the ether/buffer emulsification & evaporation 
(“reverse phase”) method detailed in Chap. 2. For LUVs containing 10 kDa FITC-dextran 
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(FD10), 200 nm vesicles were prepared by freeze-thawing and extrusion. Ten mg total lipid 
(dissolved in chloroform) were mixed to yield indicated compositions; chloroform was 
evaporated by nitrogen then lipids further dried under vacuum for two hours. Equilibration 
buffer (EB; 10 mM HEPES-KOH, pH 7.0, 100 mM KCl, 0.5 mM DTT) was supplemented 
with 50 mg/mL FD10 and added to dried lipid films and lipids rehydrated by a 30 s immersion 
in a bath sonicator. The mixture was then subjected to ten freeze/thaw cycles in liquid nitrogen 
and extruded 15 times through a membrane with 0.2 μm pores. Extravesicular FD10 was 
removed by Sephadex G-200 gel filtration respectively. 
 For oxysterol experiments, stocks of 35 mM 25-HC in isopropanol were generated. 
These stocks were diluted >700-fold into assay cuvets to yield figure-indicated solution 
concentrations, followed by addition of LUVs. LUV/oxysterol mixtures were then incubated 1 
hr at room temp to allow equilibration of the oxysterol between aqueous buffer and liposome 
bilayers. 
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CHAPTER 4 
 
BAX & BCL-XL Independently Insert Into Membranes, 
a Process Accelerated by Membrane-Bound Activators 
tBID & BIMS 
 
 
(The content of this chapter has been adapted from Christenson, E. T., Schlesinger, P. H. 
(2011) (in preparation)) 
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4.1 | Summary 
The BCL2 protein family is a primary regulator of apoptosis and its interaction 
network converges at the proapoptotic BAX/BAK nexus. BAX has soluble, membrane-bound, 
and membrane-integrated forms that are central to the management of mitochondrial 
permeabilization. These states—which lead to BAX oligomerization, pore formation, and 
cytochrome c egress—are modulated by antiapoptotic multidomain and proapoptotic BH3-
only proteins. Using purified recombinant BCL2 proteins and defined liposomes, the 
soluble→membrane transitions and pore activity modulations have been characterized. Direct 
activators cBID and BIMS instigate BAX pore formation, a process inhibitable by BCL-XL, and 
these oppositional functions are dosage-dependent. Compared to cBID, BIMS is more efficient 
an activator and less suppressible by BCL-XL. Real-time kinetic measurements of protein-
membrane binding reveal that BAX, cBID, BIMS, and BCL-XL are each capable of adsorbing to 
membranes and these adsorptions include a rapid binding step that is reversible and distinct 
from a subsequent membrane integration step. The integrated forms of each protein have 
comparable affinities for membranes indicating that the peripheral binding step is most 
determinative for their in-membrane concentrations. Of the four studied BCL2 proteins, BIMS 
apparent affinity for membranes is strongest with 1.7×, 2×, & 13× the strengths of BCL-XL, 
cBID, & BAX respectively. The membrane-integral forms of cBID and BIMS are capable of 
driving BAX and BCL-XL to tight membrane affinity conformations but the two BH3s’ 
recruiting efficiencies are equivalent, suggesting a complementary activation mechanism besides 
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strictly utilizing a membrane interaction scaffold. Overall, these data reveal receptor-like roles 
for cBID & BIMS for soluble BCL2 proteins during the initiation of apoptosis. 
4.2 | Introduction 
BCL2 family proteins are central regulators of apoptosis and comprise anti- and 
proapoptotic effectors partially defined by sequence conservation in four BCL2 homology 
(BH) domains (1,2). The family is further subclassified according to the number of BH 
domains each member contains. Antiapoptotic proteins (e.g. BCL-2, BCL-XL) are 
multidomain—encompassing three or four BH domains—and share a core tertiary fold 
consisting of a central, mostly hydrophobic α-helical hairpin surrounded by six amphipathic 
helices (3). Multidomain proapoptotic members (i.e. BAX, BAK—the apoptosis 
“executioners”) contain BH1-3 and counterintuitively display tertiary structures nearly 
identical to their antagonists (4,5). BH3-only proteins compose the third subclass and are 
stationed about the cell, serving to integrate disparate cell stress signaling pathways. In general, 
BH3-only proteins are predicted to be intrinsically-disordered, except BID whose α -helical 
arrangement mimics the multidomain proteins (6-9). 
Solution interactions between antiapoptotic and BH3-only proteins and peptides have 
been fairly well characterized and quantified via in vitro reconstitution regimes and detergent 
extractions from organelles and whole cells; a recent and thorough examination by B.H. Oh 
and coworkers comprised an array of antiapoptotics and their binding affinities to BH3 
peptides from BAX/BAK and numerous BH3-only proteins (10). Conversely, solution 
interactions between BAX/BAK and BH3-only proteins/peptides have historically proven 
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difficult to detect, leading to two competing models of activation—derepression of intrinsically 
active BAX/BAK vs. direct activation of inert BAX/BAK through a transient, hit-and-run 
interaction (11-13). The direct activation model was further refined by Kim et al. and Leber et 
al. in their hierarchical and embedded-together schemes (14,15). 
A significant aspect that has been largely overlooked in biochemical elucidation of 
BCL2 protein function is the solublemembrane transition. Many studies on membrane 
targeting have relied on cellular expression of truncated BCL2 family protein constructs and 
most often implicate the proteins’ carboxy-termini as membrane addressing sequences. The 
death effector BAX is considered dormant when cytosolically dispersed but can nevertheless 
receive an activating signal inducing redistribution of the protein to cellular membranes. Due to 
the aforementioned inconsistency in detecting BAX-BH3-only protein interactions in solution, 
the mechanism, especially localizations, of BAX activation are speculative. 
BCL-XL is known to reside both on intracellular membranes and in the bulk cytosol 
whereas BAX and BID are largely cytosolic, though BAX can be “loosely associated” with 
mitochondria (16-18). Previous in vitro assays on BAX, however, showed it could transiently 
interact with liposome membranes and expose its amino-terminus for antibody binding and, 
more recently, electron paramagnetic resonance spectroscopy of spin-labeled BAX 
demonstrated the protein’s intrinsic membrane binding functionality (19,20). BAX activator 
cBID (caspase-8 cut BID) has also been shown to disrupt membranes—rendering LUVs CF-
permeant—while BIMS, the most potent apoptosis-inducing BIM isoform, constitutively 
localizes to mitochondrial membranes (21,22). Targeting of BID & BIM BH3 peptides to 
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membranes strongly amplifies their capacity to induce mitochondrial cytochrome c egress and 
vesicular BAX pore formation (23-25). 
Thus we sought to further illuminate the process by which BAX adsorbs to membranes, 
a necessary precursor to its in-membrane oligomerization and pore formation (26). By adopting 
the now standard vesicle leakage assay (24,27,28), we demonstrate the physiological relevance of 
our reconstituted system; kinetic analysis of LUV permeabilization reveals that BIMS more 
efficiently than cBID provokes BAX pore activation and is less suppressible by BCL-XL. Surface 
plasmon resonance spectroscopy allows real-time measurement of membrane interaction by 
soluble BCL2 proteins and these data are well-fit by a two-step binding mechanism as described 
previously (29). Further application of this technique demonstrates that membrane-bound 
BH3-only activators are sufficient and functionally comparable for recruiting BAX and BCL-
XL. 
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4.3 | Results 
Vesicle membrane poration by BCL2 proteins 
BAX, BCL-XL, cBID & BIMS differentially permeabilize LUVs 
To confirm that these proteins can independently interact with membranes, LUVs 
encapsulating 20 mM carboxyfluorescein (MW: 0.38 kDa) were synthesized with a lipid 
composition modeling the mitochondrial outer membrane. As shown in Fig. 4.1A, 50 nM 
monomeric BAX, monomeric BCL-XL, cBID (native p7/p15 complex (8)), & BIMS are each 
capable of interacting with vesicles as revealed by CF dequenching. BIMS is by far the most 
effective in permeabilizing vesicles, which corresponds to the protein’s poor solubility and 
requirement of detergent to alleviate aggregation during purification. CF-leakage rate of BAX, 
BCL-XL, and cBID are similar and substantially slower than that of BIMS. 
Conversely, similar concentrations of BCL-XL, cBID, and BIMS individually induce 
trivial LUV leakage of 10 kDa FITC-dextran (FD10) (Fig. 4.1B), revealing that these proteins’ 
membrane interactions slightly disrupt bilayer integrity, rendering it permeant to small 
molecules but not to macromolecules. BAX, however, at 50 nM displays a low-level capacity to 
release FD10 from liposomes (Fig. 4.1B); this intrinsic activity is suppressible by addition of 10 
nM BCL-XL (data not shown) lending evidence that monomeric BAX (and BAK) can 
stochastically autoactivate (30-34). 
 
 
 
107 
 
A 
B 
0 1000 2000 3000
0.0
0.5
1.0
No
rm
al
ize
d 
De
qu
en
ch
in
g
time (s)
 50 nM BIMS
 50 nM cBID
 50 nM BAX
 50 nM BCL-XL
 CF LUVs
0 2500 5000
0.0
0.5
1.0
No
rm
al
ize
d 
De
qu
en
ch
in
g
time (s)
 50 nM BAX
 50 nM BIMS
 50 nM BCL-XL
 50 nM cBID
 FD10 LUVs
Fig. 4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1 | Vesicle interaction and differential permeabilization by recombinant BCL2 
proteins. In all cases, LUVs were diluted into 1 cm assay cuvets to a lipid concentration 
of 10 μM (1 mL total volume) and brought to 37°C. BAX, BCL-XL, cBID, & BIMS were then 
diluted 100-fold from 5 μM stocks, resulting in 50 nM solution concentrations and 1:200 
protein:lipid molar ratios. A, LUVs comprising the small dye (0.38 kDa) 5(6)-
carboxyfluorescein were incubated with indicated BCL2 proteins. B, LUVs encapsulating 
10 kDa FITC-dextran (FD10) were incubated with indicated BCL2 proteins. 
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BAX is more efficiently activated by BIMS than cBID 
To further validate our reconstituted in vitro experimental system, BAX pore activation 
by BH3-only direct activators cBID and BIMS was assessed. Cut or truncated BID is a 
commonly used activator but very little biochemical characterization of BIM has been 
performed, thus we sought to make direct comparisons on the efficacies of the two BH3-only 
proteins. On a dose-dependent basis, cBID and BIMS are both effective accelerators of BAX 
pore formation (Fig. 4.2). However, per nM of BH3-only protein, BIMS (Fig. 4.2B) is a more 
effective BAX activator than cBID (Fig. 4.2A); the inverse times for half-maximal LUV 
dequenching are plotted to demonstrate this activation disparity (Fig. 4.4A). Interestingly, at 
50 nM BAX, cBID-BAX activation saturates at roughly 50 nM activator and the cBID EC50 is 
12 nM. Conversely, BIMS-BAX activation saturates well above 100 nM activator and the BIMS 
EC50 is 40 nM. 
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Fig. 4.2 | BAX pore activation by cBID & BIMS. Leakage experiments were similar to Fig. 
4.1 but proteins were diluted into 37°C assay cuvets sequentially—BAX, cBID/BIMS—to 
preclude spurious solution interactions at superphysiological concentrations, followed 
by addition of FD10 LUVs within 30 seconds. In all traces, [BAX] is 50 nM. A & B, FD10 
LUVs were incubated with BAX and concentrations of cBID/BIMS are noted accordingly. 
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Having examined the differential activation efficacy of BIMS and cBID, the extent of 
BCL-XL suppression of BAX pore formation was then investigated; depicted in Fig. 4.3A & B 
are leakage traces of 50 nM BAX + 20 nM activator subjected to escalating concentrations of 
inhibitory BCL-XL. These traces demonstrate that not only is cBID a less effective BAX 
activator, it is also more susceptible than BIMS to inhibition by BCL-XL. Stoichiometric 
addition of BH3-only activator and BCL-XL most strikingly make apparent their BAX 
activation inequivalencies as 50 nM inhibitor completely ablates leakage induced by 50 nM 
cBID + BAX but merely delays pore formation elicited by 50 nM BIMS + BAX (Fig. 4.3C & 
D). Per nM of BCL-XL, cBID-BAX pore activation is proportionately suppressed to a greater 
extent than BIMS-BAX pore activation (Fig. 4.4B). Were inhibition by BCL-XL equivalent at 
similar concentrations of BH3-only activator, the fitted lines would intersect the X-axis at the 
same point. Points on the x-axis of Fig. 4.4B represent the theoretical quantities of BCL-XL 
required for insurmountable suppression of BAX pore activation; 20 & 50 nM cBID can be 
fully inhibited by 27 & 33 nM BCL-XL while 20 & 50 nM BIMS require drastically greater 
[BCL-XL] (45 & 83 nM respectively). 
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Fig. 4.3 | BAX pore suppression by BCL-XL. Leakage experiments were conducted as in 
Fig. 4.2 and BCL2 proteins were added sequentially—BAX, BCL-XL, cBID/BIMS—and 
immediately followed by FD10 LUVs. In all traces, [BAX] is 50 nM and [BCL-XL] varies 
from 0 to 50 nM as indicated. A & B, BCL-XL dose-dependent suppression of 20 nM cBID 
(A) & BIMS (B) activation of BAX. C & D, BCL-XL dose-dependent suppression of 50 nM 
cBID (C) & BIMS (D) activation of BAX. 
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Fig. 4.4 | Kinetic analyses of BAX pore activation by cBID/BIMS and suppression by 
BCL-XL. Plotted are inverse values of the time for half-maximal leakage of FD10 from 
LUVs taken from traces in Fig. 4.2 & Fig. 4.3; 1/t1/2 values plotted on the y-axis decrease 
as rate of FD10 leakage slows. Dashed lines are exponential (A) and linear (B) fits. A, 
Differential BAX pore activation by cBID & BIMS. B, Differential suppressions by BCL-XL of 
cBID- & BIMS-BAX pore activation. Points on the x-axis indicate intercepts of linear fits. 
 
 
113 
 
Vesicle membrane binding by BCL2 proteins 
BAX, BCL-XL, cBID, & BIMS independently bind vesicle bilayers 
To glean insight into these proteins’ adsorption to membranes, surface plasmon 
resonance spectroscopy was exploited. SPR is advantageous in that it requires no potentially 
interfering modifications (such as fluorophore conjugation) of the components and the system 
can be monitored in real-time by direct measurement of mass accumulation near the sensorchip 
surface (demarcated in resonance units, RU). Two hundred nm LUVs—which retain their 
vesicular structure—can be immobilized on a sensor chip’s hydrogel matrix to provide bilayers 
for protein binding (35). Given the dimensions of the L1 sensorchip flowcell (2.4 × 0.5 × 0.05 
mm) and our LUVs, we estimate the experimental lipid concentration to be 250-300 μM. L1 
sensorchip surfaces saturate at ≈7000 RU vesicles; from bound vesicle/protein values and 
molecular weights, relative concentrations can be readily calculated. For simplicity, membrane 
binding parameters (Table 4.1) are reported with respect to moles of binding sites rather than 
moles of lipid. 
As shown in Fig. 4.5, each soluble BCL2 protein is independently capable of peripheral 
membrane interaction and assuming an integrated form. Kinetic parameters of protein-
membrane binding are presented in Table 4.1. The membrane binding traces of BAX, cBID, 
and BIMS are well-fit by a two-step sequential mechanism— *P M PM PM+   —
comprising a rapid peripheral binding step that is reversible and distinct from a subsequent and 
long-lived conformational change(s) and/or reorganization of the lipids. The rate equation was 
modified for cBID to account for dissociation of the N-terminal p7 fragment upon membrane 
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binding, rendering a membrane-integral p15 tBID (36). BCL-XL also displays a rapid peripheral 
binding step but the successive steps are more complicated. The drop in RU over the last 20-30 
s of protein injection is not artifactual as similar data were gathered using multiple protein and 
LUV preparations and sensorchips. Details on correcting the BCL-XL traces to account for 
signal loss, which we attribute to immobilized vesicle swelling on the sensorchip surface, are 
included in the Supplement. 
For the four proteins studied, their membrane affinities (Kd) vary over a 13-fold range 
with BIMS binding membranes most tightly and BAX most weakly (Table 4.1). The apparent 
Kd values, however, mask important details of the membrane interaction progression. 
Correlating with its poor solubility, BIMS peripherally binds most avidly (BIMS ka1 ≈ 4.3× 
BCL-XL ka1, 6× cBID ka1, & 35× BAX ka1); while their ka1 rates vary widely, the four proteins’ 
kd1 rates are fairly similar and very rapid, resulting in membrane peripheral affinities (Kd1) 
ranging from 5.5 μM (BIMS) to 145 μM (BAX). 
 Unlike the peripheral binding steps which display widely varying kinetics, the 
integration steps for BIMS, BCL-XL, cBID, and BAX are somewhat comparable and parameters 
(ka2) lie within a 4-fold range. Despite having the weakest membrane peripheral affinity, BAX 
integrates most rapidly but this integral form also dissociates from the membrane (kd2) more 
readily compared to membrane-integral BCL-XL, BIMS, and tBID. The integrated proteins’ 
membrane affinities (Kd2) vary over a 3-fold range and have half-lives greater than 3 hours. 
Overall, BIMS apparent affinity (Kd) for membranes is 1.7×, 2×, and 13× that of BCL-XL, 
cBID, and BAX respectively. 
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To clearly illustrate their accumulations on vesicles at equimolar concentrations, 
simulations of BCL2 protein-membrane interactions were compiled (Fig. 4.5E). The protein 
concentration input was 1250 nM (vs. 250 μM lipid) which approximates the highest (5:1000) 
protein:lipid ratio used in the LUV leakage experiments (Figures. 4.1-4.3). Simulated traces 
were also corrected to molar fractions to properly contextualize the protein adsorptions to 
bilayers. Correlating kinetics between the vesicle leakage and biosensor systems should be 
approached cautiously, however, because for SPR assays the solution protein concentrations are 
constant and the comparatively high concentration of vesicles are immobilized on a hydrogel 
matrix rather than diffusing freely in solution. 
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Fig. 4.5 | Real-time measurement of BCL2 protein-membrane binding by surface 
plasmon resonance spectroscopy. A-D, Displayed are sensorgram traces and data 
fittings of protein-membrane adsorption. Soluble BCL2 proteins were injected at 
indicated concentrations for 90 s (30 μL/min.) over immobilized LUVs then dissociation 
monitored for 10 min.; note the breaks from 150-500 s in plots. The experimental data 
were globally fitted to their corresponding two-step kinetic models described in 
Materials & Methods. Correction for RU signal loss during BCL-XL injections is described 
in the Supplement. E, Simulated traces of protein-membrane binding. Traces were 
corrected for protein molecular weights and presented as membrane mole fraction 
rather than mass bound (RU). Soluble protein concentration input to simulation was 
1250 nM, approximating 5 soluble molecules per 1000 vesicular lipids as applied to LUVs 
for leakage experiments in Fig. 4.1 (i.e. 50 nM protein + 10 μM vesicular lipid). 
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Table 4.1 | Kinetic parameters of BCL2 protein-membrane binding. 
  ka1 kd1 ka2 kd2 Kd1 Kd2 Kd 
  M-1 s-1 × 104 s-1 s-1 × 10-2 s-1 × 10-4 M × 10-6 × 10-3 M × 10-9 
BAX 0.55 0.8 7.3 1.0 145 1.37 199 
BCL-XL 4.44 0.44 1.9 0.5 9.91 2.63 26 
cBID 3.21 1.04 5.7 0.5 32.4 0.88 28 
BIMS 19.0 1.04 1.8 0.5 5.47 2.78 15 
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Membrane-bound tBID & BIMS robustly recruit BAX & BCL-XL 
Having examined the kinetics of membrane binding by each BCL2 protein, we then 
hypothesized that membrane-bound BH3-only proteins are sufficient to recruit the 
multidomain proteins to membrane-integral states. Previously, Oh et al. demonstrated that 
BID BH3 peptides tethered to vesicle surfaces potentiated BAX pore activity (24). We sought 
to expand on this finding by using full-length BH3-only proteins in our experimental regime 
which precludes the presence of non-membrane bound activators and allows delineation and 
temporally-resolved comparison of protein recruitment at the membrane. Kinetic assays of 
BAX/BCL-XL membrane binding were performed as before except tBID & BIMS were applied 
to LUVs prior to sensorchip immobilization. 
As anticipated, membrane-bound tBID and BIMS substantially enhance the membrane 
association of both BAX and BCL-XL (Fig. 4.6). Presence of the BH3-only proteins (one 
protein per 6000 lipids) in the membrane increases the integrated quantities () of BAX & 
BCL-XL and commensurately enhances the bound (peripherally associated + integrated) 
protein pool (). Unexpectedly, membrane-bound tBID and BIMS display similar efficiencies 
in recruiting the multidomain proteins (4.6A vs. 4.6C, 4.6B vs. 4.6D); this finding was 
surprising given the faster BAX pore activation elicited by BIMS than by cBID. During the 90 s 
injections, tBID & BIMS increase the BAX membrane integration rate ≈75%, from 0.073 s-1 to 
0.128 s-1 at all measured soluble concentrations. Conversely, tBID/BIMS enhance the 
membrane integration of BCL-XL (ka2 = 0.019 s-1) by progressively lower rates with increasing 
soluble protein concentration (120 nM - 0.031 s-1; 240 nM - 0.029 s-1; 480 nM - 0.028 s-1; 960 
120 
 
nM - 0.025 s-1; 1920 nM - 0.023 s-1) (Fig. 4.6E). Both BH3s recruit superstoichiometric 
quantities of BAX & BCL-XL; however, BCL-XL recruitment levels off at ≈1.7 × [BH3] while 
BAX recruitment continues to rise with increasing [soluble BAX] (≈4.5 × [BH3] at 3.8 μM 
BAX). These findings comport with an interaction model in which BAX transiently binds 
BID/BIM whereas BCL-XL sequesters BID/BIM strongly to prevent further propagation of 
death signals. 
To provide a negative control, BID BH3 mutant L90A,D95A (cBIDmut) was purified; 
in studies using BH3 peptides, this mutant was ineffective in eliciting cytochrome c release from 
isolated mitochondria and activating BAX in vitro (23,37). Interestingly, 50 nM cBIDmut 
weakly activated 50 nM BAX in FD10 leakage assays (Fig. 4.S2A), though at lower efficiency 
than 5 nM wild-type cBID. When applied to vesicles to assess recruiting efficiency of BAX and 
BCL-XL, cBIDmut (1 protein : 6000 lipids) also weakly recruited BAX (Fig. 4.S2B), accelerating 
the membrane integration (ka2) ≈10% from 0.073 s-1 to 0.08 s-1. Conversely, cBIDmut had no 
discernable recruitment of BCL-XL (data not shown). 
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Fig. 4.6 | Membrane-bound tBID & BIMS robustly recruit BAX and BCL-XL. LUVs (1 mM 
lipid) were preincubated with 170 nM cBID or BIMS in EB for three hours at room 
temperature prior to loading onto the Biacore sensorchip, resulting in a 1:6000 BH3-only 
protein:lipid ratio. BAX and BCL-XL injections commenced as in Fig. 4.5. Membrane-
bound values () were taken from the end of soluble protein injection and membrane-
integrated values () after 5 min. of dissociation; these values were converted into 
protein/1000 lipids from experimental RU values to facilitate analysis. Solid lines 
represent BAX/BCL-XL injections over tBID/BIMS-charged vesicles and dashed lines 
represent BAX/BCL-XL injections over bare vesicles. A, BCL-XL binding to vesicles ± tBID. 
B, BAX binding to vesicles ± tBID. C, BCL-XL binding to vesicles ± BIMS. D, BAX binding to 
vesicles ± BIMS. E, BAX & BCL-XL ka2 (integration) rates accelerated by membrane-bound 
BH3-only activators. BAX ka2 is accelerated by ≈75% regardless of membrane-bound BAX 
concentration whereas BCL-XL ka2 acceleration diminishes (65%20%) with increasing 
membrane-bound BCL-XL. Dashed lines represent BAX & BCL-XL ka2 in the absence of 
BH3-only activators and symbols+lines indicate ka2 accelerations in the presence of BH3-
only activators. 
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4.4 | Discussion 
Despite nearly two decades of work on the BCL2 protein family, the molecular 
mechanisms of their disparate functions are only recently becoming deciphered. Much of the 
difficulty in their study derives from the proteins’ conformational promiscuity and 
amphitropicity, properties that are modulated by their bulk environments and a variety of 
discrete regulatory molecules both proteinacious and lipidic. Another hindrance is that 
traditional methods of isolating membrane proteins (i.e. detergent extraction) radically alter 
BCL2 protein conformation and the proteins themselves can affect micellar aggregation (38-
42). Thus generating a consistent pool of recombinant protein for mechanistic in vitro studies 
has proven troublesome and, due to this constraint, the field has relied largely on biochemical 
assays that provide only functional snapshots and qualitative interpretations. 
Lipid bilayer interaction and disruption has long been established as a function of the 
BCL2 family with the latter evinced by BCL-XL structural homology to bacterial toxins (43). 
As an initial test for protein-membrane interaction, LUVs containing a small fluorescent dye 
(carboxyfluorescein) were subjected to leakage assays. The four proteins studied—BAX, cut 
BID, BIMS, and BCL-XL—represent the three main classes of the BCL2 family and all elicited 
leakage of CF at nanomolar concentrations and physiological pH. Early work on the channel-
forming capacities of multidomain BCL2 proteins typically employed C-terminally truncated 
and detergent-treated forms of the proteins (44,45). Vesicle permeabilization to small dyes by 
detergent-free BCL-XLΔC can be induced by acidic pH or tethering the protein to membranes 
via His-tag chelation of DOGS-NTA-Ni2+ lipids (46,47). BCL-2ΔC tethered to membranes also 
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can generate small pores, though the addition of tBID was required for this activity (48). The 
disparity in BCL-XLΔC and BCL-2ΔC poration may be attributable to vesicle composition, with 
the former using a simple 99:1 PC:DOGS-NTA-Ni2+ mixture and the latter a complex mixture 
comprising PC, PI, PE, PS, CL, & DOGS-NTA-Ni2+ to mimic the mitochondrial outer 
membrane. Among BH3-only proteins, native cBID and detergent-separated tBID have also 
been shown to porate vesicles (47,49). Recent electrophysiological work on BAD has indicated 
that it can form membrane channels and this activity is largely a consequence of its C-terminus 
(50,51). Peptides encompassing BAX α5 and BID α6 induce leakage of calcein from vesicles and 
the C-terminal ≈20 residues of BAX, BAK, and BCL-2 also have the capacity to release CF 
from liposomes (52,53). Taken together, it is apparent that BCL2 protein-membrane 
interaction slightly disrupts bilayer integrity from both the α5-6 hairpins and C-terminal 
domains. 
Much in vitro experimental work has been performed reconstituting vesicle leakage 
systems to model mitrochondrial permeabilization; however, BID has been nearly the exclusive 
BH3-only protein used for BAX or BAK activation. Inclusion of BH3 peptides in LUV leakage 
assays and in vitro translated proteins for mitochondrial cytochrome c releases have also revealed 
that BIM and PUMA can also directly activate BAX/BAK (14,54-57). Therefore we chose to 
compare the efficacies of recombinant, full-length (cut) BID and BIMS in activating BAX; BID 
was cut by caspase-8 but left unseparated to more accurately mimic the native environment (8). 
As we surmised, the kinetics of FD10 leakage from LUVs elicited by cBID and BIMS were 
substantially different, with BIMS being the more effective trigger of BAX poration. Kinetic 
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analysis of LUV leakage elicited by escalating concentrations of the two activators exposes that 
their capacities to activate BAX saturate at dramatically different concentrations. 
The strong efficacy of BIMS for activating BAX lies in contrast to a report by Terrones 
et al. in which BIMLΔC and BIMELΔC only weakly induced BAX pore activity even when 
tethered to vesicles (25); however, their data also showed that a myristoylated BIM BH3 
peptide was more potent in activating BAX than a myr-BID BH3 peptide. When applied to 
isolated mitochondria, recombinant BIML was ineffective in promoting cytochrome c release 
and BAX membrane integration (58). It seems likely that the isoforms’ functional disparities 
are a consequence of the relative accessibility of their BH3 domains as BAX 
coimmunoprecipitates with BIMS but not BIML or BIMEL (59,60). 
Having investigated the LUV leakage kinetics induced by BAX + BH3-only activator, 
we further interrogated the process by including antiapoptotic BCL-XL. In accordance with 
prior work, inclusion of BCL-XL inhibited LUV permeabilization by BAX in a dosage-
dependent manner (61). Surprising, however, was our finding that not only was BIMS more 
effective in driving BAX pore formation, it was less suppressible by BCL-XL than cBID-BAX 
activation (Fig. 4.4). Peptide binding studies of BCL-XL have consistently shown that the 
antiapoptotic protein sequesters BIM BH3 more tightly than BID BH3 (10,37,62). The greater 
proportional suppression by BCL-XL of cBID over BIMS suggests that binding affinity is not 
the sole determinant of inhibition. 
Our attention then turned to applying a real-time, quantitative method to BCL2 
protein-membrane binding. One point of contention in deciphering the mechanisms of the 
126 
 
BCL2 family is the relevance of solution interactions, especially by those of BAX. Yethon et al. 
demonstrated that BAX independently associates with LUVs and studies using BH3 peptides 
tethered to vesicles strongly hinted that BAX can bind membranes prior to becoming activated 
(19,24,25). As our SPR data reveals, BAX can bind membranes independently of extrinsic 
factors, as can its cousins BCL-XL, cBID, and BIMS. This adsorption is well-described by a two-
step mechanism whereby the soluble proteins assume a long-lived, membrane-integral form and 
the key disparity in their interaction progression lies in the initial, peripheral association. 
Relative to cBID and BAX, BCL-XL and BIMS have very rapid on-rates and their apparent 
affinities for membranes are also tighter. These data quantify the intrinsic membrane binding 
capacity of four representative members of the BCL2 family and clarify the mechanism 
proposed by Billen et al. in which BCL-XL outcompetes BAX for tBID in membrane binding 
and permeabilization (61) (Fig. 4.5E).  
Remaining unresolved was the origin of the disparity between BIMS- and cBID-BAX 
activation. We speculated that membrane-bound BIMS would more robustly recruit BAX than 
membrane-bound tBID in our real-time binding assays; this supposition proved to be incorrect 
as the two BH3-only activators were equivalent in escalating BAX integration. Membrane-
bound tBID and BIMS showed essentially identical recruitment of BCL-XL as well. Notably, 
tBID/BIMS recruitment of BCL-XL was saturable, unlike recruitment of BAX which was 
enhanced similarly regardless of soluble concentration. This result comports with the findings 
that BCL-XL sequesters tBID very strongly on membranes while tBID-BAX interaction is 
transient and exchangeable (36,47). The BH3-only protein BAD, when bound to vesicles, has 
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also shown a capacity to enhance BCL-XL-membrane binding, demonstrating that 
multidomain protein recruitment at the membrane surface is a function of the sensitizer 
subclass, not only of direct activator BH3s (63). 
This recruitment equivalency at the membrane surface suggests that the more rapid 
accumulation of BIMS on bilayers is the origin of its greater BAX pore activation rate. However, 
BAX membrane binding is weakest and thus the limiting step; the maximal rate of pore 
activation by BIMS and cBID would converge to similar values if membrane concentration of 
BH3s were the dominant parameter (Fig. 4.4A). Direct BAX-BIMS binding in solution would 
provide a plausible explanation for BIMS superiority over cBID in triggering BAX activation. 
Frustratingly, unlike those with antiapoptotic BCL2 proteins, BH3 domain interactions with 
BAX have proven resistant to investigation. By chemically enforcing α-helicity of BH3 peptides, 
Walensky et al. demonstrated direct binding by BID and BIM BH3s to BAX in solution (37); 
intriguingly, BIM SAHB bound BAX >30× tighter than BID SAHB. Conversely, FRET assays 
of BAX and full-length tBID indicated no interaction in the bulk solvent while the addition of 
vesicles facilitated association (36). Antiapoptotic MCL-1ΔC incubated with cBID interact in 
solution via canonical BH3 domain-pocket binding; this association is very slow to due to the 
dissolution kinetics of the two cBID fragments and subsequent exposition of the BID BH3 
domain (64). Solution interactions between BCL-XLΔC & tBID also have been detected and 
quantified via fluorescence cross-correlation spectroscopy, NMR, and isothermal titration 
calorimetry (47,65). Given the observations of greatly stronger affinity of BAX for BIM SAHB 
vs. BID SAHB, inaccessibility of the BH3 domain in cBID, and tBID-BAX binding solely on 
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membranes, it seems likely that BAX can become activated via BH3 interaction both prior and 
subsequent to membrane interaction. Strongly supporting this hypothesis is a recent report in 
which BIM (and also BAX) SAHBs were employed to evoke conformational intermediates of 
the BAX activation pathway (30). 
Solution interaction and activation of BAX by BIMS, but not cBID, also reconciles the 
differential suppression by BCL-XL of vesicle leakage. Whereas cBID could activate BAX only 
subsequent to their localizations at the membrane, BIMS would lack this kinetic barrier. BCL-
XL has a stronger affinity for bilayers than cBID, thus the antiapoptotic protein has the 
advantage in “outracing” cBID, and especially BAX, to their in-membrane functional sites (Fig. 
4.5E). BIMS, on the other hand, could bypass this constraint via activating BAX prior to 
membrane binding. In the bulk solution, BCL-XL and BAX would compete for BIMS binding, 
but this impediment to BAX activation is comparatively surmountable due to BAX having 
nearly as strong an affinity as BCL-XL (24 nM vs. 16 nM respectively) for BIM SAHB (37). 
The weak activation and membrane recruitment of BAX by cBID BH3 mutant 
L90A,D95A was unexpected as the corresponding peptide was ineffective in promoting 
cytochrome c release from mitochondria and the corresponding tBID mutant also ineffective in 
promoting LUV leakage (23,24). Previously reported, however, was a BH3-independent 
enhancement of BAX pore formation by BH3 mutant tBID G94A that was attributed to the 
protein’s alteration of bilayer architecture (25). Our vesicle leakage and membrane binding 
kinetic data is consistent with tBID promoting BAX poration via modulation of the bilayer 
structure; this BH3-independent effect is quite small as cBIDmut was less than 10% as efficient in 
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driving BAX pore formation and accelerated BAX membrane integration only 15% as well as 
wild-type tBID. 
In summary, we’ve demonstrated that BCL2 family proteins—anti- and proapoptotic 
multidomain and BH3-only—have intrinsic membrane binding capacity and quantified a two-
step mechanism of their membrane interactions. BH3-only activators bound to bilayers robustly 
recruit BAX and BCL-XL by enhancing their membrane integration rates. Kinetic analysis of 
vesicle leakage elicited by BAX reveals disparities in the activation efficacies of BIMS and cBID 
and lends support to a model whereby BAX can be activated by BH3 interaction both in the 
cytosol and on the mitochondrial outer membrane. 
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4.5 | Supplement 
 
Membrane poration by the BCL2 family has been proposed to be a function of the 
proteins’ modulation of bilayer curvature (28,49,53,66); by small-angle x-ray scattering, we have 
observed that BAX and BCL-XL promote oppositional negative and positive curvatures 
(Appendix V). We attribute SPR signal loss during BCL-XL injections to LUV swelling. The 
evanescent field and thus SPR signal decays as a function of distance from the basal metal 
surface and becomes essentially undetectable at 300 nm (67). Therefore, vesicle swelling 
induced by positive membrane curvature displaces vesicle (and bound protein) mass outside the 
detection volume. We presume that BCL-XL binds to membranes in a two-step fashion similar 
to BAX & BIMS. BCL-XL dissociation curves were fit to a three-component exponential decay 
to determine off-rates kd1 & kd2 and the rate of RU signal loss; global fitting established kd1 = 
0.44 s-1 & kd2 = 0.5 × 10-4 s-1. Fitting of the first 30-45 s of 120 nM & 240 nM BCL-XL 
injections then produced lower boundary ka parameters for simulating curves for higher 
concentrations of BCL-XL (Fig. 4.5B). Simulated curves were subtracted from the raw data 
traces to yield the degree of signal loss (Fig. 4.S1A) and the first derivatives of the signal loss 
residuals (Fig. 4.S1B) were then obtained to assess consistency between the rates of signal loss at 
the end of injection (association period) and beginning of wash (dissociation period). 
To verify that BCL-XL can induce LUV swelling in solution, vesicles (10 μM total 
lipid) were diluted into EB (10 mM HEPES-KOH, pH 7.0, 100 mM KCl, 0.5 mM DTT) and 
incubated with indicated ratios of protein for 2 hr. at room temperature; each ratio was 
performed in triplicate. Vesicles were then sized by dynamic light scattering in an N5 
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Submicron Particle Size Analyzer (Beckman Coulter) and values obtained from the unimodal 
distribution analysis peaks (Fig. 4.S1C). BAX, cBID, & BIMS (5 proteins / 1000 lipids) were 
also assessed for vesicle swelling activity but none produced statistically significant values 
different from the buffer control (data not shown). 
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Fig. 4.S1 | SPR trace correction of BCL-XL-membrane binding. A, Residuals from 
subtraction of simulated two-step binding curves from raw data traces at indicated 
concentrations of BCL-XL. B, Slope of the residuals traces from Fig. 4.S1A, to assess 
consistency between signal loss during and after injection. C, BCL-XL-induced LUV 
swelling in solution as determined by dynamic light scattering. 
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Fig. 4.S2 | tBIDmut weakly recruits BAX at the membrane surface. A, Dequenching 
assays were performed as in Fig. 4.2 and protein concentrations are noted in graphs. 
cBIDmut weakly activates BAX. For comparison, the blue trace is BAX + wt cBID as in Fig. 
4.2. B, SPR data traces and fittings of 7680 nM BAX injected over bare vesicles, vesicles 
charged with tBID, or vesicles charged with tBIDmut. Assays were performed as in Fig. 4.5 
w/ BAX injected for 90 s and dissociation monitored for 10 min. Data traces are averages 
of 2-3 independent experiments. tBIDmut accelerates BAX ka2 only 15% (0.073 s-1  0.08 
s-1) as efficiently as wt tBID (0.073 s-1  0.128 s-1). 
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4.6 | Experimental Procedures 
Protein purification 
Full-length cDNAs for human BAX, BCL-XL, and BID were subcloned into pTYB1 
vector (NEB; Ipswich, MA) and constructs verified by DNA sequencing; a C-terminal glycine 
was introduced into BID to alleviate in vivo intein tag autocleavage. BCL-XL, BID, and human 
BAX-PTYB1 expression constructs were transformed into BL21(DE3) E. coli and bacterial 
cultures grown in Terrific broth at 37°C until induction by 0.1 mM IPTG. Induced cultures 
were shaken for 16 hours at 23°C, bacteria were harvested by centrifugation, and pellets 
resuspended in lysis buffer (50 mM Tris, pH 8.0, 500 mM NaCl, 1 mM EDTA) + Complete 
protease inhibitor (Roche; Indianapolis, IN). Bacteria were lysed via three Microfluidizer 
passages at 1000 bar and lysate clarified by centrifugation. Clarified lysate was applied to chitin 
affinity resin followed by a high salt wash then equilibrated with cleavage buffer (lysis buffer + 
30 mM DTT) and incubated overnight at 4°C to allow cleavage from intein tag. Recombinant 
proteins were eluted, dialyzed against 20 mM Tris, pH 8.0, and polished by MonoQ anion 
exchange chromatography. BAX and BCL-XL were also gel filtered on a Superdex 200 column 
to remove non-monomeric species. BAX was initially monomeric but aggregated with time 
(20); BCL-XL was largely aggregated (≈90%), both after initial elution from affinity resin and 
anion exchange and SEC-purified monomeric BCL-XL also aggregated over time. Inclusion of 
1% CHAPS in BCL-XL purification mitigated aggregation only slightly. 
For BIMS, the full-length cDNA was subcloned into pTYB11 (NEB) and purified 
similarly to BAX, BCL-XL, and BID except 1% CHAPS was added to lysis, column wash, and 
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cleavage buffers, and no FPLC was performed. Purifications of BCL-XL and BID typically 
yielded 15-20 mg/L culture, BIMS 2.0 mg/L, and BAX 0.75 mg/L. Concentrations were 
quantified by micro BCA assay (Pierce) or spectrophotometrically at 280 nm and proteins 
stored in 20 mM Tris, pH 8.0, 250 mM NaCl, 5 mM DTT, 1 mM EDTA, 0.01% NaN3 (BIMS 
also contained 1% CHAPS) at 4°C. 
To generate cut BID (cBID), caspase-8 was added to BID (6 mg/mL) and incubated 
with 10 mM DTT overnight at room temperature. Mutants were generated via site-directed 
PCR mutagenesis. 
Large unilamellar vesicle preparation 
LUVs of 200 nm diameter modeling the mitochondrial outer membranes were 
prepared by freeze-thawing and extrusion. Ten mg total lipid (dissolved in chloroform) were 
mixed to yield a composition of DOPC:DOPE:DOPA:CL:cholesterol 49:28:10:5:8 
(mol/mol); chloroform was evaporated by nitrogen then lipids further dried under vacuum for 
two hours. Equilibration buffer (EB; 10 mM HEPES-KOH, pH 7.0, 100 mM KCl, 0.5 mM 
DTT) was added to dried lipid films and lipids rehydrated by a 30 s immersion in a bath 
sonicator; EB was supplemented with 20 mM 5(6)-carboxyfluorescein (CF) or 50 mg/mL 10 
kDa FITC-dextran (FD10) to yield liposomes for leakage assays. The mixture was then 
subjected to ten freeze/thaw cycles in liquid nitrogen and extruded 15 times through a 
membrane with 0.2 μm pores. Extravesicular CF or FD10 was removed by Sephadex G -25 or 
G-200 gel filtration respectively. 
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LUV leakage assays 
Dequenching of LUV-entrapped CF & FD10 were monitored by a Cary Eclipse 
fluorescence spectrophotometer (Varian; Palo Alto, CA) using a 1-cm path length 
thermostatted cuvette at 37°C. The fractional dequenching at each time point was quantified 
according to the equation (Ft – F0)/(F1 – F0) where Ft is the measured fluorescence of protein-
treated LUVs at time t, F0 is the initial fluorescence of the LUVs before protein addition, and F1 
is the fluorescence after complete LUV dissolution by addition of Triton X-100 to 0.2%. Lipid 
concentration of leakage assays was 10 μM after dilution into EB. 
Surface plasmon resonance assays of protein-membrane binding 
Experiments were performed using Biacore X100 instrumentation and software 
(Biacore division of GE Healthcare; Uppsala, Sweden) at an ambient temperature of 37°C. 
Biacore running buffer (EB) was filtered through a 0.22 μm filter and degassed prior to use and 
LUVs were prepared as described above; recombinant proteins were exchanged into EB by 
dialysis or gel filtration. The sensor surface of an L1 sensorchip was equilibrated with EB and 
LUVs were deposited by injecting 1 mM lipid for 10 minutes at a flow rate of 1 μL/min. BSA (1 
mg/mL) was then injected for two min. at 15 μL/min. to assess extent of vesicle cove rage of the 
surface and block remaining nonspecific binding sites (29,35). Proteins were injected over the 
supported LUVs for 90 s at a rate of 30 μL/min. to circumvent mass transport effects and 
dissociation monitored for >10 minutes. Response traces were corrected for baseline & 
injection artifacts and data were analyzed and displayed using Berkeley Madonna 8.3.8 
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(University of California, Berkeley, CA) and Origin 7.5 (OriginLab). Data were globally fit to 
binding models derived from schemes: 
I. 1 2
1 2
*a a
d d
k kP M PM PMk k+
 
 
  BAX, BCL-XL, BIMS 
II. 1 2
1 2
a a
d d
k kNC M NCM CMk k+
 
 
  cBID 
where P/NC corresponds to soluble protein, M to the membrane, PM/NCM to the 
membrane-associated protein, and PM*/CM to membrane-integrated protein conformations. 
Membrane affinity constants are calculated: kd1/ka1 = Kd1; kd2/ka2 = Kd2; Kd1×Kd2 = Kd. 
For kinetic experiments of BAX & BCL-XL membrane recruitment by BH3-only 
activators, assays were performed as above except LUVs (1 mM lipid) were preincubated with 
170 nM cBID/BIMS for three hours at room temperature to decorate the vesicles with BH3-
only protein (1 protein per 6000 lipids). 
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5.1 | Conclusions 
The process by which BAX effects cell death comprises three basic steps: mitochondrial 
translocation, membrane integration, and oligomerization culminating in bilayer 
permeabilization. The components of this dissertation describe our interrogations of these 
steps, largely employing biophysical measurements of cell-free, reconstituted experimental 
regimes.  
In Chapter 2, we established that cholesterol impedes BAX pore activation, which 
provides a rationale for the escape of cell outer membranes from BAX predation during 
apoptosis. Mitochondrial accumulation of cholesterol also provides a means for alleviating the 
pro-death function of BAX during cell stress. Using detergent-treated BAX—to bypass 
complicating activation factors—and dye-filled synthetic vesicles, we demonstrated that 
cholesterol severely impedes leakage induced by BAX while Hill analyses revealed that BAX 
retained oligomerization capacity. Development of a vesicle-mitochondria fusion technique 
allowed filling of the organelles with dye for leakage assays, providing a complex membrane that 
retains mitochondrial defense mechanisms against poration. These fused mitochondria 
recapitulated our finding that cholesterol inhibits BAX activity. Inclusion of the total 
enantiomer of cholesterol in leakage assays showed that BAX pore inhibition by cholesterol is 
due to the sterol’s influence on bilayer architecture rather than a stereospecific interaction with 
the protein. Real-time SPR spectroscopic measurements uncovered that bilayer cholesterol 
exerts its influence on BAX function by mitigating the protein’s integration into membranes 
and thus permits fewer in-membrane BAX monomers for assembly into pore structures. 
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Chapter 3 detailed our investigation into the effects of cholesterol derivatives—
oxysterols and bile acids—on BAX activity. As with cholesterol, oxysterols and bile acids are 
associated with a number of pathological conditions and while mitochondria are typically 
cholesterol-poor organelles they perform many chemical modifications of the sterol. Whereas 
cholesterol inhibited BAX membrane permeabilization, 25-hydroxycholesterol accelerated it; 
importantly, the oxysterol promoted leakage by BAX when activated either by non-
physiological detergent or BH3-only protein cBID. Most of this poration enhancement arose at 
physiologically-plausible solution concentrations up to 5 μM 25-HC. Bile acids are natural 
detergents used to solubilize dietary fats but are toxic at high concentrations. With the finding 
that lithocholic and chenodeoxycholic acids induce apoptosis in colon cancer cells, we reasoned 
that BAX may be activated by the bile acids. Intriguingly, both LCA and CDCA activated C-
terminally truncated BAX at low μM (sub-CMC) quantities. Unfortunately, activation of full-
length BAX, which includes the auto-inhibitory C-terminal helix, requires micellar bile acids. 
Thus we conclude that while bile acids promote destabilizing the soluble fold of BAX, in 
isolation they are most likely insufficient to elicit a death-effecting conformation. 
The mechanism by which BCL2 proteins mitochondrially translocate was clarified by 
the investigations composing Chapter 4. Direct interactions between BAX and BH3-only 
proteins have been inconsistent and difficult to detect, fostering confusion over the process and 
localization of BAX activation. For the first time, two BH3-only direct activators were 
compared in their efficacies for triggering BAX poration. We demonstrated that BIMS, relative 
to cBID, more strongly potentiates BAX activity and is less suppressible by antiapoptotic BCL-
XL. We established that soluble BCL2 proteins have intrinsic membrane-binding capacity and 
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quantified their affinities for bilayers; BCL-XL binds membranes much more avidly than BAX, 
effectively “outracing” the proapoptotic protein to its membranous active sites. Vesicle-bound 
activators tBID & BIMS were then shown to be equivalent in recruiting BAX & BCL-XL, 
suggesting that BIMS more efficiently than cBID activates BAX by a means other than strictly 
employing bilayers as interaction scaffolds. 
Appendix I integrates a comprehensive array of data pertaining to BAX/BAK 
conformational alterations and mechanistic details of bilayer disruption to synthesize a new 
structural model of BAX/BAK pore activation. This model uncovers stages of BAX/BAK 
oligomer assembly that remain largely obscure and provides a framework for continued 
investigation of this deadly complex. 
 Chronicled in Appendices II-V are complementary interrogations of BAX, BCL-XL, 
and cBID interactions. The contents of Appendix II reveal that BAX activation and 
oligomerization are separable events and demonstrate the feasibility of fluorescence correlation 
spectroscopy in study of the BCL2 family. Appendix III provides confocal microscopic 
visualizations of BAX-membrane distortions and for the first time directly demonstrates that 
BAX accumulates at pore edges. Also characterized are what we dubbed BAX mega-pores—
micron-diameter membrane inclusions with half-lives on the minute to hour time scale. 
Integrating these discoveries with prior work uncovering a proteolipidic (toroidal) nature of 
BAX pores, we also extend membrane line tension theory to postulate a mechanism of BAX 
pore nucleation, persistence, and closure. Appendix IV comprises our investigation via 
fluorescence correlation spectroscopy of BAX auto-assembly and modulation by cBID & BCL-
XL. Correlating with our findings in Chapter IV, BAX demonstrates by FCS intrinsic 
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peripheral and integral membrane binding capability and that activator cBID accelerates this 
process. Inclusion of antiapoptotic BCL-XL abrogates BAX oligomerization at multiple discrete 
steps: simultaneous BAX & BCL-XL addition to vesicles prevents BAX oligomerization but not 
membrane integration while preincubation of vesicles with BCL-XL, prior to BAX addition, 
prevented BAX membrane integration (and subsequent oligomerization). Excess addition of 
cBID rescues higher-order BAX assembly from repression by BCL-XL. Finally, the oligomeric 
dynamism of BAX assembly was directly measured and these complexes increase in size in a 
time dependent manner, further supporting the hypothesis that BAX permeabilizes membranes 
by nucleating toroidal disruptions. Appendix V encompasses investigation by small-angle x-ray 
scattering of BAX pore structures. We and our collaborators uncovered that BAX and BCL-XL 
generate opposing Gaussian membrane curvatures (negative & positive respectively) to regulate 
bilayer integrity. Toroidal, proteolipidic pores are consequent of negative curvature generation 
and our study provides the first structural evidence of the BAX lipidic pore. BCL-XL was found 
to suppress negative curvature induced even by non-BCL2 molecules, providing a physical 
rationale for previous observations that BCL-XL inhibits cell death even in the absence of BAX 
binding. 
 In aggregate, the contents of this dissertation quantify and temporally resolve 
unplumbed steps of BAX pore activation and deepen our understanding of the protein’s 
physical deformation of membranes. 
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5.2 | Future Directions 
 Youle and Strasser previously deemed the biochemical mechanism of BAX/BAK 
activation to be the “holy grail of apoptosis research” (1). We’ve established that BAX and its 
brethren independently adsorb to biological membranes and that membrane-bound activators 
are sufficient to recruit BAX (& BCL-XL) to membrane-integral states. The readily apparent 
next question to be resolved is the existence and relevance of BAX interactions with BH3-only 
activators in solution. Cell-free FRET assays have indicated that BAX and activator tBID do 
not bind in solution (2). Deletion of the C-terminal membrane anchor of PUMA mitigates 
mitochondrial targeting but nevertheless induces apoptosis and BAX N-terminus exposure (3). 
Conversely, deletion of the membrane anchor of BIMS has been shown to abolish its prodeath 
activity, suggesting that mitochondrial targeting is a necessary prerequisite for BAX activation 
(4). To rectify this conundrum, direct BAX interactions by BIM/PUMA in solution could be 
probed by FRET or FCS using physiological, nanomolar protein concentrations. This 
experimental regime is easily extensible to include antiapoptotic proteins like BCL-XL.  
BAX has been shown to comprise two binding sites for activation by BH3 peptides—
the canonical BH3 groove and a shallow activation groove on the opposite side of the protein. 
Employment of engineered, intramolecular disulfide tethers and deletions of α1 or α9 could 
allow entrapment of BAX conformations and facilitate investigation of the details of BH3 
domain interactions (5-7). Engineered BAX conformational restraints would also be useful for 
interrogations of BAX unfolding mediated by membrane adsorption. 
The structure of membrane-integral, active BAX has been sought for nearly 15 years. 
This investigation has proven technically challenging as the protein seemingly resists 
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crystallization, which is not surprising given its propensity to aggregate, while detergent-
micellar BAX forms large complexes whose hydrodynamic volume is not amenable to solution 
NMR (8). Potential remedies for these experimental obstacles include generating BAX mutants 
that fail to oligomerize—G108E and G67R BAX mutants are oligomerization-defective, likely 
due to disruption of reciprocal BH3 helix:BH3 groove binding (9). Employment of cholic acid 
as membrane mimetic may mitigate large complex formation as this detergent activates BAX 
but generates macromolecular assemblies smaller than 50 kDa (Appendix II). Reconstitution of 
BAX into lipid bicelles for solution NMR is an attractive possibility but may be unfeasible due 
to the protein’s distortion of bilayer architecture (Appendices III & V). 
Deeper understanding the process of BAX activation and its structural details will 
facilitate rational therapeutic drug design. The anticancer compound ABT-737 mimics the 
BH3 domain of BAD and was developed via an NMR-based screen of small molecules which 
antagonize prosurvival BCL2 proteins (10). Similarly, compounds mimicking BH3 domains of 
activator proteins could be devised to more effectively oppose antiapoptotic BCL2 proteins 
(11) and simultaneously trigger activations of BAX/BAK. The opposite strategy could also 
prove fruitful, specifically in development of drugs that occlude the binding interfaces of 
BAX/BAK to prevent their activations or oligomerizations and subsequent cell death. 
Tantalizing are the prospects of discovering compounds that modulate BCL2 protein 
function and devising carriers for compound delivery to specific tissues. We’ve previous 
demonstrated that molecularly-targeted nanoparticles can efficiently distribute the cytolytic 
peptide melittin to mouse tumors to reduce their growth (12). Application of this method, in 
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concert with BCL2-modulating drug design, may permit delivery of small molecules or peptides 
to relevant tissues for promotion or suppression of cell death (13,14). 
 Another promising research avenue encompasses the lipid dependence of BAX/BAK 
function. Mitochondrial lipid cardiolipin provides targeting specificity for BH3-only activator 
tBID but whether BIM, PUMA, BAD, etc. migrate preferentially to certain intracellular 
membranes is unknown. Though we and others found that cholesterol dampens BAX poration, 
not uncovered was whether the sterol suppresses steps of the permeabilization pathway prior to 
BAX membrane integration e.g. recruitment of BH3-only activators or oppositional 
antiapoptotic BCL2 proteins. BAK is constitutively mitochondrially-bound and may 
countervail cholesterol inhibition of BAX; this potential compensatory mechanism thus 
warrants further scrutiny. 
 Complementary to our studies, BAX pore suppression by cholesterol has also been 
demonstrated using cellular models (15,16). These reports employed drug-treated HeLa cells 
and hepatocarcinoma cells to generate cholesterol-amplified mitochondria. Cancers very often 
aberrantly overexpress or inactivate BCL2 family members and drug-treatment may introduce 
spurious and unnoticed metabolic defects thus further validation of cholesterol’s repression of 
apoptosis should be characterized in a bona fide model of pathogenic cholesterol accumulation, 
for instance using npc1-/- mice. Anomalous cellular restriction of apoptosis can generate necrotic 
death or autophagy and discernment of BCL2 family dysregulation by cholesterol could 
provide another means for elucidating the crosstalk between various cell death pathways. 
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I.1 | Reconfiguration 
BAX & BAK undergo significant structural remodeling to become competent for pore 
formation. Frustratingly, elucidations of the membrane-active BAX/BAK structures have 
proven resistant to standard techniques like NMR and x-ray crystallography. Thus the precise 
conformational alterations have largely been obscure but a few recent studies have more clearly 
delineated the temporal process of this reconfiguration (1-5). BAX’s putative pore-forming 
domain, the α5-6 hairpin, is protected from solution by the encompassing amphipathic helices 
(6) (Fig. 1.3); deletion of this hairpin abrogates the poration functionality of BAX (7,8). 
Topological labeling of activated BAX has indicated that α5-6 and α9 helices are buried in 
mitochondrial membranes (9). A few other lines of experimentation provided support for the 
α5-6 insertion hypothesis: electrophysiological investigation of BCL-2 channel formation (10) 
and interrogation of detergent-induced unfolding of BAX and BCL-XL (6,11,12). Generation 
of pore competent BAX thus entails exposure of α5-6 by global destabilization of the protein’s 
tertiary fold. These evidences provided for adoption of the umbrella model (13) from the study 
of bacterial colicins, which posits that membrane permeabilization is effected by 
transmembrane insertion of a hydrophobic hairpin while the remaining helices lie at the 
bilayer/solution interface. Unlike the membrane-active forms of colicins, which emerge 
spontaneously upon membrane interaction, evocation of a corresponding BAX/BAK 
conformation is a tightly-regulated process. 
The first BAX conformational change discovered was its detergent-induced unfolding 
and consequent homodimerization and heterodimerization with BCL-XL (14); this unfolding 
also everts BAX α1/BH4 to render a buried epitope (residues 12-24) available for 6A7 antibody 
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binding (15). Deletion of the predicted C-terminal membrane anchor (α9) was then 
demonstrated to abrogate mitochondrial translocation (16,17). Intriguingly, α9 deletion also 
promotes α1 eversion as indicated by 6A7 antibody binding (18,19). Under non-stressed 
conditions, thiol-reactive crosslinkers intramolecularly tether the BAK N-terminus to α6; this 
crosslink is lost after cell death initiation (20). Upon apoptotic stimulus, α1 of mitochondrially-
translocated BAX becomes protease-sensitive and deletion of the first 19 amino acids promotes 
BAX membrane insertion (17). Immunostaining of fixed & permeabilized cells has indicated 
that, in vivo, eversion of α1 is downstream of death signal initiation as BAK and 
mitochondrially-targeted BAXS184V (α9 point mutant) did not expose the α1 antibody epitope 
until after a cell stressor is applied (18,21). This suggests that exposures of the two helices are 
separable events. Conversely, more recent reports indicate that BAK and mitochondrial BAX 
obligately expose their α1 or demonstrate that α1/α9 dislocation is concomitant. (5,19,22). 
A number of instigators of BAX α1/BH4 eversion have been identified. BH3-only 
BAX activators tBID & PUMA and a BIM BH3 peptide all interact with and dislocate the N-
terminal BAX helix (4,23,24). The activating interaction of tumor suppressor p53 with BAK 
was mapped to α1 of the pore-former (25). Transient BAX interaction with vesicle bilayers also 
triggers reversible dislodging of α1 (26). Gavathiotis et al. and Kim et al. have produced 
evidence that dislocation of α1 allosterically induces exposure of α9 (3,5). In aggregate, these 
findings reveal that the N & C-terminal helices reinforce the globular, monomeric fold of BAX 
(5,6,27).  
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Extrication of the BAX autoinhibitory α1/BH4 & α9 helices appears to be the initial 
stage of generating a membrane-permeabilizing conformation (Fig. I.1). After α1/BH4 
dislocation and α9 mobilization, the BH3 helix (α2) of BAX/BAK everts and its previously 
buried, hydrophobic face becomes available for antibody binding (2,3). These newly liberated 
BAX/BAK BH3s helices, no longer packed against the protein core (Fig. 1.3), are then available 
for propagating the autoactivation cascade (3,28,29), homodimerization (2,30), or 
incarceration by antiapoptotics (31-33). 
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Fig. I.1 
A 
 
 
 
 
 
 
 
  B 
 
 
 
 
Fig. I.1 | BAX translocation. A, Soluble, monomeric BAX equilibrates between aqueous 
and membrane-adsorbed states. B, Interaction with a bilayer can induce eversion of BAX 
α1 & 9 to allow membrane anchoring. Presence of a BH3-only activator (tBID/BIMS) can 
accelerate α9 mobilization and anchoring by interacting with and dislocating α1 (A). BAX 
PDBs adapted: 1F16, 2K7W 
 
 
 
BAX 
tBID/BIMS 
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Generation of the culminating, pore competent BAX/BAK conformation entails 
dissolution of the conserved hydrophobic core (encoded by BH1 & 2) which reinforces close 
packing of the α5-6 hairpin (Fig. I.2). This final step, which would permit membrane insertion 
of the pore-forming hairpin, is alluded to by a few evidential lines. Tellingly, mutation to 
alanine of an invariant tryptophan in BH1 of BCL-XL significantly destabilizes the tertiary fold 
and accelerates vesicle leakage induced by the protein (34). BAXΔC & BAKΔC, deleted of their 
α9 membrane anchors (but retaining both invariant BH2 tryptophans), are dispersed as 
cytosolic monomers when expressed in cells (2,5). Further truncation of BAXΔC, to remove α8 
(and the more C-terminal BH2 tryptophan), induces cytosolic aggregation of the protein (35); 
intriguingly, this BAX truncation also fosters detergent-free interaction with BIM. A pair of 
crosslinking studies concluded that formation of the second activated BAX/BAK interface is 
consequential of BH3 helix ingress to the BH3 groove (see two paragraphs down) (1,36). 
To summarize, we propose that the conformational rearrangement of BAX/BAK into 
their active states encompasses four steps: 1) eversions of α1 & 9, 2) eviction of the BH3 helix 
(α2), 3) disruption of the tryptophan staple restraining α5-6, and 4) spontaneous insertion of 
the hairpin. 
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Fig. I.2 
 
 
 
 
 
 
Fig. I.2 | BAX integration. BAX assumes its in-membrane monomeric state after 
disruption of the hydrophobic core that coordinates tight packing of the α5-6 hairpin. 
This collapse can occur spontaneously or is enhanced by BH3 helix (from tBID, BIMS, or 
integrated BAX) intercalation into the BAX BH3 groove. BAX acceptance of donor BH3 
helix is homology modeled on BCL-XLΔC/BIM BH3 complex (PDB: 1PQ1). For visual clarity, 
BAX α1 is deleted from integrated BAX. 
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I.2 | Oligomerization 
These previous stages describe only alterations of the monomeric species but 
mitochondrial permeabilization requires BAX/BAK oligomerization. The structural basis of 
this higher-order assembly is slowly coming unveiled. Early mutational studies revealed the 
necessity for intact BH1 & BH3 domains in dimerization (30,37,38). The canonical BH3 
groove—encompassing α2-5—was defined by a deletion/chimæra study as the minimal BAX 
unit competent for multimerization (39). This finding was followed up by Dewson et al. who 
employed disulfide trapping of introduced cysteines to uncover that activated BAK 
homodimerizes via symmetric domain swapping (BH3 helix:BH3 groove interactions) (2). 
Recombinant BAKΔC has its poration activity severely ablated by substitution with valine of an 
invariant BH1 glycine (40) and mutation to glutamic acid of the homologous BH1 glycine in 
BAX permits only dimer formation (5). Electron paramagnetic resonance spectroscopy of spin-
labeled BAX & BAK demonstrates that, as homodimers, their BH3 helices form an interface 
and lie antiparallel (40,41). Membrane-bound BAX and activator tBID also can remain 
engaged, apparently via BAX BH3 groove:tBID BH3 helix interaction, as adduced by FRET 
assays (42). Taken together, the evidence has become clear that activated BAX & BAK retain 
their canonical BH3 grooves to function as acceptor sites of donor BH3 helices (Fig. I.3). 
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Fig. I.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. I.3 | BAX dimerization. Overhead and side views of BAX reciprocal domain swap via 
BH3 helix:BH3 groove interactions. BAX α1 is deleted for visual clarity. 
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Reciprocal exchange of BH3 helices provides only a means for BAX/BAK 
dimerization; a second binding surface is required for oligomer accretion. Little evidence 
pertains to this obscurity, unfortunately. One publication indentifies an α6:α6 interface by 
which BAK symmetric dimers can further assemble (1). Another study mapped BAX interfaces 
via introduced crosslinks; these were performed in Triton X-100, (a detergent whose fidelity as 
a membrane mimetic is questionable) but the data are at least partly reconcilable with BH3 
helix:BH3 groove & α6:α6 interfaces (36). Distance constraints determined by EPR are also 
somewhat, though not entirely, consistent with the α6:α6 hypothesis (40) (Fig. I.4). 
One potential missing puzzle piece is whether BAX/BAK α1 contributes to an 
oligomer interface. Microsomal glycosylation mapping suggests that a peptide embodying BAX 
α1 assumes a transmembrane orientation while NMR of detergent-treated BAX indicated that 
α1 is excluded from micelles. Reconciling this apparent disparity, ATR spectroscopy has 
revealed that a BAX α1 peptide is shifted to a membrane parallel orientation at the 
headgroup/solvent interface by cardiolipin (43,44). One study implies a role for BAX α1 in 
oligomerization, having concluded that BAX deleted of the helix functions as a BH3-only 
protein and requires full-length BAX to foment mitochondrial permeabilization (45). 
I.3 | Pore Formation 
The preceding amasses evidence pertaining to the proteinaceous structure of oligomeric 
BAX/BAK but fails to describe the nature of the membrane pore itself. The best characterized 
biological pores are β-barrels, like porins. Structures of a number of these proteins have been 
solved to high resolution by x-ray crystallography and NMR. Pores induced by α-helical 
peptides and proteins are considerably more labile and less acquiescent to interrogation, 
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prompting introduction of multiple models of pore formation, predominantly the barrel-stave 
and toroidal (lipidic) schemes. The barrel-stave model describes bilayer pores whose edges are 
composed of transmembrane α-helices that shield the lipid acyl chains from an aqueous milieu; 
alamethicin is a prominent barrel-stave pore-forming peptide. 
Most membrane-disrupting peptides, however, are better described by the toroidal 
model, in which peptides and lipid head groups cooperate to line pore edges resulting in 
continuity (and lipid exchange) between bilayer leaflets. A growing body of data, produced by 
our lab and others, strongly support a toroidal, proteolipidic pore as the means by which 
BAX/BAK effects membrane permeabilization (Fig. I.4). 
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Fig. I.4 
 
 
 
 
 
 
 
 
 
 
 
Fig. I.4 | BAX oligomerization. BAX accumulates, locally induces negative Gaussian 
curvature, and cooperates with lipids to organize toroidal pores through which 
cytochrome c can escape. BAX α1 is deleted for visual clarity. 
 
 
 
 
 
 
 
cyt c 
163 
 
First suggesting the lipid dependence and toroidal nature of BAX pores was the 
observation that BAX destabilizes bilayers and produces arbitrary, rather than stepwise, 
variations in membrane permeability (46). Corroborating this report were demonstrations of 
BAX poration dependence on intrinsic lipid curvature and BAX induction of lipid transfer 
between leaflets (47-50). More recently, x-ray diffraction was employed to glean details of 
membrane structures induced by BAX α5 peptides (51); presence of the peptide in oriented 
membranes bent the discrete leaflets into contiguous monolayers in pore rims. Our work, using 
confocal microscopy and small-angle x-ray scattering, confirms and extends these findings that 
BAX evinces proteolipidic, toroidal pores (Appendices III & V). 
A key underlying and largely unexamined premise of BCL2 protein family study 
remains the umbrella model (13) of unfolding and subsequent pore formation. Specifically, that 
BAX/BAK unfold and orient their pore-forming α5-6 hairpins in a transmembrane, barrel-
stave fashion (52). This rearrangement almost certainly would dissolve the BAX/BAK BH3 
grooves, thus it is difficult to reconcile in-membrane dimerization via BH3 helix:BH3 groove 
interactions with the adopted umbrella model. Further weakening the case for the umbrella, 
barrel-stave model is the BAX/BAK α5-6 hairpins are, in fact, too short to span mitochondrial 
membranes (53). Therefore, we propose eschewing the umbrella scheme and instead adapting a 
competing hypothesis of colicin pore formation—the penknife model (54). This model posits 
that colicin A arranges its α-hairpin roughly parallel to the membrane-water interface to 
instigate pore formation. In actuality, a wide array of evidence has been marshaled in support of 
both models pertaining to colicin poration, suggesting that the two arrangements exist in 
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equilibrium (55,56). This insight may be apposite to BAX/BAK function but given our present 
knowledge is speculative at best. 
Our proposed quasi-penknife model integrates a host of information regarding 
BAX/BAK structural rearrangement and assembly and their perturbations of bilayer 
architecture. It is further supported by evidence relating to α-hairpin orientation across the 
three BCL2 subclasses. For instance, solid-state NMR of BCL-XLΔC treated with detergent and 
reconstituted into oriented bilayers demonstrated that the protein’s α5-6 helices can tilt relative 
to membrane normal (12).  The corresponding hairpin of BH3-only tBID has been shown to 
only shallowly tilt into the bilayer by EPR and solid-state NMR (57,58). Oriented circular 
dichroism has revealed that peptides derived from BAX α5 also assume a tilted, non-bilayer-
spanning orientation (51,59). Most pertinently, Oh et al. determined via EPR that the α5-6 
hairpin of spin-labeled, oligomeric BAKΔC is partly exposed to the hydrophobic bilayer interior 
but α6 is immersed less than 1 nm, strongly implying a shallow tilt rather than transmembrane 
arrangement of the hairpin (40). 
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APPENDIX II 
 
Detergent-Activated BAX Protein is a Monomer 
 
 
(The content of this chapter has been adapted from Ivashyna, O., García-Sáez, A. J., Ries, J., 
Christenson, E. T., Schwille, P., Schlesinger, P. H. (2009) J Biol Chem 284, 23935-23946) 
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II.1 | Summary 
BAX is a pro-apoptotic member of the BCL-2 protein family. At the onset of apoptosis, 
monomeric, cytoplasmic BAX is activated and translocates to the outer mitochondrial 
membrane, where it forms an oligomeric pore. The chemical mechanism of BAX activation is 
controversial, and several in vitro and in vivo methods of its activation are known. One of the 
most commonly used in vitro methods is activation with detergents, such as n-octyl glucoside. 
During BAX activation with n-octyl glucoside, it has been shown that BAX forms high 
molecular weight complexes that are larger than the combined molecular weight of BAX 
monomer and one detergent micelle. These large complexes have been ascribed to the 
oligomerization of BAX prior to its membrane insertion and pore formation. This is in contrast 
to the in vivo studies that suggest that active BAX inserts into the outer mitochondrial 
membrane as a monomer and then undergoes oligomerization. Here, to simultaneously 
determine the molecular weight and the number of BAX proteins per BAX-detergent micelle 
during detergent activation, we have used an approach that combines two single-molecule 
sensitivity techniques—fluorescence correlation spectroscopy and fluorescence-intensity 
distribution analysis. We have tested a range of detergents as follows: n-octyl glucoside, dodecyl 
maltoside, Triton X-100, Tween 20, CHAPS, and cholic acid. With these detergents we 
observe that BAX is a monomer before, during, and after interaction with micelles. We 
conclude that detergent activation of BAX is not congruent with oligomerization and that in 
physiologic buffer conditions BAX can assume two stable monomeric conformations, one 
inactive and one active. 
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II.2 | Introduction 
BAX is a pro-apoptotic member of the BCL-2 protein family. In a simplified apoptosis 
model, monomeric inactive BAX is localized in the cytoplasm of healthy nondying cells (1). 
During apoptosis BAX is activated and translocates to the outer mitochondrial membrane (2) 
where it inserts as a monomer (3), undergoes oligomerization (4), and forms a pore through 
which cytochrome c and other apoptotic factors are released into the cytoplasm. Once in the 
cytoplasm, these apoptotic factors induce the activation of the effector caspases that execute the 
cell death process. This mechanism, which is generally correct, requires that soluble BAX 
becomes integrated into the mitochondrial membrane where it forms a functional oligomeric 
pore capable of cytochrome c release. However, the molecular mechanism of BAX activation 
remains controversial (5, 6). 
It has been understood for some time, but frequently ignored, that activity of the BCL-
2 family proteins is exhibited in cells when these proteins are associated with the hydrophobic 
environment of membranes. Therefore, it has always seemed that attention to the effect of 
hydrophobic environments on the BCL-2 family proteins would be rewarding. It has been 
shown that BAX can be directly activated by treatment with nonionic detergents such as n-
octyl glucoside, dodecyl maltoside, and Triton X-100 (1, 7). During activation by nonionic 
detergents, to gain the ability to form pores in a bilayer membrane, BAX needs to undergo a 
major conformational transition from a globular protein with two pore-forming α-helices 5 and 
6 hidden in the protein core (8) to a conformation in which these two helices are exposed and 
inserted into a lipid membrane (3, 5, 9). The nature of this active conformation of BAX is 
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important for the understanding of the death decision in cells. Most proposals suggest that in a 
cell this activated form of BAX protein is initiated and maintained by the interactions with 
other proteins, such as tBID, or by BAX itself as a homo-oligomer (7, 10). 
Nonionic detergents have been commonly used to activate BAX for in vitro studies 
because they are reliably effective and simple to employ. However, little is known about the 
detailed molecular mechanism of BAX activation by these detergents and its comparability with 
in vivo activation of BAX. What is known is that concentrations of detergent above their 
critical micelle concentration (CMC) are necessary for BAX activation. This suggests that, to 
be activated, BAX needs to interact with detergent micelles instead of monomeric detergent 
molecules. For example, in the case of BAX activation by n-octyl glucoside, it has been shown 
that n-octyl glucoside concentration should be 1% (w/v) (7), which is well above the CMC for 
this detergent (0.6% w/v) (11). In addition, it has also been shown that above their individual 
CMC concentrations most BAX-activating detergents produce a change in BAX conformation 
that can be detected by a conformation-sensitive 6A7 antibody against BAX (1, 12, 13). In 
cellular experiments this feature of BAX reactivity to 6A7 antibody is commonly associated 
with the onset of apoptosis (14, 15). However, CHAPS does not generate the antibody-
detected conformational change or the activation of BAX. The small micelle size of this 
detergent (10 kDa) suggests that perhaps BAX cannot adopt an activated state with this 
detergent. However, cholic acid with even smaller micelle size (4 kDa) can partially activate 
BAX (1). 
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Many important detergent properties are associated with micelles. The formation of 
detergent micelles in solution is concentration-dependent beginning at the CMC. The CMC 
value for a detergent has practical importance because in most cases only monomers of 
detergent can be removed by dialysis, and therefore, it is easier to remove detergent monomers 
for a detergent with high CMC value than for a detergent with low CMC (11). For BAX this 
same consideration applies to its activation with n-octyl glucoside (CMC ∼23 mM) as 
compared with its activation with Triton X-100 (CMC ∼0.25 mM). The ease of dialysis is 
why, in most cases, OG is used to activate BAX in vitro. 
It has been shown by analytical gel filtration that, when incubated with n-octyl 
glucoside, BAX creates complexes with molecular weight larger than the combined size of a 
BAX monomer (21 kDa) and an n-octyl glucoside micelle (∼26 kDa) (7, 11). It has also been 
shown that in defined liposomes BAX pore formation requires oligomerization (16). These 
data combined with the knowledge that oligomerization is important for the biological 
function of BAX led to a hypothesis that BAX oligomerizes during its detergent activation 
prior to membrane insertion (7). However, it has been shown that in vivo activated BAX inserts 
into the outer mitochondrial membrane as a monomer (3), and to create a pore, BAX 
undergoes oligomerization in this membrane (4). This discrepancy between the oligomeric state 
of active BAX prior to its insertion into a lipid membrane in vivo (monomer) and in vitro 
(possibly hexamer or octamer) led us to study the oligomerization state of BAX in detergent 
micelles. The important issue is whether BAX activation requires protein oligomerization or 
whether active BAX conformation can be generated from a single protein monomer. To solve 
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this issue we used two single-molecule sensitivity techniques: fluorescence correlation 
spectroscopy (FCS) (17) and fluorescence-intensity distribution analysis (FIDA) (18). 
Combined use of FCS and FIDA allows simultaneous determination of the apparent molecular 
weight and the number of fluorescently labeled BAX monomers per protein-detergent micelle. 
Our results are consistent with previously established results in which BAX forms high 
molecular weight protein-detergent micelles with n-octyl glucoside (4) and show that BAX is 
present as a monomer in these complexes. In addition, we determined the apparent molecular 
weight and the number of BAX proteins bound per protein-detergent micelles formed by BAX 
and micelles of five additional detergents (dodecyl maltoside, Triton X-100, Tween 20, cholic 
acid, and CHAPS). Our data show that BAX is a monomer before, during, and after 
interaction with the micelles of all tested detergents.  
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II.3 | Results 
Detergent-activated Fluorescently Labeled BAXΔC Can Release Cytochrome c from Isolated 
Mitochondria 
For the FCS and FIDA experiments, we prepared recombinant, fluorescently labeled 
human BAXΔC containing a fluorophore at a single cysteine residue (Fig. II.1A & B). Human 
BAXΔC contains two indigenous cysteines (Cys-62 and Cys-126), which we considered 
inappropriate for fluorophore conjugation due to structural and functional reasons (8). 
Previously full-length BAX with G40C, C62A, and C126A mutations has been reported to be 
functional in vivo (3). Therefore, we removed cysteines, Cys-62 and Cys-126, by mutation to 
alanine and added an additional cysteine residue in place of glycine 40 creating 
BAXΔC(G40C) (Fig. II.1A). BAXΔC(G40C) labeled with Bodipy FL maleimide fluorophore 
became fluor-BAXΔC. 
To check the biological activity of the fluor-BAXΔC protein, we studied its ability to 
release cytochrome c using mitochondria isolated from HeLa cells (Fig. II.1C). Our results show 
that fluor-BAXΔC activated with 2% (w/v) n-octyl glucoside releases cytochrome c from 
isolated mitochondria similar to BAXΔC but with slightly lower efficiency. For both proteins 
significant cytochrome c release required detergent activation, suggesting that the detergent 
activation of fluor-BAXΔC was comparable with the detergent activation of the BAXΔC (7, 
12, 26). In each cytochrome c release experiment the final concentration of n-octyl glucoside 
was 0.005% (w/v) or lower, which is well below the CMC for this detergent (0.6% w/v) (11), 
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so that detergent micelles played no role in the release of cytochrome c or the maintenance of 
the active BAXΔC conformation during the assay. 
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Fig. II.1 
 
 
 
 
 
 
 
 
 
Fig. II.1 | A, schematic structure of human BAXΔC(G40C). Introduced mutations and 
their relative position with respect to the helices and BCL-2 homology domains are 
indicated with arrows. B, SDS-PAGE of purified recombinant proteins; protein standards 
with molecular weight indicated (lane 1), human BAXΔC(G40C) (lane 2), human BAXΔC 
(lane 3), and human fluor-BAXΔC (lane 4). C, cytochrome c release from mitochondria 
isolated from HeLa cells. Mitochondria isolated from HeLa cells were incubated for 20 
min at 37 °C with 100 nM of the indicated recombinant protein. Where indicated, 
protein was activated by incubation with 2% (w/v) n-octyl glucoside for 1 h at 4°C after 
which the protein/detergent mixture was diluted to obtain a final detergent 
concentration of 0.5% (w/v) and the 100 nM protein concentration used in the assays. 
Cytochrome c content of each fraction was normalized for the basal release of 
cytochrome c in mitochondria samples with only detergent added and in mitochondria 
samples without detergent or protein added. Error bars were calculated based on three 
independent experiments. 
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Surface Plasmon Resonance Studies of Membrane Binding and Integration by BAXΔC and Fluor-
BAXΔC 
Direct analysis of the membrane binding and integration by detergent-activated fluor-
BAXΔC was compared with that of BAXΔC using surface plasmon resonance (SPR) as 
described previously (22) (Fig. II.2). SPR has been applied to the study of membrane binding 
and integration of a number of pore-forming proteins and peptides (27, 28), including BAX 
(22). Using this technique it is not necessary to label or chemically modify the protein under 
study. Therefore, we could use this method to determine the effect of the mutations and the 
added fluorophore on fluor-BAXΔC membrane binding and integration by comparison with 
the same properties of BAXΔC.  
These SPR experiments were done using cardiolipin-containing liposomes 
(DOPC:DOPA:cardiolipin 70:20:10 mol %) immobilized on the SPR-chip surface, and the 
proteins of interest were injected over this surface. Both BAXΔC and fluor-BAXΔC required 
n-octyl glucoside activation to generate significant interaction with liposome membranes (Fig. 
II.2, A and B).  
To determine the concentration dependence of BAX integration into the liposome 
membranes, we sequentially injected increasing concentrations of BAX over the same liposome-
covered surface and determined the amount of BAX integrated into the lipid membrane based 
on sensorgram response after 300 s of washing. Our results show that, when activated with n-
octyl glucoside, fluor-BAXΔC and BAXΔC have comparable integration into the liposome 
membrane (Fig. II.2C). This similarity in membrane integration suggests that the slight 
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decrease in cytochrome c release by fluor-BAXΔC (Fig. II.1C) is not the result of reduced 
membrane retention of the labeled protein but possibly a result of reduced stability of the in-
membrane open pore conformation. However, despite a possible reduction in the stability of 
fluor-BAXΔC pores, the cytochrome c release experiments (Fig. II.1C) together with the SPR 
binding data (Fig. II.2) suggest that both BAXΔC and fluor-BAXΔC, when activated with n-
octyl glucoside, follow a similar mechanism of membrane interaction and pore formation.  
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Fig. II.2 
 
 
 
 
 
 
 
 
 
Fig. II.2 | Surface plasmon resonance data of fluor-BAXΔC and BAXΔC binding to 
cardiolipin-containing liposomes (200 nm in diameter; DOPC:DOPA:CL 70:20:10 
mol %). Increasing concentrations of protein activated with 2% (w/v) n-octyl 
glucoside was flowed over immobilized liposomes. Protein accumulation on the 
surface of the liposomes is shown with response units (RU) (28). A, data for fluor-
BAXΔC binding. B, data for BAXΔC binding. C, results of concentration dependence 
analysis of protein integration into liposomes for BAXΔC (squares) and fluor-BAXΔC 
(triangles). 
180 
 
Analytical Gel Filtration of BAXΔC(G40C) with n-Octyl Glucoside or CHAPS Present 
To show that fluor-BAXΔC interacts with detergent micelles of n-octyl glucoside and 
CHAPS comparably with BAXΔC, we performed analytical gel filtration following the 
procedure of Antonsson et al. (7). We carried out our analytical gel filtration studies using 
BAXΔC(G40C) incubated with either 2% (w/v) n-octyl glucoside or CHAPS (Fig. II.3). The 
obtained results show that in the absence of detergents BAXΔC(G40C) eluted as a monomer 
with a molecular mass of slightly less than 25 kDa (Fig. II.3A), whereas in the presence of 2% 
(w/v) n-octyl glucoside, protein eluted at a molecular mass slightly below 440 kDa (Fig. II.3C). 
In contrast, when BAXΔC(G40C) was incubated with and eluted in the presence of 2% (w/v) 
CHAPS in the column, protein eluted mostly (73%) as a monomer in a broad peak (Fig. II.3B). 
These results are consistent with previously reported analytical gel filtration of BAXΔC (7) and 
show that mutant BAXΔC(G40C) interacts with micelles of n-octyl glucoside and CHAPS 
similarly as BAXΔC.  
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Fig. II.3 
 
 
 
 
 
 
 
Fig. II.3 | Analytical gel filtration of BAXΔC(G40C) incubated with indicated 
detergents. BAXΔC(G40C) was incubated with 2% (w/v) of indicated detergent for 1 h 
at 4°C. BAXΔC(G40C) incubated with detergent was passed through a Superdex-200 
column equilibrated with 10 mM HEPES/KOH, pH 7.0, 300 mM KCl buffer containing 2% 
(w/v) of the same detergent in which BAX was incubated. The Superdex-200 column 
was calibrated with two protein standards. A, BAXΔC(G40C) without detergents. B, 
BAXΔC(G40C) + 2% (w/v) CHAPS. C, BAXΔC(G40C) + 2% (w/v) n-octyl glucoside. D, 
standards (chymotrypsinogen, 25 kDa, and ferritin, 438.7 kDa). 
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Activation of BAX with Nonionic Detergents 
Compared with the amount of protein required for the analytical gel filtration studies, 
the amount of fluor-BAXΔC required for the FCS and FIDA analyses is at least 100 times 
lower. Therefore, we decided to extend the range of the detergents used in our study. We chose 
n-octyl glucoside, CHAPS, Triton X-100, dodecyl maltoside, and Tween 20 because these 
detergents have specific and known effects on BAXΔC activity (7, 26). We also chose cholic 
acid because of its similarity in structure to CHAPS, because it is a physiologic detergent and 
because it can activate BAX (1). In all cases the 2% (w/v) concentration of the detergent was 
well above the CMC (11). 
Before proceeding to the FCS and FIDA studies, we first tested the ability of all chosen 
detergents to activate BAXΔC using an assay of carboxyfluorescein release from liposomes (Fig. 
II.4A) (22). For these experiments we used recombinant human BAXΔC purified from E. coli 
cells without detergent. This BAXΔC protein was monomeric (23 ± 4 kDa as determined by 
dynamic light scattering) and had very low (<10%) carboxyfluorescein release activity. Upon 1 
h of incubation at 4°C with selected nonionic detergents (n-octyl glucoside, dodecyl maltoside, 
Triton X-100, and Tween 20), BAXΔC released carboxyfluorescein from liposomes (Fig. 
II.4A), indicating that protein became activated. Incubation with cholic acid, an ionic 
detergent, also resulted in activation of BAXΔC. However, upon a similar 1-h incubation at 
4°C with CHAPS (detergent known for its inability to activate BAX) no significant 
carboxyfluorescein release was observed. 
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Similar carboxyfluorescein release results were obtained for BAXΔC(G40C) incubated 
with all six detergents (Fig. II.4B). Comparison of the maximum carboxyfluorescein release 
values for both proteins after 90 min presents two instructive observations (Fig. II.4C). First, 
upon incubation with all detergents BAXΔC has almost a 20% higher carboxyfluorescein 
releasing activity than its mutant, BAXΔC(G40C). Second, for both proteins incubation with 
Triton X-100 resulted in the most activated form of BAX followed by n-octyl glucoside, 
dodecyl maltoside, cholic acid, and Tween 20, whereas CHAPS failed to activate either of the 
two proteins. 
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Fig. II.4 
 
 
 
 
 
 
 
 
 
 
 
Fig. II.4 | Release of CF from liposomes by the detergent-activated BAXΔC and 
BAXΔC(G40C). A, monomeric inactive BAXΔC was incubated for 1 h at 4°C with 2% 
(w/v) n-octyl glucoside (OG), 0.6% (w/v) dodecyl maltoside (DM), 0.076% (w/v) Triton 
X-100 (TX), 0.038% (w/v) Tween 20 (Tw), 2% (w/v) CHAPS, or 2% (w/v) cholic acid 
(ChA). During this incubation the concentration of each detergent was above the CMC, 
whereas protein concentration was 70 μM. Before addition to liposomes protein was 
diluted to 50 nM. Total lipid mass in each assay was 17.5 μg. Liposomes composition 
was DOPC:DOPA 70:30 mol %. Final detergent concentration in the release assays was 
below the CMC for each detergent. Releases were normalized to carboxyfluorescein 
release by 20% Triton X-100 and corrected for basal carboxyfluorescein release by each 
detergent. Each release curve represents an average of at least three independent 
experiments. B, release of carboxyfluorescein from liposomes by detergent-activated 
BAXΔC(G40C). Protein was treated the same way as BAXΔC in A. C, single point 
comparison of the carboxyfluorescein release values at 90 min for BAXΔC and 
BAXΔC(G40C) activated with indicated detergents. Representative error bars are 
shown for each release curve. 
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CD Spectroscopy on BAXΔC in Detergent Micelles 
Circular dichroism measurements were performed to determine whether any 
significant secondary structure changes occur in BAXΔC during interaction with detergent 
micelles. BAXΔC without detergent produced CD spectra with strong α -helical pattern (Fig. 
II.5). In the presence of micelles of Triton X-100, Tween 20, or cholic acid, no significant 
changes in the BAXΔC spectra were observed. However, in the presence of micelles of n-octyl 
glucoside or dodecyl maltoside, a slight increase in the α-helical content of BAXΔC CD spectra 
was observed. The CD spectra of BAXΔC in the presence of CHAPS were not collected 
because of high CD signal from CHAPS (because of presence of amide bond in CHAPS 
structure). 
 
 
 
 
 
 
 
 
 
 
 
186 
 
Fig. II.5 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. II.5 | CD spectroscopy of BAXΔC in the presence of detergent micelles in 10 
mM HEPES, pH 7.0, 100 mM KCl. A, comparison of the CD spectra for BAXΔC alone 
and in the presence of either 0.08% Triton X-100 (TX), 0.04% Tween 20 (Tw), or 2% 
cholic acid (ChA). B, comparison of the CD spectra for BAXΔC alone and in the 
presence of either 2% n-octyl glucoside (OG) or 0.6% dodecyl maltoside (DM). 
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FCS Detection Volume Is Not Affected by the Presence of Detergents 
The maintenance of consistent detection volume is critical for accurate comparison of 
FCS characteristics of different particles. Size and shape of the FCS detection volume depend 
on a number of parameters, one of which is the refractive index of solution (29, 30). The latter 
can be affected by the presence of detergents leading to the distortion of the FCS detection 
volume. 
Commonly AlexaFluor 488 dye is used for calibration of the FCS detection volume 
(30, 31). During this calibration procedure the diffusion time (τD) of the dye molecules and the 
structure parameter of the FCS detection volume (ω) were obtained by fitting the measured 
autocorrelation curve using Equation 1. Using such analysis for AlexaFluor 488 diffusing freely 
in solution in the absence of detergent, we get the following values: τ D 22.7 ± 0.9 μs, ω = 5.5 ± 
0.8. To determine whether the presence of detergent has an effect on our FCS measurements, 
we determined τ D and ω values for AlexaFluor 488 in solution containing increasing 
concentrations of n-octyl glucoside detergent (Fig. II.6). The results of these experiments show 
that over the range of 0–5% (w/v) of n-octyl glucoside, the diffusion time of the dye and the 
structure parameter of the detection volume do not change indicating that the FCS detection 
volume is not affected by the detergent presence. Similar experiments were done with the rest of 
the detergents, and they yielded analogous results (data not shown). 
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Fig. II.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. II.6 | Effect of detergent on the shape and size of the FCS detection volume. 
Measurement of the diffusion time (τD) of AlexaFluor 488 and the structure parameter of 
the detection volume (ω) at various detergent concentrations. n-Octyl glucoside was used 
as a detergent of choice, whereas buffer composition was 10 mM HEPES, pH 7.2, 100 mM 
KCl. Error bars were calculated based on nine 10-s measurements. For some data points 
error bars are smaller than the symbol. 
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FCS Characterization of Fluor-BAXΔC in Detergent Micelles 
We used fluorescence correlation spectroscopy to confirm the detergent-dependent 
change in the apparent molecular weight of BAXΔC protein as seen by analytical gel filtration. 
The diffusion characteristics of fluor-BAXΔC were studied in the absence and in the presence 
of 2% (w/v) of selected detergents (Fig. II.7 and Table II.1). The FCS diffusion times were 
obtained by fitting the autocorrelation curves (Fig. II.7) and are shown in Table II.1. Fluor-
BAXΔC incubated with 2% (w/v) of either n-octyl glucoside, dodecyl maltoside, Triton X-100, 
or Tween 20 had a significant increase in diffusion time, τ D, compared with the diffusion time 
of fluor-BAXΔC monomer in the absence of detergent. In contrast, the diffusion time of fluor-
BAXΔC in the presence of 2% (w/v) CHAPS or cholic acid did not increase significantly 
(Table II.1).  
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Fig. II.7 
 
 
 
 
 
 
 
Fig. II.7 | Normalized FCS autocorrelation curves of fluor-BAXΔC incubated with 
various detergents, as indicated (OG, n-octyl glucoside; DM, dodecyl maltoside; TX-
100, Triton X-100). For each autocorrelation experiment, protein was incubated in 10 
mM HEPES/KOH, pH 7.2, 100 mM KCl, with 2% (w/v) of the indicated detergent at 4 °C 
for 1 h. In each graph the normalized autocorrelation curve for fluor-BAXΔC in the 
absence of detergent (dashed line), normalized autocorrelation curve for fluor-BAXΔC 
incubated with 2% (w/v) of the indicated detergent (solid line), and normalized 
autocorrelation curve for fluor-BAXΔC after detergent was diluted to the 
concentration below its CMC (dotted line). Raw data for each autocorrelation curve 
are shown with thin jagged line. See Table II.1 for the numerical results of the analysis 
of these autocorrelation curves. 
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Table II.1 | Results of the FCS studies with fluor-BAXΔC-detergent micelles 
The molecular weight of the fluor-BAXΔC-detergent micelles was calculated using 
Equation 6. 
Fluor-BAXΔC [Detergent] 2% (w/v) After Detergent Dilution 
+ τD Mol. mass [Detergent] (w/v) τD Mol. Mass 
 μs kDa % μs kDa 
No detergent 91±4  0 91±4  
n-Octyl Glucoside 223±5 280±12 0.003 100±5 25±1 
Triton X-100 366±8 1236±223 0.003 158±4 99±2 
Dodecyl Maltoside 262±21 453±31 0.003 90±4 18±1 
CHAPS 115±4 38±1 0.004 87±3 17±1 
Cholic acid 124±5 48±1 0.003 86±2 17±1 
Tween-20 161±12 105±2 0.003 112±3 35±1 
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Using Equation 6 and the diffusion time of the fluorescent particles, we calculated the 
apparent molecular weight of the BAXΔC-detergent micelle complexes for each detergent 
(Table II.1). The apparent molecular weight of fluor-BAXΔC in the presence of n-octyl 
glucoside and CHAPS calculated from the FCS data are the same as the molecular weight 
obtained by analytical gel filtration of BAX in the presence of these detergents (Fig. II.3). The 
large molecular weight complexes of BAX generated in the presence of n-octyl glucoside, 
dodecyl maltoside, and Triton X-100 detergents were significantly larger than the sum of BAX 
and micelle of the respective detergents. 
To determine the size of fluor-BAXΔC after interaction with detergent micelles, we 
removed micelles by diluting detergent concentration below CMC. In most cases this resulted 
in dissociation of the protein-detergent micelles as well as of the detergent micelles in solution. 
Each measurement of fluor-BAXΔC size after detergent dilution was done at least 1 h after 
dilution to allow dissociation of the detergent micelles bound to the protein. In all cases the 
diffusion time of fluor-BAXΔC decreased significantly upon detergent dilution (Table II.1 and 
Fig. II.7). For all detergents, except Triton X-100, the diffusion time decreased close to that of 
fluor-BAXΔC monomer. These observations indicate that upon detergent dilution the 
molecular weight of the protein-detergent micelle complexes is reduced, and for most of the 
detergents this molecular weight is reduced to that of a fluor-BAXΔC monomer. In addition, it 
should be mentioned that n-octyl glucoside-treated fluor-BAXΔC used in the FCS dilution 
experiments was used with similar dilution as in the cytochrome c release experiments (Fig. 
II.1C).  
193 
 
 
Fluorescence Intensity Distribution Analysis of Fluor-BAXΔC in Detergent Micelles 
Analysis of the distribution of the photon counts in the FCS data sets was used to 
determine the number of fluor-BAXΔC molecules per protein-detergent micelle formed with 
micelles of all tested detergents. This analysis used the FIDA algorithm developed by Kask et al. 
(18). Using FIDA we determined fluorescence brightness of BAX molecules before, during, and 
after interaction with detergent micelles. Comparison of these fluorescence brightness values 
shows that BAX is a monomer in all cases (Table II.2). However, in case of dodecyl maltoside 
and Triton X-100, the calculated values of fluorescence brightness per protein-detergent 
micelle were 90% higher than the fluorescence brightness of the fluor-BAXΔC monomer. It is 
possible that BAX is dimerized in micelles of these detergents. Interestingly, in the presence of 
cholic acid or Tween 20 protein fluorescence brightness decreased by 36 and 15%, respectively, 
whereas in the presence of the rest of the detergents protein fluorescence brightness increased 
or stayed the same as in the absence of detergents. Therefore, because protein fluorescence 
brightness was clearly affected by the detergent we studied this effect directly. 
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Table II.2 | Analysis of the fluorescence-intensity distribution of the fluor-BAXΔC 
protein detergent-micelle complexes 
Protein (at the concentration indicated in the table) was preincubated with detergent 
for 1 h at 4°C. Upon incubation with detergent, the protein was diluted below 0.5 μM 
into a solution containing the identical detergent concentration as during activation. The 
measurements were done immediately upon this dilution. Mean and standard 
deviations of the brightness values were calculated based on nine measurements at 50 s 
each.  
Fluor-BAXΔC [Detergent] 2% (w/v) After Detergent Dilution 
+ Fluorescence 
Brightness 
25 μM BAX 
Fluorescence 
Brightness 
3 μM BAX 
[Detergent] (w/v) Fluorescence 
Brightness 
 kHz kHz % kHz 
No detergent   0 5.5±0.1 
n-Octyl Glucoside 7.4±0.2 7.2±0.3 0.003 4.7±0.2 
Triton X-100 10.5±0.1 10.4±0.1 0.003 7.1±0.1 
Dodecyl Maltoside 8.5±0.1 10±0.1 0.003 5.0±0.1 
CHAPS 5.9±0.1 5.8±0.1 0.004 5.6±0.1 
Cholic acid 3.49±0.06  0.003 4.71±0.09 
Tween-20 4.70±0.24  0.003 5.41±0.06 
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For three detergents where micelle size was significantly increased by the addition of 
BAX (n-octyl glucoside, dodecyl maltoside, and Triton X-100), we varied the degree of protein 
to detergent ratio while holding either detergent or protein concentration constant. First, we 
varied the concentration of the fluor-BAXΔC from 25 to 3 μM while keeping detergent 
concentration constant at 2% (w/v). We reasoned that, if fluor-BAXΔC forms oligomers in 
micelles, the decrease in protein concentration while keeping detergent concentration constant 
would lead to a change, e.g. reduction, of the oligomeric state of protein in detergent micelles. 
Such change in the oligomeric state of protein with increasing detergent concentration has been 
previously demonstrated for some transmembrane peptides in detergent micelles (32). In this 
case there was no significant change in the fluorescence brightness of the fluor-BAXΔC-
detergent micelles (Table II.2).  
Second, we measured the effect of increasing detergent concentration on the 
fluorescence brightness of fluor-BAXΔC at constant protein concentration. If protein 
fluorescence brightness increases because of the presence of detergent, then the total 
fluorescence intensity of the sample containing constant protein concentration will increase 
with increasing detergent concentration. As shown in Fig. II.8A (empty circles), for constant 
protein concentration in the presence of increasing n-octyl glucoside concentrations total 
fluorescence intensity increases. Furthermore, fluorescence brightness per particle of protein-
detergent micelles determined by single-component fitting of resulting FCS autocorrelation 
curves also increased (Fig. II.8A, filled squares). The ratio of the total fluorescence intensity to 
the fluorescence brightness per particle (also known as cpp) represents the average number of 
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particles in the FCS observation volume. As expected, this number stayed constant for all n-
octyl glucoside concentrations clearly showing that increase in n-octyl glucoside concentration 
leads to increase in protein fluorescence brightness. For n-octyl glucoside the FCS and FIDA 
yield similar protein fluorescence brightness values (Table II.2 and Fig. II.8). Such an agreement 
between FCS and FIDA results further shows that fluor-BAXΔC is present as a monomer in n-
octyl glucoside micelles.  
Analogous detergent titration experiments were performed for the rest of the 
detergents giving the same result that protein fluorescence brightness of the fluor-BAXΔC is 
changing with increasing concentrations of detergent (Fig. II.8C). In addition, in the n-octyl 
glucoside titration experiment gradual increase in the protein diffusion time was observed 
together with increase in protein fluorescence brightness. This observation suggests that with 
increasing n-octyl glucoside concentration protein-detergent micelles grow in size (Fig. II.8B).  
For all tested detergents after micelle removal by dilution, the fluorescence brightness of 
the fluor-BAXΔC returned to that of a protein monomer. However, upon removal of Triton 
X-100 protein fluorescence brightness decreased but was still 29% higher than that for the 
protein monomer in the absence of the detergent. This result suggests incomplete dissociation 
of the Triton X-100 molecules from BAX and is in accordance with the FCS diffusion time, 
which shows that upon Triton X-100 dilution below CMC, the apparent molecular weight of 
the fluor-BAXΔC was higher than that of a protein monomer. 
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Fig. II.8 
 
 
 
 
 
 
 
 
 
 
Fig. II.8 | Enhancement of the fluor-BAXΔC fluorescence intensity upon interaction with 
detergents. A, constant concentration (3 μM) of fluor-BAXΔC was incubated with 
increasing concentrations of n-octyl glucoside (OG) for 1 h at 4°C. The fluorescence 
intensity of the protein samples incubated with detergent was measured using ConFocor 
3 (Zeiss, Germany). For each measurement the protein incubated with detergent was 
diluted to a final concentration of 24 nM in EB buffer containing the same detergent 
concentration as in the protein sample. All measurements were done at 22°C. cpp values 
were determined using the single-component fit of the FCS autocorrelation curves. B, 
increase in the apparent molecular weight (MW) of BAXΔC upon interaction with 
micelles of n-octyl glucoside. Molecular weight values were calculated using Equation 6. 
C, change in the cpp value of fluor-BAXΔC with increasing detergent concentration. 
Samples were prepared, and measurements were done similar to the Fig. II.6A. 
Detergent abbreviations are similar to Fig. II.5. 
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FCCS Analysis of BAXΔC in Detergent Micelles 
To show the absence of BAX oligomerization in detergent micelles, FCCS analysis was 
used. FCCS is a variation of the FCS that allows determination of the degree of interaction 
between two fluorescent molecules or macromolecular assemblies. In these experiments we used 
two types of fluorescently labeled BAX as follows: fluor-BAXΔC and Bodipy 630/650 
maleimide-BAXΔC. The degree of interaction between these two proteins in detergent 
micelles is proportional to the cross-correlation value that is determined by FCCS analysis. The 
results of these FCCS experiments show low cross-correlation values between two fluorescent 
forms of BAXΔC compared with the theoretically predicted cross-correlation value of BAXΔC 
dimer. These FCCS results suggest the absence of interaction between the two fluorescent 
variants of BAXΔC in detergent micelles of all tested detergents (Fig. II.9). 
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Fig. II.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. II.9 | Results of the FCCS experiments with fluor-BAXΔC (50% labeled) and Bodipy 
630/650 maleimide-BAXΔC (80% labeled) in the presence of the indicated detergents. 
Lane 1, cross-correlation standard (double-stranded RNA with AlexaFluor 488, Cy5 
labels); lane 2, no detergent present; lane 3, +2% n-octyl glucoside; lane 4, +2% Triton X-
100; lane 5, + 2% CHAPS; lane 6, + 2% cholic acid; lane 7, + 2% Tween 20; lane 8, + 2% 
dodecyl maltoside; lane 9, maximum expected cross-correlation value for a formation of 
protein dimer from a mix of 50 and 80% labeled protein. Experiments were done in 10 
mM HEPES, pH 7.2, 100 mM KCl buffer at 22 °C. All detergent concentrations are given in 
% of w/v. 
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II.4 | Discussion 
Fluorescently Labeled BAXΔC Is Active 
To apply FCS to the study of BAX, we generated a soluble form of the protein. We 
employed the BAXΔC in these solution studies of the protein activity and oligomerization 
because we found that it remained in solution and could be activated by detergent throughout 
all the manipulations that were used in these studies. To label this protein with a fluorophore, 
we substituted endogenous cysteines with alanine (C62A and C126A) and converted glycine 
40 in an unstructured region of BAX to a cysteine. The position of these changes in the 
BAXΔC protein are shown not to interfere with the function of the full-length BAX in vivo 
(3), and the resulting protein was well expressed by bacteria. The added cysteine was exposed in 
the engineered protein and formed disulfide cross-linked BAXΔC(G40C) dimers at high 
concentrations (data not shown). After substitution with the fluorescent probe, the disulfide 
formation did not occur. Therefore, further characterization of the activity of the engineered 
protein was performed on the fluor-BAXΔC.  
To assess the functional capability of fluor-BAXΔC, we tested its ability to promote 
cytochrome c release from isolated mitochondria as compared with that of BAXΔC. Because 
our engineered BAXΔC was based upon the human protein, we used mitochondria isolated 
from HeLa cells to study cytochrome c release (33). In these experiments we observed that 
fluor-BAXΔC releases 71 ± 15% of the mitochondrial cytochrome c when activated with n-
octyl glucoside, whereas BAXΔC releases 100 ± 30% (Fig. II.1). Based on this result we 
conclude that mutation and fluorophore labeling of BAXΔC alter pore forming activity of this 
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protein but only in a minor way. In addition, to these experiments, we also studied the ability of 
various detergents to activate BAXΔC and its mutant in liposomes (Fig. II.4). Again we saw a 
reduction in pore activation by the mutant protein. However, it is clear that the reduction is 
consistent across the range of tested detergents (Fig. II.4C). Finally, we compared the 
integration of BAXΔC and its mutant into lipid membranes using SPR. We have recently 
developed methods to quantitatively study binding and integration of BAX to membranes 
using SPR (22). In those studies protein integration into lipid membranes was critical for pore 
formation and only occurred after protein incubation with n-octyl glucoside. In the SPR 
comparison mutant of BAXΔC, BAXΔC(G40C) was fully functional and integrated into lipid 
membranes as well as BAXΔC (Fig. II.2). Taken together these studies indicate that 
BAXΔC(G40C) is fully functional, but its specific activity for pore formation is slightly 
lessened by the introduced mutations, possibly due to lower oligomerization rate or changed 
pore topology.  
Fluor-BAXΔC Forms High Molecular Weight Protein-Detergent Micelles with Most Activating 
Detergents 
BAXΔC has been shown to form high molecular weight complexes with n-octyl 
glucoside but not with CHAPS (7). To show that our mutated BAX, BAXΔC(G40C), can 
form high molecular weight complexes with n-octyl glucoside and not with CHAPS, we 
performed analytical gel filtration studies similar to those in Ref. 7. The results of these 
analytical gel filtration experiments show that in the presence of 2% (w/v) of n-octyl glucoside, 
BAXΔC(G40C) elutes at a molecular mass slightly below 440 kDa, whereas in the presence of 
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2% (w/v) CHAPS this protein elutes mostly as a monomer (73%). These results are similar to 
the previously published results for BAXΔC (7) indicating that mutations introduced into 
BAXΔC do not interfere with formation of high molecular weight complexes of this protein 
with n-octyl glucoside.  
Next we proceeded to measure the molecular weight of fluor-BAXΔC in the presence 
of n-octyl glucoside and CHAPS using FCS. In the FCS experiments we measured the diffusion 
time, τD, of fluor-BAXΔC molecules in the presence of 2% (w/v) of these detergents. Then by 
using Equation 6, we calculated the molecular weight of the fluor-BAXΔC protein-detergent 
micelle complexes (Table II.1). The molecular weights of BAXΔC protein-detergent micelle 
complexes determined by FCS and analytical gel filtration were fairly similar, further 
demonstrating that mutagenesis and fluorescent labeling of BAXΔC do not affect the 
interactions of this protein with n-octyl glucoside and CHAPS. This result also shows that FCS 
can be used to determine the apparent molecular weight BAXΔC with other detergents. 
Therefore, we extended the range of detergents used in our study to dodecyl maltoside, Triton 
X-10, Tween 20, and cholic acid. As a result of these FCS studies, we determined that fluor-
BAXΔC forms high molecular weight complexes in the presence of activating nonionic 
detergents (n-octyl glucoside, dodecyl maltoside, Triton X-100, and Tween 20). However, in 
the presence of cholic acid, activating ionic detergent, fluor-BAXΔC does not form high 
molecular weight complexes. Fluor-BAXΔC also did not form high molecular weight 
complexes with CHAPS, a zwitterionic detergent known for its inability to activate BAXΔC. 
203 
 
In addition, all of the tested activating detergents did not induce significant secondary structure 
changes in the BAXΔC protein (Fig. II.5).  
For the studies of BAXΔC pore formation in lipid membranes, it is desirable that 
detergent is removed after BAXΔC activation because detergent at concentrations above the 
CMC can alter the integrity of lipid membranes. Therefore, it is important to know the 
molecular weight of BAXΔC after interaction with detergent micelles. To determine the latter, 
excess detergent was removed from fluor-BAXΔC by dilution below the CMC. After removal 
of detergent micelles, the molecular weight of fluor-BAXΔC decreased to that of the fluor-
BAXΔC monomer for most of the detergents (Table II.1). The results for fluor-BAXΔC 
treated with Triton X-100 were an exception. Upon Triton X-100 dilution the molecular 
weight of fluor-BAXΔC was five times larger than that of fluor-BAXΔC monomer. There are 
two possible explanations for this result. The first explanation is based on incomplete 
dissociation of Triton X-100 molecules bound to fluor-BAXΔC upon detergent dilution, and 
the second explanation is possible formation of fluor-BAXΔC homo-oligomers. To 
differentiate between these two explanations and to determine the stoichiometry of fluor-
BAXΔC before, during, and after interactions with detergent micelles we performed FIDA.  
BAXΔC Is Present as a Monomer in Protein-Detergent Micelles 
To further investigate the stoichiometry of the fluor-BAXΔC-detergent micelles, we 
performed FIDA on the FCS data (Table II.2). The fluorescence brightness of the individual 
protein-detergent micelles varied ∼90% as a function of the detergent used, but all of them 
contained one BAX protein molecule. The reason for such variation of the fluorescence 
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brightness of the protein monomer in various detergents was because of the enhancement or 
quenching of the Bodipy FL fluorophore brightness upon transfer into the hydrophobic 
environment of a detergent micelle. Similar effects of the fluorophore brightness enhancement 
were reported previously for the fluorescently labeled diphtheria toxin T-domain interacting 
with detergent micelles (34). In our case there appears to be an enhancement of the 
fluorescence brightness of fluor-BAXΔC in the presence of n-octyl glucoside, dodecyl 
maltoside, and Triton X-100 detergents, and a decrease in protein fluorescence brightness in 
the presence of cholic acid and Tween 20. Studies of detergent titration into constant protein 
concentration show that this effect is because of the enhancement of the fluorophore brightness 
and not because of protein oligomerization (Fig. II.8). In addition, detergent dilution studies 
show that upon detergent dilution, which leads to the dissolution of the fluor-BAXΔC-
detergent micelles, the fluorophore brightness of the protein returns to that of the protein 
monomer prior to the interaction with detergent micelles (Table II.2).  
The FIDA results mean clearly that before, during, and after interaction with detergent 
micelles the fluor-BAXΔC protein is a monomer. This observation suggests that BAXΔC 
interaction with micelles is fundamentally different from the interaction that it establishes in 
bilayer membranes. In a bilayer membrane BAXΔC assumes conformation, which allows 
assembly of homo-oligomers resulting in pore formation. In contrast, in a detergent micelle 
BAXΔC assumes conformation that in the case of nonionic detergents leads to a dramatic 
enlargement of the resulting protein-detergent micelle without necessary protein homo-
oligomerization (Table II.1 and Fig. II.3). Because this increase in size can no longer be 
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attributed to additional BAX molecules per micelle, it must be due to the incorporation of 
additional detergent.  
To study the interaction of the fluor-BAXΔC with detergent micelles, we used 
detergents at 2% (w/v) concentration, which is well above the CMC for all tested detergents. If 
expressed in molar units, this detergent concentration will be on the order of millimolars for all 
tested detergents (n-octyl glucoside, 68 mM; Triton X-100, 32 mM; CHAPS, 33 mM; dodecyl 
maltoside, 40 mM). In contrast, in all of the experiments the concentration of fluor-BAXΔC 
during incubation with detergent was 20–30 μM. Solution containing 20–30 μM protein and 
>30 mM detergent has an excess of detergent micelles over the number of protein molecules. 
Fleming (32) has shown that an excess of detergent micelles moves the protein to a more 
dissociated state. Fleming (32) also shows that for a glycophorin A transmembrane α-helix, 40% 
of dimers of this α -helix are detected for a 40 times lower mole ratio of protein to detergent 
than was used in our experiments. This demonstrates that if fluor-BAXΔC is forming 
oligomers in detergent micelles, then we would not have been prevented from detecting them. 
The above outlined argument together with the FCCS results (Fig. II.9) led us to the 
conclusion that fluor-BAXΔC is present as a monomer in detergent micelles.  
The outcome of this conclusion is that during and after detergent activation BAXΔC is 
a monomer. Therefore, this protein has two stable monomeric conformations in physiological 
buffer conditions, one inactive and one active. Second, this implies that the detergent-activated 
species of BAX is a monomeric protein, and the large molecular weight in the presence of the 
micelles of nonionic detergents is a result of the detergent component of the complex.  
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Consequences for the Physiological Activation of BAX 
These studies suggest that detergent activation of BAX is not merely a mimicry of the 
physiologic BAX activation. The characteristics of the detergent activation indicate two 
intriguing characteristics that may concern in vivo activation of BAX. First, because BAX 
remains active after we effectively remove the detergent substrate upon which it has activated, 
there must be two stable conformations of monomeric solution BAX, one active and the other 
inactive. Because this activation requires a large template and is distinct from the oligomer-
competent conformation, which BAX assumes in membranes, we can consider the possibility 
that BAX is activated as a soluble protein and then integrates into the membrane. Second, the 
existence of a soluble active form of BAX suggests that this process can be reversed, which is a 
potential therapeutic approach.  
II.5 | Conclusion 
In this work we studied in detail the process of BAXΔC activation by nonionic 
detergents. Based on the results of our study we conclude that BAXΔC is a monomer before, 
during, and after interaction with detergent micelles. In this study we used fluorescently labeled 
analogue of BAXΔC in combination with two single-molecule sensitivity techniques (FCS and 
FIDA). Because the determination of the oligomeric state of proteins in detergent micelles is 
important for structural and functional studies of integral membrane proteins (35, 36), we are 
hopeful that the method presented here can be used for other proteins.  
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II.6 | Experimental Procedures 
All chemicals used in this paper were from Sigma, unless otherwise stated. All lipids were 
obtained from Avanti Polar Lipids. Fluorescent dyes for protein labeling were purchased from 
Molecular Probes. 
Protein Constructs, Protein Purification, and Protein Labeling 
The cDNA for human BAX with 19-amino acid truncation on the C terminus 
(BAXΔC) was fused to the C-terminal intein/chitin-binding domain of the pTYB1 vector 
(New England Biolabs) (8). Three mutations (G40C, C62A, and C126A) were introduced 
into each of the DNA plasmids using a QuikChange mutagenesis kit (Stratagene), and the 
presence of mutations was confirmed by sequencing. The resulting construct and purified 
protein were dubbed as BAXΔC(G40C). All proteins (human BAXΔC and human 
BAXΔC(G40C)) were purified from BL21(DE3) Escherichia coli cells without detergent. 
Briefly, bacterial cultures were grown at 37°C in Terrific Broth (19) to an A600 of 1.5–2.0, and 
then the cultures were induced with 0.1 mM isopropyl 1-thio-β-d-galactopyranoside (Research 
Products International. Corp., Mt. Prospect, IL), and the temperature was dropped to 25 °C. 
After 12–15 h, bacteria were collected via centrifugation; the resulting pellet was resuspended 
in lysis buffer (phosphate-buffered saline, pH 7.2, 1 mM EDTA, 0.25 mM 
phenylmethylsulfonyl fluoride), and cells were broken by four passages through a 
Microfluidizer (Microfluidics) at 1000 bar. Lysate was clarified by centrifugation, and the 
supernatant containing BAX was incubated with chitin affinity resin (New England Biolabs) 
overnight at 4°C on a rocker. Resin was subjected to a high salt wash and then equilibrated in 
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cleavage buffer (10 mM HEPES/NaOH, pH 8.0, 100 mM NaCl, 50 mM dithiothreitol) and 
incubated for 48 h at 4°C. The purity of the proteins were assessed by SDS-PAGE. 
BAXΔC(G40C) was labeled with Bodipy FL c5-maleimide (Molecular Probes) according to the 
manufacturer's protocol. Labeled protein was separated from the free dye using a Sephadex G-
25 column. The degree of protein labeling was determined using a NanoDrop 
spectrophotometer (Thermo Scientific) by measuring absorbance at 280 nm (for protein 
concentration) and 504 nm (for Bodipy FL concentration). Resulting protein was ∼ 80% 
labeled and was stored in EB buffer (10 mM HEPES/KOH, pH 7.2, 100 mM KCl) at 4°C.  
Incubation of BAX with Detergent Micelles 
Prior to FCS studies and cytochrome c and carboxyfluorescein release experiments, 
fluorescently labeled BAXΔC(G40C) or BAXΔC (20–30 μM) was incubated with 2% (w/v) 
of the indicated detergent in EB buffer for 1 h at 4 °C. For FCS studies of the fluor-BAXΔC in 
detergent micelles, after incubation with detergent, protein was diluted to a concentration 
below 0.5 μM in a solution containing the same detergent concentration as the activated 
protein. This dilution was done to ensure that the fluorescent signal emitted by the protein 
sample is within the dynamic range of the detector in the ConFocor 3 (Zeiss, Germany). To 
remove detergent micelles for the cytochrome c release and for the FCS studies of post-micelle-
activated fluor-BAXΔC, the BAX/detergent mixture was diluted below the CMC of each 
particular detergent. The disappearance of micelles occurred at different rates (<1 min for OG 
and longer but <60 min for Triton X-100) but was allowed to finish before further studies on 
the sample (cytochrome c release or FCS) proceeded. 
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Cytochrome c Release Assay 
Mitochondria from HeLa cells were isolated using a previously published procedure 
(20). Isolated mitochondria were resuspended in 10 mM HEPES/KOH, pH 7.4, 100 mM 
KCl, 1 mM EGTA, 200 mM sucrose. For the cytochrome c release assay isolated mitochondria 
were incubated with 100 nM of protein that was detergent-activated but micelle-diluted as 
described above or inactive protein at 37°C for 20 min. After the incubation with BAX protein 
or detergent control solutions, mitochondria were spun down at 10,000 × g for 10 min at 4°C 
and then pellet and supernatant fractions were collected and stored at −20°C. For the 
cytochrome c release assay we used 0.5 μg of mitochondria in a 30 μl volume. Protein 
concentration in the preparation of isolated mitochondria was determined by protein assay 
(Bio-Rad). Cytochrome c content in the pellet and supernatant fractions was determined using 
TiterZyme EAI human cytochrome c enzyme immunometric assay kit (Assay Designs) in 
combination with Synergy HT plate reader (Bio-Tek Instruments, Inc.). 
Surface Plasmon Resonance Studies of BAX Binding to Liposomes 
These studies were done using Biacore X instrument (GE Healthcare) at an ambient 
temperature of 25°C. Liposomes with lipid composition of DOPC:DOPA:bovine heart 
cardiolipin (70:20:10 mol %) were prepared using the reverse-phase evaporation method (21) 
following the procedure described in detail in Ref. 22. The buffer was EB unless otherwise 
noted. The rest of the experimental conditions, experimental protocol, and data analysis were 
the same as described previously (22). 
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Analytical Gel Filtration 
Analytical gel filtration experiments were performed on a Superdex 200 HR 10/30 
column (GE Healthcare) equilibrated with 20 mM HEPES/KOH, pH 7.5, 300 mM KCl, 0.2 
mM dithiothreitol. In the corresponding samples, 2% (w/v) of the indicated detergent was 
included in the equilibration buffer. Prior to loading the sample on the column, 2.5 nmol of 
BAXΔC(G40C) were incubated in 2% (w/v) of the corresponding detergent for 1 h at 4°C. 
Then samples were loaded into the column and run at 0.5 ml/min. BAXΔC(G40C) elution 
was detected by light absorption at 280 nm. 
Carboxyfluorescein Release Assay 
Liposomes containing 50 mM carboxyfluorescein (CF) were prepared following the 
procedure described previously (22). Incubation with detergent protein was diluted into wells 
in a black bottom 96-well plate (NUNC, Denmark) using EB buffer. Liposomes (200 nm in 
diameter, DOPC:DOPA, 70:30 mol %) were added to the wells last. Immediately upon 
addition of liposomes, measurement of CF fluorescence was done using a Synergy HT plate 
reader (Bio-Tek Instruments, Inc.). CF releases for all protein samples containing detergent 
were corrected for the base-line CF release in the presence of detergents without protein. Data 
were analyzed in Origin 6.1 (OriginLab Corp.).  
Circular Dichroism Spectroscopy 
Samples for CD spectroscopy were prepared at 5 μM protein concentration in 10 mM 
potassium phosphate buffer, pH 7.0. Detergents (n-octyl glucoside (2% w/v), dodecyl 
maltoside (0.6% w/v), Triton X-100 (0.08%), Tween 20 (0.04% w/v), cholic acid (2% w/v)) 
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were added to protein samples 1 h prior to measurements and stored at 4°C. Samples were 
measured at 20°C on Jasco J-715 spectropolarimeter using a 1-mm path length cell. Data were 
collected every 0.1 nm at 50 nm/min scan speed from 260 to 200 nm, and results were averaged 
from five scans. Because of high CD signal from Triton X-100 at 200 nm for samples 
containing this detergent, data were collected from 240 to 205 nm. Spectra for all protein 
samples containing detergent were corrected for the base line of detergents in the absence of 
protein. 
FCS, FCCS, and FIDA Analyses, Instrumentation, and Measurements 
LSM 510 ConFocor 3 system coupled with a Zeiss Axiovert 200 M inverted 
microscope (Zeiss, Germany) was used for FCS and FIDA experiments. A water immersion C-
Apochromat ×40 objective (Zeiss, Germany) focused the excitation light to a diffraction-
limited spot. The pinhole size was set to 70 μm for 488 nm excitation laser light. The excitation 
light of a 25-milliwatt 488 nm argon laser was set at 1% of the acousto-optical tunable 
transmission. Laser power in the sample was 7 microwatts. In front of the detector LP 530-nm 
filter was used. For the FCS and FIDA analyses, each sample was measured at least nine times 
for 50 s. The detection volume was previously calibrated with free Bodipy FL maleimide in 
solution (diffusion time 22.6 ± 0.5 μs, structure parameter 5.0 ± 0.4). 
FCS Analysis 
FCS measurements provide three characteristic parameters for interpretation as 
follows: τD, diffusion time of a fluorescent particle (i.e. the average time a particle spends in the 
detection volume); N, number of fluorescent particles in the detection volume, and the 
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counts/particle (cpp) or the average fluorescent intensity per particle. These parameters are 
extracted by performing a fit of FCS auto-correlation data to one component diffusion model 
as shown in Equation 1, which takes into account photophysical dynamics of fluorophores, 
 
In this equation G(τ) is the auto-correlation function; τ is the lag time; T is the fraction of 
molecules in the triplet state; τT triplet decay time; ω is the structure parameter (aspect ratio) of 
the Gaussian detection volume. Fitting of the FCS auto-correlation curves was done using 
Equation 1 with software written in MATLAB (Mathworks) using a weighted nonlinear least 
squares fitting algorithm. 
Calculation of Protein-Detergent Micelle Molecular Weight Based on FCS Diffusion Time 
For a particle in solution the diffusion time is inversely proportional to the diffusion 
coefficient as shown in Equation 2, 
 
In general, protein molecules diffusing in solution are assumed to approximate a spherical shape 
permitting the Einstein-Stokes relationship to be used in evaluating the diffusion constant as 
shown in Equation 3, 
 
where, kB is the Boltzmann constant; T is temperature in degrees Kelvin; η is viscosity of 
solution in which particle is diffusing, and R is the radius of the spherical particle. The radius of 
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diffusing particle depends on the molecular weight of the particle (R ∝ (MW)). Under these 
conditions a relationship can be established between the FCS diffusion time of a particle and its 
molecular weight as shown in Equations 4 and 5. 
 
 
In the case of BAXΔC, we know diffusion time of a BAXΔC monomer, τ D,monomer, and its 
molecular weight, MWmonomer = 19 kDa. We also know the diffusion time of BAXΔC protein-
detergent micelle, τD,oligomer. Using Equation 5 we can determine the apparent molecular weight 
of the BAXΔC protein-detergent micelle as shown in Equation 6. 
 
FCCS Analysis 
FCCS employing BAX labeled with dyes having nonoverlapping fluorescence spectra 
and a two-channel collection of data was used to determine the presence or absence of BAX 
homo-oligomers in detergent micelles (23, 24). Using Bodipy FL maleimide-BAXΔC and 
Bodipy 630/650 maleimide-BAXΔC, we studied cross-correlation in micelle-associated 
protein. The cross-correlation value, a ratio of the number of the fluorescent complexes 
containing both proteins of interest to the number of the fluorescent species of one of the 
proteins, was used to estimate the micelles with more than one BAX molecule. As a positive 
control and as a calibration sample, the 21-bp-long double-stranded RNA labeled with 
AlexaFluor 488 and Cy5 on each 3′-end was used (25). 
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Fluorescence Intensity Distribution Analysis 
Analysis of the fluorescence brightness of a particle can provide an additional measure 
of the number of fluorescent proteins associated with a detergent micelle. The particle 
fluorescence brightness determined by FIDA is extracted by fitting the distribution of the 
number of photon counts and is similar to the cpp value determined by FCS for a 
monodisperse fluorophore solution. Determination of the particle brightness of the BAX-
detergent micelle and comparison with particle brightness of monomeric BAX molecules 
estimate the number of BAX molecules in detergent micelles. FIDA was performed according 
to Kask et al. (18). The raw data of photon arrival times was binned to 20 μs, and photon 
counting histograms were constructed. Parameters describing the detection volume were 
determined in a solution of fluor-BAXΔC in the absence of detergent. As indicated, histograms 
were fitted to model functions for one or two components, as described in Kask et al. (18) 
subtracting a background of 310 Hz for the buffer solution. 
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APPENDIX III 
 
Evidence for a Giant BAX Pore 
 
 
(The contents of this chapter were adapted from Ivashyna, O., García-Sáez, A. J., Christenson, 
E. T., Schwille, P., Schlesinger, P. H. (2011) (in preparation)) 
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III.1 | Summary 
BAX is a proapoptotic member of the BCL2 protein family that induces 
permeabilization of the outer mitochondrial membrane, likely via oligomeric pores. In vitro 
reconstitution experiments strongly support BAX oligomerization and membrane poration 
which correlates with genetic and biochemical evidence. The size and composition of BAX 
pores remains controversial, however, largely due to the absence of high-resolution structural 
information on membrane-affiliated BAX. To interrogate BAX pore formation and its long-
term effects on artificial lipid membranes we developed a system consisting of giant unilamellar 
vesicles (GUVs) and recombinant fluorescently-labeled BAX and unlabeled BH3-only activator 
cBID which we studied using confocal microscopy. Our data show that BAX can bind and 
permeabilize lipid bilayers of GUVs and prolonged exposure of GUVs to BAX leads to 
dramatic morphological changes in and disintegration of GUV structure. In addition, we found 
that in the large format of GUVs BAX forms giant pores which we have termed mega-pores. 
The line tension in the rim of a BAX mega-pore was calculated to be 3.7±1.7 fN while the size 
distribution of these pores was 5-20 μm and lifetime ranged from 8 min. to many hours. The 
presence of BAX mega-pores supports the proposal that BAX can form pores of varying 
diameters, not only on the nanoscopic scale but also the microscopic, and suggests there is no 
upper limit on the number of BAX monomers that can participate in a BAX pore. 
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III.2 | Introduction 
BCL-2 associated protein X (BAX), a member of the B-cell lymphoma-2 (BCL2) 
protein family, is directly involved in controlling integrity of the outer mitochondrial 
membrane (OMM) (1). In a cell, the function of BAX is to permeabilize the OMM, possibly 
via formation of oligomeric pores, through which mitochondrial intermembrane proteins can 
escape into the cytoplasm and activate the cascade of caspases which dismantle the cell. 
However, such BAX pores have not been directly observed in vivo but only via cell-free 
reconstitution schemes. In vitro BAX pores were observed in systems consisting of purified 
BAX and artificial lipid membranes – in most cases represented by the unilamellar lipid vesicles 
of 0.1-0.2 µm in diameter (2-4). Such small liposomes can only be imaged by electron 
microscopy where samples have to be dried and fixed prior to imaging, which conceivably can 
introduce artifacts (5). Therefore, we developed an in vitro system consisting of fluorescence-
labeled (fl-) BAX, BH3-only direct activator cut BID (cBID), antiapoptotic BCL-XL, and giant 
unilamellar vesicles (GUVs) – with diameters ranging from 10-100 µm – which can be non-
invasively studied in physiological buffer conditions over relatively long periods of time.   
We began our studies by establishing the ability of fl-BAX to form pores in unilamellar 
vesicles of 0.2 µm in diameter, after which we transitioned to confocal imaging studies of fl-
BAX binding and permeabilization of GUVs. To ensure that fluorescence-labeling of BAX did 
not interfere with its ability to permeabilize lipid membranes, we produced two forms of fl-
BAX, labeled with structurally distinct fluorophores. The relevance of our experimental regime 
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is evinced by employing cBID to enhance the permeabilization activity of BAX and BCL-XL to 
suppress BAX poration. 
Confocal microscopy experiments allowed observation of  intriguing BAX effects on 
the morphology and stability of GUVs, the most striking being formation of gigantic BAX 
pores which we have dubbed BAX mega-pores. To characterize these pores with respect to 
other known types of giant pores in GUVs we measured the line tension in the rims and the 
lifetimes of these mega-pores. Our evidence reveals that BAX mega-pores are the most stable 
giant pores yet observed. While BAX mega-pores should not exist in a cellular environment, 
their interrogation provides insight into the assembly of mitochondrial, nanoscale pores. 
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III.3 | Results 
Fluorescently-labeled BAX is functional 
For our imaging experiments human full-length BAX—with a single cysteine residue 
engineered at position 4 (S4C) and the two endogenous cysteines, C62 and C126, mutated 
to serine and alanine respectively—was produced in E. coli without use of detergent as 
described in Methods section. This protein was labeled with Alexa Fluor 488 dye (BAX-G) or 
with Atto 655 dye (BAX-R). The two dyes were used to ensure that fluorescence labeling does 
not interfere with the liposome permeabilization activity of BAX. The liposome 
permeabilization activity of both fluorescently labeled proteins was checked using assay of 
carboxyfluorescein release from liposomes (6,7). In this assay cBID was used to activate the 
liposome permeabilization by BAX. However, without the addition of cBID, BAX produced a 
slow release of carboxyfluorescein from liposomes, suggesting an intrinsic permeabilization 
activity of BAX in our preparation (8) (Fig III.1).  Interestingly, addition of BCL-XL, an 
inhibitor of BAX pore formation, inhibited only the cBID induced permeabilization of 
liposomes by BAX but not the permeabilization of liposomes induced by BAX alone, (Fig. 
III.1B). However, the intrinsic permeabilization activity of BAX was inhibited by BCL-XL, 
when both proteins were added simultaneously to liposomes in the absence of cBID.  
 Further verification of fl-BAX functionality was done using GUVs prepared from 
DOPC:bovine heart cardiolipin mixture of 80:20 mol% (Fig. III.1C). In these experiments 
BAX-R (25 nM), BAX-G (25 nM), cBID (4 nM), and free Alexa 546 dye (1 µM) were added to 
GUVs and time series of images were taken to follow the GUV permeabilization. As a result 
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BAX bound and permeabilized GUVs (Fig III.1C). BAX binding to the GUVs can be seen 
from the time-dependent increase in the fluorescence in the GUV membranes, while 
permeabilization of GUVs can be seen from the filling of GUV lumen with free dye and with 
BAX (Fig. III.1C).  
We also tested the effect of BCL-XL on BAX binding and permeabilization of GUVs 
(Fig. III.1D-E). In these experiments, as expected BCL-XL prevented pore formation by BAX 
without inhibiting the ability of BAX to bind GUV membranes (Fig. III.1D). However, when 
liposomes were initially preincubated with BCL-XL and cBID for one hour and then BAX 
added, no BAX binding to GUVs was observed, suggesting that BCL-XL, when present in a 
lipid membrane, inhibits BAX binding to the membrane (9) (Fig. III.1E). Taken together, 
these results show that both fluorescence-labeled BAX proteins can bind lipid membranes and 
form pores in liposomes and thus recapitulate native BAX function. 
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Fig. III.1 
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Fig. III.1 | Assays of liposomes permeabilization by BAX. A, Kinetics of 
carboxyfluorescein release from liposomes. Each release curve is normalized and 
represents an average of three independent measurements. Protein concentrations 
used: 100 nM wild-type (wt) BAX, 100 nM BAX-R, 100 nM BAX-G, 10 nM cBID, 100 
nM BCL-XL. Total lipid concentration was 16 μM, while lipid composition was 
DOPC:cardiolipin 80:20 mol%. B, End point measurement of the % release one hour 
after addition of indicated proteins to liposomes filled with carboxyfluorescein. C, 
Confocal microscopy images of GUV permeabilization by BAX-R (25 nM) and BAX-G 
(25 nM) activated with cBID (4 nM). Alexa 546 was used as a small soluble 0.5 kDa 
dye to follow the GUV permeabilization (1 μM). Time stamps indicate time after 
protein addition to GUVs. D, Confocal microscopy images with overlayed spectral 
channels from BAX-R and BAX-G of BAX binding to GUVs in the presence of BCL-XL 
(50 nM) and cBID (4 nM). BAX-R and BAX-G total concentration is 50 nM. E, BAX 
does not bind GUVs preincubated for one hour with 50 nM BCL-XL and 4 nM cBID. 
In all images scale bar is 20 μm. 
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Morphological changes in GUVs upon BAX binding 
The ability of BAX to from pores in GUVs has been reported previously but not with a 
fluorescence-labeled protein or with the intent to characterize the evolution of membrane 
morphology upon prolonged interaction with BAX protein (10,11). Here, we used confocal 
microscopy to establish the effect of the fl-BAX on GUVs. We determined that incubation 
with 50 nM BAX and 4 nM cBID allowed us to simultaneously observe the accumulation of fl-
BAX in and permeabilization of the GUV membrane (Fig. III.1C) and that the GUVs were 
stable for 7 to 8 hours after protein addition.  However, after 24 hours this preparation became 
a mass of collapsed GUV remnants, reflecting the gross distortions by BAX of bilayer 
architecture (Fig. III.2F).  After one hour of incubation with this BAX concentration, 100% of 
GUVs were permeabilized and had homogeneous distribution of labeled BAX on the bilayer 
membrane. At the same time, in these experiments, we noted variable fluorescence intensity in 
various GUV membranes, representing a diversity of BAX concentration in these membranes 
(Fig. III.S1A). We hypothesize that this heterogeneity of BAX binding to GUVs stems from 
variation in cardiolipin content of the GUVs which is known to affect the BAX, BAK, and 
cBID binding (2,5,12) (See Supplement Discussion). After 3-4 hours of incubation with BAX 
and cBID the heterogeneity of BAX binding to GUVs was no longer visible suggesting BAX 
saturation in the lipid membrane of GUVs (Fig. III.2A). Prolonged incubation of GUVs with 
these concentrations of BAX and cBID led to major morphology changes in the GUVs. The 
vesicles change shape from spherical to potato- and tubule-like forms reflecting BAX-induced 
changes in the elastic coupling to lipid bilayer forces in membranes (Fig. III.2A-D). 
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Additionally, we observed formation of gigantic BAX mega-pores and other large visible BAX 
aggregates in GUV membranes (Fig. III.2B, 3, 4). During incubation with BAX occasional 
GUVs ruptured into smaller liposomes (Fig. III.2E-F) and by 24 hours of incubation with BAX 
almost no GUVs were left in the observation chamber. These proceedings clearly defined the 
time period when these GUVs could be studied by confocal microscopy. BAX binding to 
GUVs and consequent deformation and rupture of GUVs is dependent upon BAX 
concentrations demonstrating that mass action and thermodynamics governs these processes. 
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Fig. III.2 
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Fig. III.2 | BAX binding to GUVs: confocal microscopy images. A, Distortion of spherical 
GUVs by BAX. B, Aggregates of BAX in GUV membranes. C, Agglomeration of GUVs after 
four hours of incubation with BAX. D, Formation of tubule-like lipid membrane 
structures after 7-8 hours of incubation with BAX. E, Rupture and collapse of GUVs upon 
BAX addition. Time steps represent the time after BAX addition. F, Transformation of 
GUV shape upon BAX binding (4 nM cBID and 50 nM combined concentration of BAX-R 
and BAX-G). In all images scale bar is 20 μm. 
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BAX forms long lived mega-pores in GUVs 
While using confocal microscopy to study BAX-R and BAX-G binding to GUVs in the 
presence of cBID, we were intrigued by the formation of giant BAX pores which we named 
BAX mega-pores (Fig. III.3, 4). These pores ranged from 5-20 µm in diameter (Fig. III.4D), 
appeared within 10 minutes of BAX addition to GUVs, and were extremely stable, with 
lifetimes of 8 minutes up to many hours. Interestingly, all observed BAX mega-pores had 
increased BAX concentration in the rim of the pore, which can be seen from increased 
fluorescence signal from the membrane portion creating the pore edge. In addition, these mega-
pores did not expand or lead to GUV collapse (13). Although the mega-pores usually closed 
over the observation period of 1-2 hours, the presence of a simple obstacle in the pore closure 
path, e.g. another liposome, was observed to arrest the closure process (Fig. III.3C). For 
comparison, an impedimentary lipid vesicle present in the closure path of a giant pore opened 
by the stimulation with visible light was cut into two vesicles when the pore closed (14). This 
observation shows that BAX reduces the line tension in the pore rim, thus resulting in the 
arrest of the pore closure by an impedimentary vesicle. The line tension is the energy per unit 
length of the membrane contour at the pore edge, and it arises due to the exposure to water of 
the hydrophobic lipid tails in the rim of the pore. In GUVs where a BAX mega-pore did close, 
fl-BAX concentrated at the rim of the pore dispersed over the GUV surface producing a 
homogeneous BAX fluorescence signal (Fig. III.3B, 4A). Additionally, GUVs which have gone 
through the process of the mega-pore formation and closure did not have another mega-pore 
open and appeared to be stable for hours afterwards. 
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Fig. III.3 
 
 
 
 
 
 
 
 
 
 
Fig. III.3 | BAX mega-pore visualization. A, 3D reconstruction of the BAX mega-pore 
shown together with confocal images used to produce this reconstruction. Values in μm 
indicate distance from the bottom of a GUV resting on the coverslip surface. B, Confocal 
images of the time series of opening, persistence, and closure of the BAX megapore. 
Arrow in the first image indicates the position at which the BAX mega-pore opened. 
Time stamps represent time since the opening of the pore. C, Confocal images of other 
examples of BAX mega-pores. 
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Size distribution of BAX mega-pores 
 To determine whether a correlation exists between the sizes of BAX mega-pores and 
GUVs, we performed the Pearson’s correlation test. In this test we compared the distribution of 
BAX mega-pore diameters with diameters of encompassing GUVs (Fig. III.4C-D); only weak 
correlation was found between these two sets of values (with the Pearson correlation coefficient 
of 0.25). The maximum value for the Pearson correlation coefficient is 1 which corresponds to 
a direct positive correlation between two sets of values, i.e. increase in the value of one data set 
leads to linear increase in the values of the other data set. The relatively small correlation 
between the diameter of a mega-pore and its cognate GUV diameter weakly suggests that the 
larger the GUV the larger mega-pore it can accommodate. However, a GUV with a certain 
diameter can have mega-pores of various diameters which are most likely distributed around a 
certain mean value. For example, a GUV 22 µm in diameter can support a mega-pore of 15±5 
µm (n=3) (Fig. III.4D). The latter observation suggests that there is effectively no limit on the 
number of BAX monomers participating in the formation of a BAX mega-pore and reveals a 
continuum of BAX mega-pore sizes. 
Line tension in the rim of a BAX mega-pore 
Kinetics and thermodynamics of giant pores in GUVs can be explained by theoretical 
models (14,15) where the energy rE  of a pore of radius r  is described as 
    σππ 22 rrEr −Γ=     (Eqn. 1) 
where Γ  is the line tension while σ  is the surface tension. Interplay between line and surface 
tension allows opening, persistence, and closure of giant pores in GUVs. Following the model 
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of Brochard-Wyart F. et al. (16) the life of a pore in a GUV can be described in four steps: (i) 
pore opens due to an increase of the membrane surface tension (σ ) which can be induced by 
application of an electrical field (17,18), insertion of molecules with non-zero spontaneous 
curvature such as detergents (14), or insertion of BAX α5-derived peptides (19); (ii) while the 
surface tension term in Equation 1 is larger than the line tension term the pore expands to some 
critical radius ( cr ); (iii) while the surface tension and line tension terms in the equation 1 are 
equal (i.e. pore energy 0=Ε r ) the pore exists in an unstable equilibrium state; (iv) when the 
line tension begins to increase the pore initiates closure. Using this theoretical framework the 
line tension in the rim of the pore during the pore closure stage can be calculated using  
πη3
2Γ
−=k     (Eqn. 2) 
where k  is the slope of the )ln(2 rR  versus time and η  is the solution viscosity (1.035×10-3 
Pa·s for 30 mM sucrose solution), R  is the radius of a GUV containing a pore of radius r . 
Examples of the evolution of BAX mega-pore radii ( r ) are shown in Figure III.4B-C. From 
these data we estimate the line tension in the rim of the BAX mega-pore to be 3.7±1.7 fN 
(n=3) which is four orders of magnitude lower than the line tension of a pore opened by 
intense illumination of a DOPC vesicle (Γ= 20.7±3.5 pN) (14) and two orders of magnitude 
lower than the line tension of a detergent stabilized giant pore (0.2 pN). 
The ability of the BAX to reduce the line tension of artificial lipid membranes has been 
reported previously but without a direct measurement of the line tension (20). Here, we 
quantify BAX reduction of bilayer line tension and find the protein to be drastically more 
effective in eliciting membrane poration than other previously studied effectors. It is 
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hypothesized that cone-shaped detergents reduce the line tension in giant lipid pores based on 
their propensity to partition to the high curvature regions in the edge a pore (14,21). Therefore, 
the ability of BAX to reduce line tension lower than that of detergents indicates that BAX is a 
remarkable protein evolutionarily crafted to stabilize edges of lipid membranes. 
Interestingly, the line tension generated by full-length BAX is three orders of 
magnitude lower than the line tension generated by the pore-forming BAX α5 peptide in a 
supported lipid bilayer (Γ= 3.8±0.4 pN) (19).  This disparity indicates that the full length 
protein is able to stabilize the pore edge more efficiently than a single α-helix of BAX, 
suggesting that the non-pore forming helices of BAX also contribute to edge stabilization. 
Previously the non-pore forming helices were attributed two major roles in the function of 
BAX: first, to shield the pore-forming helices of BAX (α5-6) from interaction with lipid 
membranes in the inactive conformation of BAX (22); and second, to facilitate the 
communication between BAX and other proteins involved in the apoptosis decision via BH3 
domain interaction. Our findings ascribe a third role for these non-pore forming helices of 
BAX: stabilizing the edges of BAX mega-pores and thus likely stabilizing the edges of kindred 
nanoscopic BAX pores. A substantial fraction of this improved edge stabilization of the full-
length protein vs. the α5 peptide is probably an effe ct of BAX homo-oligomerization which 
locally concentrates the α5s (23-25). 
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Fig. III.4 
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Fig. III.4 | Analysis of line tension and distribution of BAX mega-pore diameters. A, 
These confocal images represent an overlay of three channels: red (BAX-R), green (BAX-
G), and pink (free dye Alexa 546). Time stamps indicate time after protein addition to 
GUVs. The GUV positioned in the center of each frame has a daughter liposome inside. 
The outer GUV develops a BAX mega-pore; the inner liposome is then ejected thorough 
the BAX mega-pore and the mega-pore then closes. Scale bar is 40 μm. B, The R2ln(r) 
versus time plot for the GUV shown in panel A. C, The R2ln(r) versus time plot for the 
GUV shown in Fig. 3B. D, Bar plot of GUV diameters (gray bars) and corresponding 
diameters of BAX mega-pores (white bars). Number of GUVs used for this plot is 44. E, 
Result of Pearson correlation test for the correlation between GUV and corresponding 
BAX mega-pore diameters. Pearson correlation test value is 0.25 (maximum possible 
value is 1). 
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The lifetime of BAX mega-pore 
The lifetime of lipid pores in DOPC vesicles immersed in water solution is estimated to 
be 10-200 ms which can be extended by increasing the viscosity of solution (15). Therefore, 
66% glycerol solution, having 30 times higher solution viscosity than water, is commonly used 
to measure the lifetimes of giant lipid pores (14,26,27). The reported lifetimes of giant pores in 
66% glycerol ranges from seconds for lipid pores opened by a physical method to minutes for 
lipid pores stabilized with detergent (14) while the lifetime of BAX mega-pores ranges from 8 
min to many hours when measured in 30 mM sucrose solution (which has viscosity very close to 
that of water). Hence, if the lifetimes of all three types of giant pores are compared in the same 
solution, the BAX mega-pore will have the longest lifetime, as explained by the extremely low 
line tension measured in the rim of this pore. 
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III.4 | Discussion 
The size and oligomeric state of a BAX pore is somewhat controversial in the field of 
apoptosis. In fact, the BAX pore has not been observed in vivo by electron microscopy in 
mitochondria of cells undergoing apoptosis, where BAX appears to aggregate at the fission sites 
on the surface of the OMM (28). Nonetheless, in vitro studies using electrophysiological and 
pore-sizing techniques have shown that BAX forms pores of 2-5 nm in diameter 
(7,10,11,29,30) while electron and atomic force microscopies revealed the formation of 100-
200 nm disruptions in liposomes and supported lipid bilayers incubated with BAX (5,23,31). 
In light of this controversy about the size and composition of BAX pores, our observations of 5-
20 µm diameter BAX mega-pores in GUVs support the hypothesis that BAX is able to form 
pores of various sizes (32).  
 In addition to extremely large diameters, BAX mega-pores also exhibited uncommonly 
long life times ranging from 10 min to hours. Based on the lifetime and size, these BAX mega-
pores are very similar to the giant pores formed in GUVs by detergents or by the physical 
disruption of GUVs (14-16,18,26,27,33). The latter two types of giant pores can be 
differentiated on the basis of the magnitude of the force responsible for closing a pore – the line 
tension (14,21). The line tension is highest in giant pores opened by physical disruption (10-20 
pN) (14,33) and is two orders of magnitude lower in the giant pores stabilized by detergents 
(0.2 pN) (14). Therefore, to characterize the BAX mega-pores with respect to the other two 
known types of giant pores we used an established microscopy technique to measure the line 
tension in the rim of the BAX mega-pore; this quantity was ascertained to be two orders of 
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magnitude lower than the line tension in the rim of a detergent stabilized giant pore (16). 
Furthermore, integrating this line tension measurement with other knowledge of BAX 
interaction with lipid membranes, we introduce a model of the formation, persistence, and 
closure of BAX mega-pores. 
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Fig. III.5 
 
 
 
 
 
 
Fig. III.5 | Model of BAX interaction with lipid membranes. A, Schematic of BAX 
binding, integration and oligomerization in a lipid membrane. B, Proposed 
mechanism of BAX mega-pore opening and closure. 
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Model of BAX mega-pore formation, persistence, and closure 
We propose the following mechanism for BAX mega-pore assembly based on GUVs 
shown in Figures III.3 and III.4. In this mechanism BAX inserts into a lipid membrane from 
the outside of a GUV and transforms from a globular soluble protein (22) to a membrane-
integrated protein with an extended structure shallowly inserted into the membrane (3,34) 
(Fig. III.5A). BAX insertion produces a dramatic area increase in the outer membrane leaflet 
while the area of the inner leaflet remains unperturbed (Fig. III.5B). The localized area 
differential between the two membrane leaflets induces curvature frustration and increase in 
the surface tension of the membrane (35,36) (Δσ>0). When surface tension increases to a 
critical value the membrane structure ruptures and the mega-pore is formed. Once the pore is 
formed its line tension provides a force for reclosure of the mega-pore which counteracts the 
surface energy such that the GUV continues to persist and does not collapse (See also Eqn. 1). 
However, now through the open mega-pore soluble BAX is able to diffuse into the lumen of 
the GUV and insert into the inner leaflet of the GUV membrane. This results in an area 
increase of the inner leaflet leading to an increase in surface tension in this leaflet. Meanwhile, 
membrane BAX has accumulated in the rim of the pore, reducing line tension and decreasing 
the rate of pore closure as surface energies of the inner and outer leaflets equilibrate (Fig. 
III.5B). Consequently the BAX mega-pore closes very slowly over tens of minutes even though 
the surface energy of the two leaflets is equalizing. After pore closure, membrane-integral BAX 
monomers, dimers, or small oligomers diffuse away from the position where the membrane 
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resealed such that within seconds after pore closure no heterogeneities are observed on the 
GUV surface (Fig. III.3B, 4A). 
BAX mega-pore: connection to physiology 
It is clear that the BAX mega-pore structures we observed in GUVs cannot occur in 
vivo simply due to their size (5-20 µm) versus the size of mitochondria (0.2-1 µm). Furthermore 
BAX mega-pores scaled for the smaller size of mitochondria would need to be scaled for the 
reported localization of BAX to fission sites (28). Also, the simple lipid composition of our 
synthetic GUVs (DOPC:cardiolipin, 80:20 mol %) provides only a basic mimic of the complex, 
heterogeneous distribution of lipids and proteins of mitochondrial outer membranes. 
Therefore, on the mitochondrial surface BAX has a relatively limited membrane area to form 
protein-membrane complexes, while on the surface of GUV membrane the area available to 
BAX is many times greater and can generate the mega-pores that we observed. Nevertheless, 
mechanistic insights gleaned from microscale BAX mega-pores are applicable to nanoscale, 
mitochondrial BAX pores. 
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III.5 | Conclusion 
 The existence of microscopic BAX mega-pores further supports the hypothesis that 
BAX can form a variety of pore sizes in artificial lipid membranes and that the BAX pore is a 
lipidic pore stabilized by the presence of the BAX protein in the pore rim (20,30). 
Accumulation of BAX in the pore rim not only reduces the line tension to extremely low values 
but also leads to the dramatic increase of the pore lifetime. Furthermore, existence of BAX 
mega-pores implies that theoretically an unlimited number of BAX monomers can participate 
in the formation of a BAX mega-pore, i.e. the larger the diameter of a mega-pore, the bigger the 
number of BAX monomers participating in the formation of this mega-pore.   
BAX is not the first protein which is reported to form giant pores in GUVs. For 
example, protein talin and other FERM domain-containing proteins have been shown to 
stabilize the edges of giant pores in GUVs but only in conditions of zero salt concentration 
(37,38). At physiological salt concentrations these proteins do not promote the formation of 
giant pores. Furthermore, the physiological relevance of pore stabilization by talin and other 
FERM domain-containing proteins is not clear—the in vivo function of these proteins is to 
connect actin filaments to the cell membrane. In contrast to these proteins, BAX forms giant 
pores in physiologic buffer conditions and is a bona fide pore-forming protein whose activity is 
directly linked to its cellular function, thus making the discovery of the ability of BAX to form 
mega-pores more significant. 
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III.6 | Experimental Procedures 
Protein preparation and labeling. 
Human cDNA for BAX, BID and BCL-XL were subcloned into pTYB1 vector (New 
England Biolabs). For production of the fluorescently-labeled BAX two endogenous cysteines 
of BAX were substituted (C62S, C126A) and additional cysteine was engineered, S4C. All 
proteins were expressed in BL21(DE3) E. coli, and purified as an intein/chitin-binding domain 
fusion protein without use of detergents similar to Ivashyna et al. (6). Purified proteins were 
estimated to be >95% pure by Coomassie staining SDS-PAGE gels and stored at 4°C. BID was 
cut with recombinant caspase-8 to produce cBID. Mutant BAX with single cysteine was labeled 
according to the manufacturer’s protocol with Alexa Fluor 488 maleimide (Invitrogen) and 
Atto 655 maleimide (AttoTech).  
Protein functionality check  
Functionality comparison of the fluorescently-labeled BAX to the wild-type BAX was 
performed using liposome-carboxyfluorescein leakage assays and fluorescence was measured by 
96-well plate format (Tecan) (6). All release assays were done in triplicate using 10 mM 
HEPES, pH 7.2, 100 mM KCl buffer, at room temperature. Protein concentrations used: BAX 
(100 nM), BAX-R (100 nM), BAX-G (100 nM), cBID (10 nM), BCL-XL (100 nM). Total 
lipid concentration in each release assay was 16 µM; liposomes were prepared from 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC):bovine heart cardiolipin (80:20 mol%; Avanti Polar 
Lipids) using a reverse phase method and containing 50 mM carboxyfluorescein (Invitrogen).  
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Preparation of giant unilamellar vesicles 
GUVs were prepared by the electroformation method (39) from a lipid mixture 
containing 80 mol% DOPC and 20 mol% bovine heart cardiolipin. For the confocal 
microscopy observation 50 µl of solution containing GUVs was transferred into a Lab-Tek 
observation chamber (Fisher Scientific) containing 450 µl of 10 mM HEPES, pH 7.2, 100 mM 
KCl and a mixture of BAX, cBID and BCL-XL. 
Confocal Microscopy  
Assays were performed at 22°C on a laser-scanning confocal microscope Meta 510 
system (Carl Zeiss) using 40× NA 1.2 UV-Vis-IR C Apochromat water-immersion objective. 
For excitation the 488 nm line of an Argon-ion laser (25 µW) and the 633 nm line of the HeNe 
laser (15 µW) were used. Collection and processing of images was done using Zeiss software 
provided with the microscope (AIM, version 4.2). 
Line tension measurement  
Calculations were performed using the theoretical framework developed by Brochard-
Wyart F. et al. (16). For this time lapse confocal microscopy images of GUVs which developed 
mega-pores were analyzed to derive a time-dependent relationship between the radius of a 
GUV (R) and the radius of a BAX mega-pore (r). Then a scatter plot of )ln(2 rR  versus time 
was plotted in Origin 6.0 and fitted to a line. The slope of a fitted line was used to calculate the 
line tension of a mega-pore using Equation 2. 
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III.7 | Supplement 
Heterogeneity of BAX binding to GUVs 
In all confocal microscopy experiments the lipid composition of GUVs was 
DOPC:bovine heart cardiolipin (80:20 mol%). Assuming homogeneous distribution of lipids 
among GUVs during electroformation we expected homogeneous BAX binding to GUVs, i.e. 
similar fluorescence brightness of bound BAX on the GUV surface for all GUVs in an 
observation chamber. However, we observed wide variation in the amount of BAX binding to 
GUVs electroformed from the same lipid mixture, which can be seen in the different 
fluorescence intensity of GUV membranes (Fig. III.S1A). We hypothesize that this 
heterogeneity of BAX binding to GUVs is based on the heterogeneity of lipid distribution 
among GUVs during the electroformation. In particular, we hypothesize that the heterogeneity 
comes from unequal distribution of cardiolipin among the GUVs. Cardiolipin is known for its 
ability to promote non-lamellar lipid bilayer formation (i.e. lipid bilayers with high curvature) 
and in our GUV preparations with 80:20 mol% of DOPC:cardiolipin we observe formation of 
both unilamellar and multilamellar vesicles (Fig. III.5B), with the multilamellar vesicles 
showing high curvature regions. We hypothesize that these multilamellar vesicles contain 
higher concentration of cardiolipin than the rest of the vesicles from the same GUV 
preparation. However, we do not have a direct way to measure the cardiolipin concentration in 
these vesicles.  
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Fig. III.S1 | Heterogeneity of BAX binding to GUVs. GUVs were prepared by 
electroformation from DOPC:bovine heart cardiolipin (80:20 mol%) and added to 
the solution containing BAX-R (50 nM), BAX-G (50 nM) and cBID (10 nM). The 
confocal image was taken approximately 30 minutes after mixing. The confocal 
image is an overlay of red and green channels corresponding respectively to BAX-R 
and BAX-G. A, Confocal image of the field view of multiple GUVs with the 
fluorescently labeled BAX bound. Scale bar is 50 µm. B, Confocal image of a giant 
multilamellar vesicle containing high concentration of the bovine heart cardiolipin 
which resulted in the production of high curvature in the portions of this vesicle. 
Images A and B were taken in the same chamber, indicating that these vesicles 
were from the same preparation and were exposed to the same concentration of 
the cBID and fluorescent BAX. Scale bar is 20 µm. 
Fig. III.S1 
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APPENDIX IV 
 
FCCS Study of BAX Self-Assembly and Modulation by 
BCL-XL & cBID 
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IV.1 | Summary 
It is widely accepted that during apoptosis, permeabilization of the outer mitochondrial 
membrane by the pore-forming members of the BCL2 protein family is a critical point after 
which the cell cannot be resuscitated. However, without direct evidence of how they interact in 
bilayers the molecular mechanism of the mitochondrial permeabilization remains controversial. 
Here we have reconstituted the pore formation by protein BAX in giant vesicles and show that 
in this environment BAX can form a heterogeneous distribution of coexisting pore sizes 
ranging from 1 nm to 20 μm in diameter. Evidence is provided by directly examining 
oligomerization and mobility change of BAX molecules in GUVs by fluorescence cross-
correlation spectroscopy and by studying the large complexes by confocal microscopy. We show 
that in the presence of BCL-XL, an inhibitor of BAX pore formation, membrane bound BAX 
was primarily monomeric. We also show that, in the large length scale format of a GUV, BAX 
form structures that reveal its affinity for highly curved membranes, and that it dramatically 
reduces line tension while stabilizing its lipidic pores. Finally, our results demonstrate that BAX 
forms pores by increasing membrane surface energy and changing curvature of lipid 
membranes, thus manifesting an ability to sculpt lipid bilayers. 
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IV.2 | Introduction 
BAX is a pro-apoptotic member of the BCL2 protein family and its paramount 
function is to permeabilize the OMM during apoptosis (1,2). Upon apoptotic stimulation 
BAX translocates to the OMM where it changes conformation, inserts as a monomer, and then 
undergoes in-membrane homo-oligomerization to form a pore. Once the BAX pore is formed, 
cytochrome c and other mitochondria-resident proteins escape into the cytoplasm where they 
activate the cascade of caspases that dismantle the cell. To date the structure of the inactive, 
cytoplasm-resident, form of BAX is known (3); however, the structure of the active, membrane-
integrated, form of BAX remains unsolved. The absence of a membrane structure for this 
protein has lead to a vigorous debate about:  the nature of the BAX pore (lipidic versus barrel-
stave) (4-6), the number of BAX monomers participating in the pore formation (7-10), the 
possible molecular interactions formed among them in a pore (11,12), and  the progression and 
variety of pores formed by BAX (i.e. dimer, tetramer and higher order polymers (4,5,13,14). To 
address these questions we used two-focus two-color scanning FCCS (15-17) to non-intrusively 
measure the mobility and self-association of the fluorescently-labeled BAX in a hydrated lipid 
membrane of GUVs for 5-7 hours after BAX insertion into the lipid membrane (See Chapter 5 
for the confocal microscopy analysis of the fluorescent BAX binding to GUV). In these FCCS 
experiments the microscope output was multiplexed for simultaneous determination of the 
membrane diffusion coefficients and concentrations of BAX-R, BAX-G and BAX-RG 
complexes and the analysis of the BAX pore activation. Using the membrane diffusion 
coefficients for the monomeric BAX-R and BAX-G proteins and for the BAX-RG complexes 
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we estimated the hydrodynamic radius of these complexes in lipid membranes which is close to 
the reported in the literature values. Furthermore, using the values for the membrane diffusion 
coefficient we were able to clearly differentiate between two monomeric species of BAX in lipid 
membranes – membrane associated and membrane integrated BAX. In support of this analysis 
we used cBID to activate BAX and BCL-XL to regulate the membrane integration and self-
association of BAX. 
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IV.3 | Results 
BAX is monomeric in solution and oligomerizes only in lipid membranes 
It was recently shown by a FRET study that BAX does not oligomerize prior to 
membrane binding (14). To confirm this finding, we compared the cross-correlation of BAX-R 
& BAX-G in the presence or absence of GUVs. Using FCCS we observe a similar result that 
BAX-R and BAX-G in the presence of cBID are monomeric and do not oligomerize in solution 
(Fig. IV.1A). In solution, the diffusion coefficient for BAX-G is 114±6 µm2/sec (mean±s.e., 
n=3) and for BAX-R it is 134±12 µm2/sec (mean±s.e., n=3) which is similar to that of 
monomeric tBID and BCL-XL (17). Having established the membrane-binding functionality of 
BAX (Fig. IV.1A), FCCS measurements were done on a population of GUVs (10 min 
measurement time per GUV) (Fig. IV.C). We observe oligomerization of BAX-R and BAX-G 
only in the environment of a lipid membrane as shown by the increased cross correlation in Fig. 
IV.1C (blue line). 
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Fig. IV.1 | FCCS on BAX in solution and a lipid membrane. A, Confocal microscopy 
images of BAX-GUV binding. BAX-R (25 nM), BAX-G (25 nM) and cBID (4 nM) were 
added to GUVs upon which collection of the time-series of images was initiated. Time 
stamps represent the time after protein addition to GUVs. B, Normalized auto-
correlation curves and cross-correlation curve (blue) for BAX-R and BAX-G in solution in 
the presence of cBID. C, Normalized auto-correlation curves and cross-correlation 
curve (blue) for BAX-R and BAX-G in a GUV membrane in the presence of cBID. 
Fig. IV.1 
   a 
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In a lipid membrane BAX forms a population of varying in size oligomers 
Two-color two-focus scanning FCCS allows simultaneous measurement of the 
fluorescent protein concentration, diffusion coefficient and self-association in a lipid 
membrane (15-18). To study BAX self-association in a lipid membrane we used BAX-R and 
BAX-G proteins (50 nM total concentration) activated with 4 nM cBID (as was determined by 
the confocal microscopy experiments described in Appendix III). 
The FCCS analysis of membrane BAX produced a clear result that BAX protein 
complexes increased in size with time as can be seen from the decrease in the average mobility of 
these BAX-RG containing complexes (Fig. IV.2D, blue squares). At the same time the number 
of membrane BAX particles (which include monomers and oligomers) was increasing, so it was 
clear that for the >6 hours of these experiments BAX was continuing to accumulate in the 
membrane.  Each time point on the Figure IV.2C and IV.2D represents an independent GUV 
measurement such that amount of BAX in the membrane and the average diffusion coefficient 
of the BAX particles is not uniform and reflects the variation in the vesicle lipid composition 
(See Appendix III for discussion). 
The average diffusion coefficient of BAX-RG complexes in GUV membranes 
incubated for five hours with 50 nM of the fluorescent BAX and 4 nM cBID is 2.0±0.4 
µm2/sec (mean±s.d., n=21) which is slower than the membrane diffusion coefficient of 
monomeric tBID and BCL-XLΔC measured by the same technique (5 µm2/sec) (17) suggesting 
formation of a bulky, slowly-diffusing BAX-RG complex in a lipid membrane (Table IV.1). 
Since the diffusion coefficient of a particle in a lipid membrane depends on the in-membrane 
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hydrodynamic diameter of the particle, we can use the value for the diffusion coefficient of 
BAX-RG complexes to determine their approximate in-membrane hydrodynamic diameter 
using a modified Saffman-Delbruck formula (19) but for this the membrane diffusion 
coefficient of a BAX monomer must be determined. 
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Fig. IV.2 | Two-color two-focus scanning FCCS experiments on BAX. A & B, FCCS of 
BAX-R/BAX-G cross-correlation (50 nM total BAX concentration) in the presence of 50 
nM BCL-XL and 4 nM cBID. C & D, FCCS of BAX-R/BAX-G cross-correlation (50 nM total 
BAX concentration) in the presence of 4 nM cBID (BCL-XL absent). E, Schematic of 
various diffusion species of BAX in a lipid membrane. 
 
Fig. IV.2 
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BCL-XL prevents the self-assembly of BAX in lipid membranes 
To determine the membrane diffusion coefficient of a BAX monomer, BAX self-
assembly and pore formation in a lipid membrane should be inhibited. This was accomplished 
by using full length human BCL-XL protein which is an anti-apoptotic member of the BCL2 
family that inhibits BAX pore formation (20). When GUVs were preincubated with BCL-XL 
(50 nM) and cBID (4 nM) for one hour and then BAX (50 nM) was added, no binding of BAX 
to GUV membranes was observed (Fig. III.1E, Appendix III) which does not allow for the 
FCCS measurements. However, this observation reflects the ability of BCL-XL to sequester 
cBID in an inactive complex which is unable to activate and promote membrane integration of 
BAX (14,17,20). Simultaneous addition to GUVs of BAX, cBID and BCL-XL at these same 
concentrations resulted in sufficient membrane binding of BAX for the FCCS measurements 
but did not result in GUV permeabilization (Fig. III.1D, Appendix III). Comparison of the 
fluorescence intensity of BAX-R accumulation in the GUV membranes in the presence and 
absence of BCL-XL shows that in the presence of BCL-XL the amount of BAX binding to the 
GUV membranes is lower than in the absence of BCL-XL (Fig. IV.3).  
Based on the results of the FCCS experiments shown in Figure IV.2A&B in the 
presence of BCL-XL the membrane concentration of BAX increased over 7 hours and its 
diffusion coefficient decreased from 8.3±1.0 µm2/sec (mean±s.d, n=6) to 5.2±0.7 µm2/sec 
(mean±s.d., n=26). The latter diffusion coefficient value is typical of a transmembrane alpha-
helical peptide (21) and it is also similar to the in-membrane diffusion coefficient of 
monomeric membrane integrated tBID or C-terminal truncated BCL-XL described by the 
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Saffman-Delbruck model of membrane protein diffusion (Table IV.1) (17,22). In addition, we 
observed no cross-correlation between BAX-R and BAX-G at this concentration of BCL-XL 
(Fig. IV.2B). Based on these data we conclude that the diffusion coefficient of membrane 
integrated BAX monomers is 5.2±0.7 µm2/sec.  
Furthermore, we propose that the gradual decrease in the membrane diffusion 
coefficient of BAX in the presence of inhibiting concentrations of BCL-XL represents the 
transition of BAX from being a monomeric membrane-associated protein sliding on the 
membrane surface with fast diffusion to becoming a monomeric membrane-integrated protein 
with appropriately slower diffusion (Fig. IV.2E). However, we do not discount the possibility 
that the monomeric integrated BAX forms heterodimers with BCL-XL in lipid membranes 
(20). In the Saffman-Delbruck theory scaling of the diffusion coefficient with the in-membrane 
diameter of the protein is logarithmic implying that integrated monomeric BAX would have 
membrane diffusion coefficient similar to that of a BAX/ BCL-XL heterodimer. 
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Fig. IV.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. IV.3 | Comparison of BAX-R binding to GUV membranes in the presence and 
absence of BCL-XL. A, Map of fluorescence intensity changes in a line scan through the GUV 
membrane (vertical direction) with time (horizontal direction). This membrane trace comes 
from a GUV exposed only to BAX-R protein and cBID. B, Change in cumulative fluorescence 
intensity in membranes of GUVs exposed to BAX-R and cBID in the absence and presence of 
BCL-XL. The trace for the last point in each measurement is shown in A and C. C, Map of 
fluorescence intensity changes in a GUV exposed to BAX-R, cBID, and BCL-XL. In these 
experiments following protein and lipid concentrations were used: 25 nM BAX-R, 25 nM 
BAX-G, 50 nM BCL-XL, 4 nM cBID, and 5 μM total lipid. 
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Table IV.1 | Comparison of BAX diffusion coefficients with lipid diffusion coefficients. 
Type of molecule Diffusion coefficient, 
µm2/sec 
in-membrane 
diameter,  
nm 
in solution:   -  
     monomeric inactive BAX 114±5  
     monomeric tBID (17) 143±9  
     monomeric BCL-XLΔC (17) 78±10  
in a lipid membrane:   
    lipids 10.0±0.5 1 
    monomeric membrane associated BAX 8.3±1.0 - 
    monomeric membrane integrated BAX 5.2±0.7  ≈1  
    monomeric tBID (17) 5.0±0.3 - 
    monomeric BCL-XLΔC (17) 4.8±0.7 - 
    BAX pore complex  
    (at 50 nM total BAX concentration ) 
2.0±0.4 53±12 
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Calculation of the BAX pore complex diameter  
Traditionally the Saffman-Delbruck equation is used to calculate the hydrodynamic 
radius of a membrane inclusion from its diffusion coefficient (21-25)  (See Eqn. 1 in the 
Experimentals section). It has also been shown that Saffman-Delbruck equation faithfully 
describes diffusion of membrane inclusions traversing both leaflets of a lipid membrane in the 
case of small proteins, however, in the case of larger membrane inclusions (for example, such as 
lipid rafts) this theory underestimates the diameter of membrane inclusions. As a consequence 
of this, a modified version of a Saffman-Delbruck equation has been developed by Petrov and 
Schwille for the description of the diffusion of large membrane inclusions (19) (See Eqn. 2 in 
the Experimental Procedures section). 
In the case of the diffusion of BAX in lipid membranes the diffusion coefficient of a 
BAX monomer (5.2±0.7 µm2/sec) is consistent with the Saffman-Delbruck theory, however, 
the diffusion coefficient of BAX-RG protein complex is two times slower than the diffusion of 
a BAX monomer and thus according Petrov and Schwille the in-membrane hydrodynamic 
diameter of this complex should be calculated according to the modified Saffman-Delbruck 
formula. As a result the diameter of the BAX-RG protein complex diffusing with diffusion 
coefficient of 2.0±0.4 µm2/sec is 53±12 nm. This value is one order of magnitude larger than 
the size of a BAX pore measured by the dextran blocking of a pore and by the electrophysiology 
methods (13,26). However, this value is consistent with the electron microscopy imaging of a 
BAX pore in liposomes and AFM measurement of the pore in supported lipid bilayers (4,27) 
where it has been shown that the diameter of a BAX pore can be 100-200 nm. 
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It is worth noting here that the calculated hydrodynamic radius of a BAX-RG complex 
does not necessarily represent the size of a pore formed by this complex. In spite of the obvious 
connection between the calculated diameter of a BAX-RG complex and the electron 
microscopy and AFM experiments, it is still possible that the size of the pore is smaller than 53 
nm and the rest of the size of the pore is occupied by the lipids trapped in the concerted motion 
of a lipidic pore. 
Titration of BAX in lipid membranes: mass action law 
We next asked a question whether by increasing the amount of BAX in a lipid 
membrane we can control for the size and the concentration of BAX-RG complexes. For this 
purpose the various amounts of total soluble BAX-R and BAX-G proteins were added to the 
constant concentration of GUVs and the FCCS measurements were done on these GUV 
populations. In each case BAX binding to GUVs was activated by the addition of 4 nM cBID. 
As a result of these experiments we find that with the increasing concentration of total BAX 
added to the system the higher concentration of BAX particles is found in a lipid membrane 
(Fig IV.4, grey bars). It is important to note that these BAX particles include monomers and 
oligomers of BAX. Additionally, with increasing concentration of BAX particles in a lipid 
membrane the greater number of the BAX-RG complexes was observed (Fig. IV.4, black bars). 
Analysis of the diffusion coefficients for the BAX-RG complexes formed at different total 
concentrations of BAX also showed an increase in the average size of these complexes (Table 
IV.2). Such correlation between the size and concentration of BAX-RG complexes with the 
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total concentration of BAX in a system shows that BAX pore formation follows the mass 
action law. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. IV.4 
 
 
 
 
 
 
 
Fig.  IV.4  |  Titration  of  BAX.  BAX‐R  and  BAX‐G were  added  to GUVs  (5µM  total  lipid 
concentration)  in  the  presence  of  cBID  and  FCCS  measurement  were  done  on  a 
population  of no less than 10 GUVs upon 1‐2 hours after protein addition to GUVs. 
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Table IV.2 | FCCS results of the titration of BAX. Experimental conditions were the same 
as described in the legend to Fig. IV.4. The hydrodynamic diameter was calculated using 
modified Saffman-Delbruck formula (19). 
Total BAX 
concentration, 
nM 
BAX-RG 
complexes, 
particles/µm2 
measured diffusion 
coefficient, 
µm2/sec 
calculated in-membrane 
hydrodynamic diameter, 
nm 
50 7.9 2.0±0.4 53.2 
83 8.8 1.5±0.4 102.2 
100 9.6 1.4±0.3 120 
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Moderating the activity of BAX with cBID 
To study the effects of increasing concentrations of cBID onto the distribution of BAX 
particles in a lipid membrane we varied cBID concentrations in our FCCS experiments while 
keeping BAX and total lipid concentration constant.  As a result we observed correlation 
between the increase of cBID concentration and the resulting concentration of BAX particles 
in the lipid membrane (Fig. IV.5). However, the concentration of BAX-RG complexes did not 
follow this correlation pattern. The concentration of BAX-RG complexes in a lipid membrane 
remained constant (within the margin of error) for all cBID concentrations (Fig. IV.5, blue 
bars). This observation indicates that cBID must be affecting only the kinetics of BAX 
integration into the lipid membranes without a significant effect on the resulting concentration 
of the BAX oligomers. 
 
 
 
 
 
 
 
 
 
 
Fig. IV.5 
 
 
 
 
 
 
Fig. IV.5 | Effects of cBID titration on the distribution of the membrane forms of BAX. 
Results were obtained using two‐color two‐focus scanning FCCS analysis. 
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Interactions among BAX, cBID, and BCL-XL: rheostat model 
In Fig. IV.2 we have shown that BCL-XL inhibits oligomerization of BAX in a lipid 
membrane. However, we were intrigued to know whether the inhibitory effect of BCL-XL on 
BAX can be rescued by the addition of excess cBID. According to the rheostat model proposed 
by Korsmeyer et al. the apoptosis decision in cells depends on the relative concentrations of 
pro- and anti-apoptotic proteins (28). Therefore, in our minimal in vitro system we expect to 
observe an increase in the oligomerization of BAX in a lipid membrane containing BCL-XL 
when cBID concentration is increased due to the competition for cBID between BAX and 
BCL-XL (29). 
Simultaneous addition to GUVs of 50 nM BAX and BCL-XL at 1:1 protein to protein 
ratio with 4 nM cBID resulted in complete inhibition of BAX oligomerization as can be seen 
from the absence of BAX-RG complex formation, while in the absence of BCL-XL the same 
concentrations of BAX and cBID resulted in the formation of 16% of BAX-RG complexes 
(normalized to the total concentration of BAX particles in the membrane) (Fig. IV.6). This 
observation is consistent with the rheostat model where cBID can interact with both BAX and 
BCL-XL while having higher affinity for the interaction with BCL-XL (14,17,29) and thus 
when BCL-XL is present majority of the cBID molecules is sequestered in the interaction with 
BCL-XL (assuming 1:1 stoichiometry of protein binding) leaving few cBID molecules for the 
interaction with BAX. However, when excess of cBID is added—equimolar BAX, BCL-XL and 
cBID in the system—then there is sufficient cBID for the interaction with both BAX and 
BCL-XL, and as a result we observe rescue of the BAX-RG complex formation (Fig. IV.6). 
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Therefore, using a minimal in vitro system we were able to show that the outcome of the 
interaction among BAX, cBID, and BCL-XL can be described by the rationale of the rheostat 
model. 
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Fig. IV.6 
 
 
 
 
 
 
Fig. IV.6 | BAX, cBID, and BCL-XL: rheostat model. Results were obtained using two-
color two-focus scanning FCCS analysis. 
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IV.4 | Discussion 
For use with two-color two-focus FCCS we produced two forms of the fluorescently 
labeled full length BAX protein, BAX-R and BAX-G. These fluorescently-labeled BAX 
proteins have been shown to have the pore formation activity similar to that of the 
recombinant wild type BAX (See Appendix III for details). Furthermore, we show that these 
two fluorescent forms of BAX are monomeric in solution and oligomerize only in lipid 
membranes (Fig. IV.1).  
BAX binding to lipid membranes: associated versus integrated BAX  
Using two-color two-focus scanning FCCS we show that prior to oligomerization in a 
lipid membrane monomeric BAX associates with the lipid membrane, and then becomes 
membrane integrated. The transition between the membrane associated and integrated forms 
of BAX most likely occurs via a conformational change, which is aided by cBID protein already 
present in the membrane. We differentiate between these two monomeric forms of BAX based 
on their diffusion coefficient: membrane-associated monomeric BAX, due to incomplete 
insertion into a lipid bilayer, has faster diffusion coefficient (8 μm 2/sec) than the monomeric 
membrane-integrated BAX (5 μm 2/sec). It is important to note, that this transition from 
associated to integrated BAX could only be observed by scanning FCCS in the presence of 
BCL-XL protein in GUV membranes. BCL-XL slows down membrane binding of BAX, and 
thus allowed us to observe this transition process. BCL-XL has been proposed to inhibit the 
pore formation by BAX in three ways: by directly binding monomeric integrated BAX, by 
binding cBID protein and thus eliminating it as an activator of BAX, and by preventing BAX 
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binding to a lipid membrane (20,30). However, the mechanism of the last inhibition pathway is 
not clear. Therefore, BCL-XL inhibition of BAX binding, oligomerization, and pore formation 
in lipid membranes, which were observed in our experiments, agree with literature.  
In the absence of BCL-XL in the membrane, the association and integration of BAX is 
rapid, and cannot be resolved by the scanning FCCS. In this case we observe the decrease in the 
average diffusion coefficient of BAX from 5 μm2/sec to 2 μm 2/sec, which likely represents the 
transition from monomeric integrated BAX to a proteo-lipidic complex containing multiple 
BAX monomers. Furthermore, the time frame of the BAX transition from the associated to 
integrated protein in the presence of BCL-XL is longer than the time frame of the transition 
from the monomeric membrane integrated protein to the proteo-lipid complex in the absence 
of BCL-XL (Fig. IV.2B&D), thus supporting our proposal that BCL-XL slows down the process 
of BAX integration in a lipid membrane. Our observation of the transition from membrane 
integrated to membrane associated forms of BAX can be further supported by the SPR studies 
(31) and by the studies of the conformation of BAX loosely associated with the lipid membrane 
of LUVs (32).  
Self-assembly of BAX in lipid membranes  
It has been shown that in order to form a pore in artificial lipid membranes, BAX must 
undergo self-assembly in the lipid membrane environment (4,10,13,14,33) while in vivo, during 
apoptosis, BAX has also been shown to form large aggregates (10,34,35). Therefore, our 
observation of the BAX-RG complex formation was expected. However, what was unexpected, 
is the progressive decrease in the diffusion coefficient of BAX upon membrane integration. 
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According to the Saffman-Delbruck formula, diffusion of a membrane protein is primarily 
affected by the in-membrane hydrodynamic diameter of the protein. Therefore, dimerization 
and even tetramerization of a protein in a lipid bilayer would not result in a significant change 
in the diffusion coefficient of the resulting complex, compared to that of a monomer (36,37). 
Therefore, our observation of the significant decrease in the diffusion coefficient of BAX-RG 
complex compared to that of a BAX monomer, indicates that BAX is not simply oligomerizing, 
but most likely is forming lipidic pores (4,6,38). These lipidic pores involve lipids which 
contribute to the size of the in-membrane hydrodynamic diameter of a complex (See Fig. IV.2E 
for a proposed model of a BAX lipidic pore). Therefore, our estimation of the diameter of these 
slowly diffusing BAX-RG proteo-lipidic complexes most likely over-estimates the size of pores 
formed by these complexes in a lipid bilayer. However, we do not have direct experimental 
evidence for the presence of pores in these complexes. The reason for our assumption, that 
these BAX-RG proteo-lipidic complexes contain a pore, is based on the transmission electron 
microsocopy and AFM measurement of the BAX pore diameters, which show that BAX is 
capable of forming pores with the diameter of 100-200 nm. Calculated in-membrane diameter 
of a BAX-RG complex falls into this range.  
Rheostat model: connection to physiology  
The finding that pro- and anti-apoptotic proteins of the BCL2 family can 
heterodimerize, and that their relative concentrations to each other affects the decision whether 
a cell should undergo apoptosis, lead to the proposal of the rheostat model by Korsmeyer et al. 
(28). The results obtained using our model system of BAX pore formation in GUVs support 
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this hypothesis (Fig. IV.6). These results show that, when equimolar concentrations of BAX 
and BCL-XL are present in a lipid membrane together with low concentration of cBID, there is 
no oligomerization and pore formation by BAX. However, when cBID is added, such that there 
is approximately one cBID molecule for each BAX and BCL-XL molecule, then oligomerization 
and pore formation by BAX is rescued. Similarly, in the presence of low cBID concentration 
and the complete absence of BCL-XL, BAX is able to oligomerize and form pores.  
The results of scanning FCCS shown that BAX, cBID and BCL-XL obey the law of 
mass action (Fig. IV.4, IV.5, IV.6). These results show that increase in the concentration of 
soluble protein leads to the concentration increase of the membrane bound protein, with a 
certain saturation limit. Results of the titration experiments with BAX-R and BAX-G show 
that not only the total concentration of membrane bound BAX monomers increases, but also 
that the distribution of BAX-RG proteo-lipidic complexes changes, resulting in the larger mean 
diameter of complexes (Table IV.2). 
IV.5 | Conclusions  
The work presented in this appendix represents the first example of the application of 
two-color two-focus scanning FCCS to study oligomerization and pore formation by BAX in 
lipid membranes of GUVs. The results of this study provide an insight into the mechanism of 
BAX pore formation in lipid membranes and the regulation of this mechanism by the pro-
apoptotic BH3-only protein cBID and anti-apoptotic protein BCL-XL. These results show that 
BAX binds lipid membranes containing cBID as a monomer, by first associating with the lipid 
membrane, likely via electrostatic interaction, and then undergoing conformational transition 
to become a membrane integrated protein, likely due to the interaction with cBID. Once in 
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lipid membrane, integrated BAX monomers initiate self-association which leads to the 
formation of pores. Formation of pores reduces the concentration of monomeric BAX 
monomers in the lipid membrane, thus allowing for the integration of additional BAX 
proteins. This continual insertion of BAX monomers into the lipid membrane leads to increase 
in the average BAX pore size resulting in the heterogeneous distribution of BAX pores. Increase 
in the number of BAX pores in the lipid membrane leads to the disruption of elastic forces of 
the lipid membrane, thus leading to the deformation and destruction of GUVs.  
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IV.6 | Experimental Procedures 
Protein purifications and labelings were performed as described in Chapter 4 & 
Apendix III. 
Sample preparation for the FCCS experiments 
 For the FCCS experiments GUVs were prepared from a lipid mixture of DOPC:bovine 
heart cardiolipin (80:20 mol%) using the electroformation method described in Appendix III. 
After the preparation 50 µl of GUVs were transferred to an observation well containing 450 µl 
of 1xEB buffer (10 mM Hepes, pH 7.2, 100 mM KCl) and a mixture of proteins (BAX, cBID, 
BCL-XL) depending on the experiment. For all experiments observation chambers (8 well 
LabTak, Nunc) were treated for at least one hour with a solution containing 4 mg/ml BSA. 
BSA treatment was done with the purpose to prevent protein adsorption to the plastic walls of 
the observations chamber.  All FCCS measurements were performed at room temperature (22 
°C) in a dark room. 
Fluorescence cross-correlation spectroscopy 
FCCS measurements were performed on a laser-scanning microscope Meta 510 system 
(Carl Zeiss) using 40× NA 1.2 UV-Vis-IR C Apochromat water-immersion objective. For 
excitation the 488 nm line of an Argon-ion laser (25 µW) and the 633 nm line of the HeNe 
laser (15 µW) were used, while detection was done using a home-built detection unit at the 
fiber output channel. A dichroic mirror and band-pass filters (D555, HQ520/40 and 
HQ700/75; AHF Analyze Technik) were used behind a collimating achromat to split the 
emission for the dual-color detection and to reject residual laser and background light. We then 
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used achromats (LINOS Photonics) to image the internal pinhole onto the apertures of the 
fibers connected to the avalanche photodiodes (APD, PerkinElmer). The photon arrival times 
were recorded in the photon mode of the hardware correlator Flex 02-01D 
(http://correlator.com). 
For scanning FCCS, the detection volume was repeatedly scanned perpendicularly 
through the equator of a GUV. We controlled its movement directly with the Zeiss LSM 
operation software. We used the frame mode with Nx2 pixels to scan the two parallel lines. We 
measured their distance d by repeatedly scanning over a film of dried fluorophores and 
measuring the distance between the bleached traces in a high-resolution LSM image. 
Data analysis was performed with software written in MATLAB (MathWorks). For 
scanning FCCS, we binned the photon stream in bins of 2 µs and arranged it as a matrix such 
that every row corresponded to one line scan. Corrected for movements of the membrane was 
done by calculating the position of the maximum of a running average over several hundred line 
scans and shifting it to the same column. We fitted an average over all rows with a Gaussian and 
we added only the elements of each row between -2.5σ and 2.5σ to construct the intensity trace. 
We computed the auto- and cross-correlation curves of the resulting intensity traces with a 
multiple tau correlation algorithm and fitted them with a nonlinear least-squares fitting 
algorithm. In all FCCS data processing, we excluded from further analysis irregular curves 
resulting from major instabilities identified by distortions of the curves and a systematic change 
in the intensity trace. For details of data fitting see Supplementary information. 
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Calculation of the diameter for the BAX pore complex 
According to the Saffman-Delbruck theory of the diffusion of particles in lipid 
membranes translational diffusion coefficient (D ) of the particle depends on the radius (R ) of 
the particle in the following way 






−= γ
µ
µ
πµ R
h
h
TkD
sol
mem
mem
B ln
4
   (Eqn.1) 
where memµ  is membrane viscosity, solµ  is solution viscosity, h is membrane thickness, 
T temperature, Bk  is Boltzmann constant, and γ  is Euler's constant (0.5772) (22). Schematic 
representation of a diffusing particle in a lipid membrane is shown in Figure IV.7. 
 
Fig. IV.7 | Schematic representation of the hydrodynamic model of a particle diffusing in a lipid 
membrane described by the Saffman-Delbruck equation (Eqn. 1). 
 
 As was mentioned previously that Saffman-Delbruck formula describes well diffusion 
of small proteins in a lipid membrane but fails to describe the membrane diffusion of larger 
complexes such as lipid rafts (19). Since BAX-RG proteo-lipidic complexes have diffusion 
coefficient two times smaller that the diffusion coefficient of a BAX monomer we used 
modified Saffman-Delbruck formula (17) to determine the in-membrane hydrodynamic radius 
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of these complexes. In our analysis we made assumptions that membrane viscosity is 0.7 cP (15), 
membrane thickness is 5 nm. The expression for the modified Saffman-Delbruck formula is 
following 
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where, ε  is the reduced radius, memsolR µµε 2= , while 1c , 2c , 1b , and 2b  are constant 
( 0.737611 =c , 0.521192 =c , 74819.21 =b , 61465.02 =b  ). 
To calculate the error for this value we used the fact that membrane viscosity is not very 
well defined and according to Ramadurai et al. (15) it varies for a lipid membrane composed of 
DOPC/DOPG mixture from 0.6 cP to 0.8 cP. Using this uncertainty in the actual value for the 
membrane viscosity together with the fact that lipid composition used in our work has similar 
viscosity as the one used in Ramadurai et al. based on the measurements of translational lipid 
diffusion we estimated that standard error for the diameter of the BAX pore complex is 12 nm. 
Therefore, we estimate that the diameter of the BAX pore complex in a lipid membrane is 
53±12 nm. 
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(The content of this chapter has been adapted from Lai, G. H., Ivashyna, O., Sanders, L. K., 
Christenson, E. T., Mishra, A., Schmidt, N. W., Santangelo, C. D., Schlesinger, P. H., Wong, G. 
C. L. (2011) (in preparation)) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
284 
 
V.1 | Summary 
The morphologic expression of programmed cell death, apoptosis, has a clear genetic 
basis on the B cell lymphoma-2 (BCL2) family of proteins. Critical interactions among BCL2 
protein members occur in the outer mitochondrial (OM) membrane where they control 
mitochondrial function and permeability to initiate the mortality decision via cytochrome c 
release (1,2). While BCL2 regulation of apoptosis has been demonstrated, difficulties 
elucidating intra-membrane binding partners, and tracking protein structure after membrane 
insertion, oligomerization, and direct binding have made a consistent, molecular picture elusive 
(3-5). Here we report a parallel mode of BCL2 action, mediated by induced membrane 
curvature, with recombinant BAX (pore forming), BID (activator) and BCL-XL (inhibitor). 
Using synchrotron x-ray scattering, we found activated BAX induces strong negative Gaussian 
membrane curvature topologically necessary for pore formation and other membrane 
destabilizing mechanisms. Fluorescence microscopy demonstrated this behavior correlates with 
vesicle permeation and is cognate to that of antimicrobial peptides and cell-penetrating peptides 
(6,7). Furthermore, x-ray evidence suggests BCL-XL generates a complementary membrane 
curvature that cancels out the pore-enabling curvature induced by BAX. Consistent with a 
membrane-mediated mechanism, curvature generated by BCL-XL similarly suppresses negative 
Gaussian curvature induced by pore-forming peptides unrelated to BCL2 proteins, and in pure 
lipid systems without proteins. These observations are supported by a model based on linear 
membrane elasticity. 
V.2 | Introduction 
To characterize membrane poration and its regulation, recombinant full-length human 
BAX, caspase-8-cleaved BID (cBID), and BCL-XL were studied in cell-free assays. BAX, BID, 
and BCL-XL have remarkably similar secondary structures given their drastically different 
functions (3,8). The multidomain executioner proteins BAX and BAK present obligate but 
alternate gateways to mitochondrial outer membrane permeabilization (MOMP). BAX is 
available as a stable soluble full-length protein as found in the cytosol of healthy cells. BID, 
widely used to activate BAX, has a single BCL2 homology (BH) domain and belongs to the 
large BH3-only pro-apoptotic subfamily. BCL-XL has all four BH domains and is an inhibitor 
of apoptosis prominent in oncogenic transformation (1-5). 
Unilamellar vesicles, both large (≈200 nm LUVs) and giant (≈10 μm GUVs), were 
prepared at different lipid compositions mimicking mitochondrial membranes, primarily with 
unsaturated (dioleoyl-) lipids (to avoid liquid-gel transition) like dioleoylphosphatidyl choline 
(DOPC), and lipids with nonzero intrinsic (spontaneous) curvature c0, such as unsaturated 
ethanolamine (PE) and cardiolipin (CL). CL is concentrated mainly at highly curved contact 
sites (25 w% or ≈16 mol%) that connect the outer (≈3 mol%) to the inner mitochondrial 
membrane (≈10 mol%) (9,10). With a ternary lipid system comprising anionic CL, 
zwitterionic DOPE and DOPC, we can independently adjust membrane charge density and 
intrinsic curvature through typical ranges of physiological compositions to study the effects of 
BAX, cBID, and BCL-XL. Vesicles were incubated with ternary mixtures of BAX (pore 
former), BCL-XL (inhibitor/antagonist), and cBID (activator/agonist) at defined 
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stoichiometries (BAX/lipid molar ratios at 1/500-1/600) under physiological relevant 
conditions (pH 7.0, 100 mM KCl).  
V.3 | Results & Discussion 
Tracking efflux from dye-loaded GUVs with confocal microscopy allowed macroscopic 
characterization of pore formation, and results were consistent with cell-based experiments. 
With a lipid composition of 70/20/10 mol% PE/PC/CL, we observed complete dye efflux 
from all GUVs with cBID-activated BAX (≈0.35 μM, cBID/BAX ≈1:1) in several tens of 
minutes (Fig. V.1A-C), whereas addition of equimolar BCL-XL significantly suppressed BAX-
induced dye leakage, as expected, with most GUVs full of dye hours after introduction (data not 
shown). 
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Fig. V.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. V.1 | Verifying permeabilization activity of activated BAX in GUVs. A-C, Confocal 
microscopy of 70:20:10 PE:PC:CL GUVs (+1% DiO, green) filled with 4 μM Alexa-Fluor 
633 C5-maleimide dye (1.3 kDa, red). Scale bar is 20 μm. Panels B and C track dye 
leakage of same vesicles after introducing 0.35 μM cBID-activated FL BAX (15 and 30 
minutes later, respectively). Movie of GUV evolution in supplement. 
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High-resolution synchrotron small angle x-ray scattering (SAXS) revealed nanoscopic 
details of the protein-membrane interactions. Before exposure to BAX, SAXS data measured 
from LUVs at 75/20/5 mol% PE/PC/CL showed a broad feature consistent with the form 
factor of single lipid bilayers and typical of LUVs (Fig. V.2A, bottom trace). Incubating LUVs 
at 37°C with full-length (FL) BAX at 1/500 protein/lipid (P/L) molar ratio (≈25 μM protein 
to ≈12.5 mM lipids), activated with cBID (1:1 or ⅕:1) cBID/BAX molar ratio with similar 
result, latter not shown), gave rise to a drastically different diffraction signature. SAXS data 
displayed many sharp correlation peaks (Fig. V.2A, red trace) with q-value ratios √2, √3, √4, √6, 
√8, √9, and so on, that indexed precisely (Fig. V.2B) to a Pn3m (Q224) ‘double-diamond’ lattice, 
an inverse bicontinuous cubic phase where two non-intersecting water channels are separated 
by a lipid bilayer (11) (Fig. V.2C). The centre of the bilayer traces out a minimum surface with 
negative Gaussian curvature K (also known as saddle-splay curvature). Like a saddle, the surface 
curves upwards (principal curvature c1) in one direction and downwards (c2) in the orthogonal 
direction, so that the Gaussian curvature K≡c1c2<0. Negative Gaussian membrane curvature is 
broadly enabling: saddle-shaped (anticlastic) surfaces line the hole of a torus, the base of a bleb, 
and the neck of a bud, but are absent on spheres (which lack holes). Consistent with this 
physical picture, extensive mitochondrial fragmentation occurs almost simultaneously with 
MOMP in a caspase-independent fashion (12), and significant crosstalk has been reported 
between machineries of apoptosis and mitochondrial dynamics: BAX and BAK can promote 
mitochondrial fusion and fission (13-15); conversely, Drp1 from the mitochondrial fission 
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machinery is recently shown to stimulate BAX oligomerization and resultant MOMP in a 
manner sensitive to the spontaneous membrane curvature (16). 
Slope fitting of measured peak q-values (Fig. V.2B) gave a lattice constant dPn3m of 
15.58±0.03 nm. A weak Im3m (Q229) cubic phase was sometimes also observed (Fig. V.2C), 
with a lattice constant that related to the Pn3m phase by the Bonnet ratio (1.279), indicating 
equivalent Gaussian curvature in the two coexisting cubic phases (11). Accounting for 
membrane thickness (2.5 nm), effective lipidic pore diameter in the Pn3m phase is ≈11.6 nm, 
which is sufficiently large for cytochrome c efflux. The apoptotic pore is known to be highly 
variable in size, and our result is comparable to those derived from vesicle leakage studies with 
BAX proteins (1-4 nm (8)) and truncated BAX peptides (11.6 nm (17), ≈4.6 nm (18)), from 
patch clamp conductance studies (1-6 nm (19)) and from cryo-electron microscopy of BAX-
permeabilized liposomes that revealed BCL-XL-inhibitable openings of varying sizes (25-100 
nm (20)). 
In vivo, BAX must be activated to cause apoptosis (1-5,21). Experimentally, we have 
triggered BAX activation to a pore-forming state with the active form of BID (cBID), or with 
nonprotein factors like non-ionic detergent and pH cycling (8,22,23). In addition, we have used 
both FL BAX and BAXΔC (transmembrane domain removed) activated by these protocols (see 
methods) to study their capacity to generate pore-forming geometries with bilayer membranes. 
With 85/7/8 PE/PC/CL LUVs, all the different activation methods induced drastically 
stronger cubic phases than native untreated FL BAX (Fig. V.2F) or BAXΔC (data not shown). 
Strikingly, different activation routes resulted in porous cubic structures with slightly different 
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amounts of negative Gaussian curvature, but activation by cBID consistently generated the 
strongest correlation peaks as well as the most negative Gaussian curvature (Fig. V.2F-G).    
When BCL-XL was introduced with cBID-activated FL BAX (½:1:1 molar ratio), all 
correlation peaks corresponding to negative Gaussian membrane curvature generation 
weakened and systematically shifted to lower q-values (Fig. V.2A, blue trace), with an indexed 
dPn3m of 21.59±0.04 nm. Weaker peak intensities indicate reduced occurrence of the cubic 
phase. The increased lattice constant reflects decreased saddle-splay curvature within the cubic 
phase, because the average Gaussian curvature is inversely proportional to the square of the 
cubic lattice constant (11) (Fig. V.2B). At BCL-XL to BAX molar ratios 1:1 and greater, all 
correlation peaks were fully quenched (Fig. V.2A, top two traces), signaling the absence of 
saddle-splay curvature characteristic of porated spongy phases.  
The physiologic functions of BAX (pore formation), cBID (BAX-activator) and BCL-
XL (inhibitor of pore formation) in OM membranes are entirely consistent with the structural 
tendency each protein introduces when incorporated into liposomes composed of OM 
membrane-like lipids. BCL-XL’s antagonistic action against BAX’s pore forming activity and 
ensuing inhibition of cytochrome c release can be correlated with its suppression of negative 
Gaussian curvature generation, a crucial ingredient for pore formation. Supporting this 
interpretation, we consistently found BCL-XL reduced correlation peak intensities (less pores) 
and increased the cubic lattice constant (lower curvature) before complete shutdown of BAX. 
We find BAX activity is strongly influenced by the composition of mitochondrial 
lipids, which have distinct spontaneous curvatures: neutral (c0≈0) for PC, negative (c0<0) for 
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PE(24), and tunable for CL depending on the bound cation (25) (c0≈0 with monovalent salt, 
Js<0 with divalent cations like Ca2+ and Mg2+). To modify effective membrane c0, we varied PE 
content. PE headgroups are small compared to their tails (wedge-shaped) and tend to bend the 
lipid monolayer towards the water region and away from the hydrocarbon chain region 
(negative intrinsic curvature) (24). By increasing PE content to 85/12/3 PE/PC/CL, FL BAX 
was enough to induce cubic correlation peaks (Fig. V.2D, bottom red trace) without help from 
activator cBID. Conversely, increasing CL from 3 mol% (Fig. V.2D) to 8 mol% (Fig. V.2F), 
keeping PE at 85 mol%, gave significantly weaker cubic correlation peaks for FL BAX alone. 
This decrease is more pronounced in the absence of cBID, whose targeting of mitochondria 
(26) and activation of BAX (20) are widely cited as CL dependent. We next examined 
membrane structures induced by BAX, activated using all three different methods, for a broad 
range of lipid compositions relevant to mitochondrial membranes (Fig. V.2H for phase diagram 
of ternary PE/PC/CL liposomes with activated BAX at P/L=1/500). Occurrence of porous 
phases correlates with high PE and low mitochondrial-like CL levels. No porous cubic phases 
were observed when CL content approached and exceeded levels found in the inner 
mitochondrial (IM) membrane (10-16 mol%) (9,10), the integrity of which remains 
undisturbed following BID/BAX-induced cytochrome c release (27,28). 
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Fig. V.2 
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Fig. V.2 | cBID activates BAX to induce saddle-splay curvature, while BCL-XL suppresses 
curvature generation. A, Experimental SAXS data on 75/20/5 PE/PC/CL LUVs, offset 
vertically for comparison. While FL BAX alone was insufficient, 1:1-activation with cBID 
(red) precipitated a dominant cubic Pn3m phase. Annotations denote BCL-XL/BAX molar 
ratio (X), showing clear suppression of BAX-induced cubic diffraction peaks at high X. B, 
Pn3m peak indexing for X=0 (red) and ½ (blue) gave lattice constants d=15.58±0.03 nm, 
21.59±0.04 nm respectively. Peak q-values relate Miller indices (h, k, l) to d by 
q=2π√(h2+k2+l2)/d, so a left shift on log-log plot denotes an increase in d, with a 
commensurate decrease in saddle-splay curvature because K ≈2πχ/d2A0, with Euler 
characteristic χ and unit cell surface area A0 (11). C, Top schematic show double-
diamond topology of inverse bicontinuous cubic Pn3m phase, bottom show 
representative repeating units of cubic Pn3m and Im3m. D, FL BAX alone induced cubic 
phases in 85/12/3 PE/PC/CL. Annotations denote X. E, Peak positions in D indexed for 
X=0 (red) and X=½ (blue). Triangle and square markers denote Pn3m and Im3m peak q-
values respectively. At X=0, dPn3m=14.98±0.03 nm, dIm3m=19.1±0.1 nm. At X=½, 
dPn3m=16.87±0.03 nm, dIm3m=21.34±0.03 nm. F, Different methods of activating BAX gave 
rise to the same class of curvature with 85/7/8 PE/PC/CL LUVs, with dPn3m comparison in 
G. H, Composite protein-membrane phase diagram for BAX (P/L=1/500) activated with 
all 3 methods in ternary PC/PE/CL LUVs show propensity for porous states at high PE 
and low CL.  
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Although BAX and BCL-XL are structurally similar, they remodel membranes in 
drastically different ways.  BCL-XL did not induce sharp correlation peaks for a broad range of 
lipid compositions, suggesting its curvature generation ability is weaker than BAX’s. 
Considering PE’s strong role in BAX-induced porous phases, we examined the action of BCL-
XL on pure hydrated PE lipids, which possess sufficient negative c0 to self-assemble into an 
inverted hexagonal (HII) lipidic phase (peak q-positions at 1:√3:√4:√7 ratios, Fig. V.3A). The 
HII PE phase has negative curvature only along one direction (11) (and zero curvature 
orthogonally, so that H≡c1+c2<0, but K≡c1c2=0). SAXS data showed that BCL-XL was able to 
grow porous cubic phases that have negative curvature along one principal direction and 
positive curvature along the other (c1c2<0). This suggests that BCL-XL has restructured the 
negative mean curvature target membrane to produce new positive curvature. Isotropic 
generation of positive curvature leads to positive Gaussian curvature. Since both BAX and 
BCL-XL can act on the OM membrane, we need to understand how positive Gaussian 
curvature induced by BCL-XL interacts with negative Gaussian curvature induced by BAX (Fig. 
V.3B for possible picture). 
We developed a theoretical model for mixtures of two membrane-bound proteins, one 
inducing negative GC (BAX-like), the other positive GC (BCL-XL-like). Each protein is taken 
to induce local principal curvatures in the membrane, ξ 1 and ξ 2, which works against the 
membrane deformations given by the Helfrich free energy, FHelfrich=(B/8)∫dA(c1+c2)2, with the 
integral over the membrane area, and bending rigidity B. The energy of a single protein is 
EProtein=(∆E/2)[(c1-ξ1)2+(c2-ξ2)2], where ΔE(ξ12+ξ22)/2 is the energy cost of binding a protein to 
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a flat membrane, and the induced principal curvatures depend on the protein type (see 
supplementary for calculation details). Analogous to classical nucleation theory, the free energy 
scales as E=-σπr2+τ2πr for a pore of radius r and pore rim line tension τ on a membrane with 
effective surface tension σ. This model exhibits an energy barrier Ebarrier=πτ2/σ at a radius r0=τ/σ. 
When this energy is comparable to thermal energy, pore formation becomes favourable. We 
find that BAX-like K<0-inducing proteins universally suppress the free energy barrier, while 
BCL-XL-like proteins inducing positive Gaussian curvature (K>0) enhance it. Mixtures of 
proteins inducing competing curvatures can control pore formation via the free energy barrier 
(Fig. V.3C). Setting ξ 1≈0.5 nm-1, commensurate with the curvature on the inside of a pore, and 
ΔE(ξ12+ξ22)/2≈4kBT, we find ξ 2=-0.05 nm-1 induces an average Gaussian curvature of -0.022 
nm-2, consistent with a Schwartz’ D (Pn3m) surface of lattice size 17 nm (11). We use 
ξ1=ξ2=0.375 nm-1 for K>0-inducing proteins. Even at very modest area fractions, a K>0-
inducing protein will inhibit pore formation by raising the energy barrier drastically (Fig. 
V.3C). The precise values used for constants do not change the generic behaviour observed in 
the model, and computed dPn3m grows with increasing BCL-XL/BAX ratio (Fig. V.3D) in good 
agreement with our measured lattice constants. 
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Fig. V.3 
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Fig. V.3 | BCL-XL introduces positive curvature to curb BAX-induced pore formation. A, 
Annotations denote BCL-XL/lipid molar ratios (X/L). Hydrated PE self-assembles into a HII 
phase (negative mean curvature, dark blue) with dH=7.5 nm and principal curvatures 
c1<0 and c2=0, but addition of BCL-XL grew cubic phases (dPn3m=13.2 nm, dIm3m=16.9 nm) 
with c1<0 and c2>0, indication that positive curvature was introduced into the system. B, 
Schematic portray possible end-states when curved membrane patches interact.  
Saddle-splay patches (K<0, green) induced by proteins can come together to stabilize a 
pore, while introducing patches of isotropic positive curvature (K>0, orange) separate 
saddle defects to frustrate pore formation and leave an “egg-carton” surface (29). C, 
Barrier height of pore opening in mixtures of positive (orange) and negative (green) 
Gaussian curvature-generating proteins in theoretical model. Bare line tension τ0=10-11 
J/m, bare surface tension σ0=10-3 N/m. Barrier without proteins E0=π τ02/σ0, with 
contours spaced 10 kBT apart. D, Pn3m lattice constants grow with increasing molar 
ratio of K>0-generating proteins to K<0-generating proteins in theoretical model, and 
the range of lattice constants are in rough agreement with experimental data on BAX 
and BCL-XL. 
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Taken together, these observations propose the possibility that BCL2 family proteins, 
in addition to direct protein-protein binding, may also interact with one another via a 
membrane-curvature mediated mechanism. To test our hypothesis, we examined whether BCL-
XL could be used to turn off pore-formers other than BAX. Cell-penetrating peptides (CPPs) 
and antimicrobial peptides (AMPs) are obvious targets that can generate pores through 
negative Gaussian curvature (6,7). Mitochondrial membranes also resemble bacterial 
membranes (presence of CL, rich in PE and low cholesterol) (30). We incubated 80/20 PE/PS 
(phosphor-L-serine) LUVs with varying BCL-XL levels while the cell-penetrating peptide TAT 
is kept at a peptide/lipid (P/L) molar ratio of 1:40. TAT induced correlation peaks 
characteristic of coexisting lamellar Lα (peak q-positions at 1:2:3 ratio), Pn3m cubic, and 
inverted hexagonal HII lipid phases (6) (Fig. V.4A, bottom trace). Upon raising BCL-XL/lipid 
molar ratios (X/L), BCL-XL first quenched diffraction peaks of the HII phase at X/L=1/500, 
before completely suppressing the TAT-generated Pn3m peaks at X/L=1/100. Synthetic cell-
penetrating peptides, polyarginine-(polyethylene-glycol) or R4(PEG)XR4, were also tested with 
BCL-XL. R4(PEG)5R4 restructured 80/20 PE/PS LUVs to give diffraction peaks similar to 
TAT’s, and BCL-XL was again able to suppress all correlation peaks (Fig. V.4B) in a manner 
analogous to its antagonistic effect on BAX. Strikingly, BCL-XL can even quench negative 
Gaussian membrane curvature in a pure lipid system. High monovalent salt (300 mM KCl) was 
used to restructure 80/20 PE/PS LUVs into porous cubic phases (Pn3m and Im3m) with a 
coexisting hexagonal HII phase (Fig. V.4C). Incubation with BCL-XL suppressed the low-q 
cubic diffraction peaks, while higher BCL-XL levels grew the lamellar Lα phase at the expense of 
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the HII phase (Fig. V.4C, top trace), consistent with BCL-XL’s generation of positive curvature. 
In line with a membrane-mediated mechanism, BCL-XL was able to suppress negative Gaussian 
membrane curvature generation across a broad range of systems, ranging from pore forming 
peptides drastically different from BAX in charge, hydrophobicity and molecular weight, to a 
pure lipid system lacking protein-protein interactions. 
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Fig. V.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. V.4 | BCL-XL inhibits pore formers unrelated to the BCL2 family. A, TAT in 80/20 
PE/PS liposomes generated Pn3m (diffraction peaks at low q) and HII phases 
suppressible by high BCL-XL/lipid levels (X/L, annotated), leaving only the lamellar Lα 
phase. B, R4(PEG)5R4 in 80/20 PE/PS induces Pn3m and HII phases, both suppressed at 
high X/L. C, 300 mM KCl can induce 80/20 PE/PS liposomes into cubic and hexagonal 
phases, but increasing X/L blocked any growth of cubic peaks.  
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V.4 | Conclusion 
The formulation of BCL2 regulation has largely been based on BH3 domain 
interactions. Specific protein-protein contacts produce allosteric and displacement changes that 
modulate protein activity to control apoptosis (2-5). Our findings here demonstrate that in 
addition to BH3-mediated interactions between family members, a parallel mechanism 
mediated by BCL2 induced mitochondrial membrane curvature plays an important role. It is 
possible that under different biological conditions, specific protein-protein interactions can 
appear dominant or secondary (5,21,31,32). This model comports well with a recent finding 
that reduced BH3 interactions between BAX and BCL-XL do not suppress inhibition of 
apoptosis (33), and suggests a new general class of strategies for engineering apoptosis. 
V.5 | Experimental Procedures 
Protein/peptide preparation 
Recombinant human BCL-XL, cBID, and BAX (both FL and truncated (ΔC19)), were 
produced as intein constructs, expressed in BL21 (DE3) E. coli, isolated and purified without 
exposure to detergent (22,23). All proteins were found homogeneous (denaturing gel 
electrophoresis) and monomeric (fluorescence correlation spectroscopy) at physiological salt 
conditions. Octyl glucoside-activated BAX (OG BAX) was obtained by incubating BAXΔC 
with 1% (w/v) OG for 1 h at 4°C, and dialyzing for 4 h at room temperature against pH 7.0 
buffer (10 mM Hepes, 100 mM KCl). pH-activated (pH BAX) was prepared by dialyzing 
against pH 5.0 buffer (10 mM NaOAc, 100 mM KCl), then back against pH 7.0 buffer just 
before sample preparation. Activation by cBID involved mixing FL BAX or BAXΔC with cBID 
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at 1:1 or 5:1 stoichiometry. Cell penetrating peptide TAT 47-57 (trans-activator of 
transcription protein transduction domain from HIV-1) was purchased (Anaspec) and 
R4(PEG)XR4 peptides were prepared using automated solid-state synthesis (Protein Sciences 
Facility, University of Illinois). 
GUV preparation for confocal microscopy 
1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (DOPC), 1,2-Dioleoyl-sn-Glycero-3-
Phosphoethanolamine (DOPE), 1,2-Dioleoyl-sn-Glycero-3-Phospho-L-Serine (DOPS, sodium 
salt), bovine liver L-α-phosphatidylinositol (PI, sodium salt), bovine heart cardiolipin (CL, 
sodium salt) were purchased from Avanti Polar Lipids. Giant unilamellar vesicles (GUVs) 
labelled with DiO (Invitrogen) were prepared using electroformation. Lipid solutions in 
chloroform were desiccated on indium tin oxide (ITO) coated glass slides and swelled in 100 
mM sucrose solution containing Alexa Fluor 546 C5-maleimide or succinimidyl ester dye (≈1 
kDa, non-reactive after Tris pretreatment) under 10 Hz sinusoidal AC electric field. After 
GUV detachment with 4 Hz square AC, suspension was diluted 100× into 100 mM glucose, 
100 mM KCl medium and imaged in a 200 μl chamber with a Leica TCS SP2 laser scanning 
confocal microscope (63×, 1.4 N.A.). 
LUV preparation for x-ray measurements 
Lipid solutions in chloroform were dried under N2 and desiccated overnight under 
vacuum, then rehydrated in pH 7.0 buffer to 20 mg/ml at 37°C overnight before sonication to 
clarity and extrusion through 0.2 μm Nucleopore (Whatman) filters to yield  large unilamellar 
vesicles (LUVs). BCL2 proteins were mixed with LUVs at specific molar stoichiometries 
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(BAX:lipid = 1:500 or 1:600) while cell-penetrating peptides were introduced at peptide-to-
lipid molar ratios (P:L) just below the isoelectric point (P:L=1:40). Samples were incubated at 
37°C overnight and sealed in quartz capillaries. 
Synchrotron x-ray scattering 
Small angle x-ray scattering (SAXS) data were collected on BL4-2 (9-11 keV) at 
Stanford Synchrotron Radiation Laboratory (Palo Alto, CA), BL7.3.3 (10 keV) at Advanced 
Light Source (Berkeley, CA), and BESSRC-CAT (BL12-IDC) and BioCAT (12 keV) at the 
Advanced Photon Source (Argonne, IL). Scattered intensity was collected with MAR-Research 
(Hamburg, Germany) CCD detector (79 μm pixel)  and integrated using NIKA 
(http://usaxs.xor.aps.anl.gov/staff/ilavsky/nika.html) on Igor Pro (Wavemetrics) and FIT2D 
(http://www.esrf.eu/computing/scientific/FIT2D/). 
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